MINECONOMY

MINISTRY OF HEALTH OF UKRAINE



STRONGER TOGETHER:

Ukraine's Pharmaceutical Sector and EU Partnerships

STRONGER TOGETHER:
UKRAINE'S PHARMACEUTICAL SECTOR AND EU PARTNERSHIPS

2025

UDC 615.012:338.45](477+4-6ЄС)=111
S89

Slobodnichenko M., Pytel L., Isaieva O., Lukyanchuk Ye., Pilkiewicz M., Hrabova I.

S89 Stronger Together: Ukraine's Pharmaceutical Sector and EU Partnerships. — K., Morion, 2025. — 208 p.

This book is a deep analytical and educational review dedicated to the formation, power and prospects of the Ukrainian pharmaceutical industry in the context of modern economic and social challenges. The book focuses on Ukraine as a pharmaceutical state, which, despite the trials of the war, demonstrates extraordinary vitality, professionalism and desire for innovation. The publication shows how the industry, relying on the scientific school, educational potential and production traditions, is turning into one of the drivers of economic stability and international reputation of the country.

The authors examine the macroeconomic conditions in which the pharmaceutical sector develops, its contribution to national GDP, production dynamics, exports and structural changes occurring under the influence of reforms and European integration. Particular attention is paid to the internal resources of the industry — from qualified personnel and educational opportunities to modern technologies and capacities of Ukrainian factories capable of competing in the global market.

This is not just an economic study — it is a philosophy of the revival of pharmaceuticals as a strategic industry that combines science, innovation, social responsibility and state-building. The book affirms faith in the Ukrainian manufacturer, in the potential of domestic pharmaceutical education, in the power of partnership between the state, business and science.

The publication is addressed to international institutions, investors, the scientific and professional community, as well as to everyone who believes that Ukrainian pharmaceuticals is not only an industry, but a symbol of sustainability, development and intellectual future of the country.

ISBN 978-966-2066-84-5

©Slobodnichenko M., Pytel L., Isaieva O.,
Lukyanchuk Ye., Pilkiewicz M., Hrabova I. 2025

ACKNOWLEDGEMENTS

Medicines are not just products, but also intelligence, science, care and trust, embodied in every pill, in every drop, in every vial. They save lives, restore health, and give hope. And that is why their path — from the laboratory to the patient, from Ukraine to the European market — is not only economic, but also deeply humanitarian and strategic.

Today, bringing Ukrainian medicines to the European consumer is not just an ambitious goal, but a recognition of the maturity of our science, the sustainability of our industry and the strength of our state. This is a way that proves that Ukraine is not only a consumer, but a creator of high-quality, innovative and reliable solutions for human health.

This book is the result of joint work, unity and faith in the Ukrainian pharmaceutical industry.

Sincere thanks to everyone who participated in its creation — representatives of state authorities who form the strategic vector of development of the pharmaceutical sector, Ukrainian manufacturers of medicines, who prove every day that domestic quality can be at the level of the best European standards, the Association of Drug Manufacturers of Ukraine, which initiated its creation, Proxima Research International, IQVIA and all partners, experts and specialists, who contributed their experience, knowledge and inspiration to the creation of this publication.

Ukraine today is not only a country of brave people, but also a state of powerful pharmaceutical manufacturers capable of creating high-quality, effective and safe medicines that can compete with dignity at the world level. Bringing this truth to Europe is not just a step towards cooperation, but a strategic mission that strengthens national security, increases confidence in Ukrainian science and production, and opens a new page in the pharmaceutical history of Ukraine. Let this book become a symbol of partnership, development and confidence that Ukrainian medicines are not only about the health of the nation, but also about contributing to the common European future.



VIKTOR LIASHKO,
MINISTER OF HEALTH OF UKRAINE:

"Ukraine produces high-quality, reliable and innovative medicines. Our manufacturers are our national asset. Even in the most difficult times, they do not stop, continuing to work in line with global Good Manufacturing Practice (GMP) standards. This ensures that every pill made in Ukraine meets the highest European requirements. But the pharmaceutical sector is not only about production. It is about people: scientists, technologists, pharmacists who work every day to create solutions that protect the nation's health. They are the driving force behind the European integration of Ukraine's pharmaceutical industry.

Today, Ukrainian companies are actively implementing innovative technologies, digital quality-control tools and biotechnological approaches. They are developing effective and affordable medicines. Aligning our national standards with those of the European Union is not merely a technical process. It is our ticket to a European pharmaceutical future, where Ukrainian medicines hold a rightful place on the shelves of pharmacies across Europe. It is about global recognition of our products, our technologies and our achievements.

Our goal is both simple and ambitious: for Ukrainian medicines to become synonymous with quality, innovation and trust throughout Europe. We support domestic manufacturers, advance science, invest in innovation – and are confidently moving towards a single European health space.

The future of Ukrainian pharmaceuticals is in Europe. And that future begins today!"



MARYNA SLOBODNICHENKO,
DEPUTY MINISTER OF HEALTH FOR EUROPEAN INTEGRATION:

"We are actively working to ensure that Ukrainian high-quality production becomes an integral part of the European market. And these are no longer just plans — these are concrete results.

The European Commission is already considering Ukraine as a potential supplier of medicines for its strategic reserve, and this is the highest level of trust, recognition of our quality and reliability. This means that Ukrainian medicines are considered not just as goods, but as part of a common European health security system.

At the practical level, we are actively negotiating the mutual recognition of GMP (Good Manufacturing Practice) certificates. This will open up a direct and barrier-free path for our producers to export to EU markets. At the same time, we are accelerating the implementation of the medicines verification system, which is critical for combating counterfeiting and meeting the requirements of the European Union. This is not just a technology, it is a tool of trust that guarantees each patient that the drug in his hands is real and safe. All these steps make Ukraine an attractive partner for international clinical trials, opening up new opportunities for science, investment, and innovation. After all, it is here, in Ukraine, that a new European center for pharmaceutical development and biomedical research is being formed.

We are confidently moving towards Ukrainian pharmacy being part of a single European medical space — not only geographically, but also in terms of content, values, and quality. Our place is in the common European health system. And we prove every day that Ukraine is not only striving for this, it is already shaping the standards of the future".



TARAS KACHKA,
DEPUTY PRIME MINISTER FOR EUROPEAN AND EURO-ATLANTIC INTEGRATION:

"We have successfully completed the fastest screening of national legislation in the history of the EU, confirming our readiness for deep integration. Our priority is maximum trade liberalization and full integration into the EU internal market. We are working ambitiously to remove technical barriers, which is especially critical for medical and pharmaceutical products, allowing our manufacturers to export seamlessly.

Ukrainian manufacturers already demonstrate high quality standards, and we are ready for any inspections to prove that we are reliable and responsible European partners. Our goal is to ensure that high-quality Ukrainian pharmaceutical products are available throughout Europe. We are very striving, so we are already working with inspiration and doing everything to ensure that Ukrainian medicines and medical products become an integral part of the European supply chain".



MYKHAILO RADUTSKYI,
CHAIRMAN OF THE VERKHOVNA RADA COMMITTEE ON PUBLIC HEALTH, MEDICAL CARE AND HEALTH INSURANCE:

"To fully unlock the potential of Ukraine's pharmaceutical sector, it is crucial to accelerate the implementation of key European mechanisms. In this context, it is particularly important to highlight the launch of the National System for Verification of Medicines that uses 2D coding. This is one of the most advanced European standards, enabling the tracking of every package from the manufacturer to the patient. For consumers, it ensures confidence in the authenticity of their medicines, and for the state, it serves as an effective tool to combat counterfeits. In fact, 2D coding transforms each package into a unique digital passport of a medicinal product.

Another important step is the establishment of a new state authority for the quality control of medical products. Its role extends beyond verification to fostering a culture of responsibility, trust, and professionalism within the pharmaceutical sector. This authority should be a modern institution built on the principles of independence, digitalized processes, and transparency to the society. Taken together, these changes represent a genuine reboot of the entire quality control system, laying the foundation for renewed trust, both from our European partners and from Ukrainians".



ROMAN ISAENKO,
HEAD OF THE STATE SERVICE OF UKRAINE ON MEDICINES AND DRUG CONTROL:

"The State Service of Ukraine on Medicines and Drugs Control has decided to intensify scheduled inspections in the field of drug trafficking. This is a conscious step towards ensuring the proper status of all licensees in the pharmaceutical sector. This active control is already yielding tangible results: we are recording and withdrawing from circulation an increasing number of substandard drugs, which demonstrates our transparency and commitment to eradicating counterfeiting. Our main task is to guarantee the uncompromising quality of each drug on the Ukrainian market. This is critical to building trust in our regulatory system, which is a key prerequisite for mutual recognition of certificates and full integration. We are building a market that meets the highest EU standards to become a reliable and responsible partner in the common European medical space".



MYKHAILO BABENKO,
DIRECTOR OF THE STATE ENTERPRISE "STATE EXPERT CENTER OF THE MINISTRY OF HEALTH OF UKRAINE":

"The state and manufacturers have a single goal: the full integration of Ukrainian medicines into global circulation. That is why the State Expert Center is focused on radical digitalization and harmonization of regulatory procedures.

We successfully implement the submission of registration dossiers in the electronic format eCTD. This is not just a change of paper to "digital", it is a key international standard used by regulators of the European Union and the United States. The implementation of eCTD is critically important for our manufacturers, as it removes technical barriers and greatly simplifies the preparation of documents for the registration of Ukrainian drugs abroad. The dossier prepared according to this standard is technically ready for European regulators. In addition, we are creating a single digital platform that will unite all standards and guidelines, ensuring maximum transparency and quality of examination. At the same time, we are strengthening bilateral international cooperation with EU regulatory authorities. It builds trust and opens doors. Our path is a transparent, digital, and harmonized regulatory space that guarantees the success of Ukrainian manufacturers on the global stage".

STRATEGIC DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY OF UKRAINE

For me, medicines have never been just products. They are intelligence, science, care, and trust embodied in every tablet, every drop, every vial. They are tools that save lives, restore health, and give people hope. That is why their journey — from the laboratory to the patient, from Ukraine to the European market — is, in my view, not only economic but also deeply humanitarian and strategic.

Today, bringing Ukrainian medicines to the European consumer is not merely an ambitious goal but a recognition of the maturity of our science, the resilience of our industry, and the strength of our state. It is a path that demonstrates that Ukraine is not only a consumer but a creator of high-quality, innovative, and reliable solutions for human health.

This book is the result of collective work, unity, and a shared belief in the Ukrainian pharmaceutical sector. I sincerely thank everyone who contributed to its creation: the representatives of state authorities who shape the strategic direction of pharmaceutical development; Ukrainian manufacturers, who prove every day that domestic quality can meet the highest European standards; the Association of Drug Manufacturers of Ukraine, which initiated this publication; Proxima Research International, IQVIA, and all partners, experts, and specialists who shared their knowledge, experience, and inspiration.

Today, Ukraine is not only a country of brave people. It is a state with powerful pharmaceutical manufacturers capable of producing high-quality, effective, and safe medicines that compete with dignity on the global level. Communicating this truth to Europe is, for me, not just a step toward cooperation, but a strategic mission that strengthens national security, enhances confidence in Ukrainian science and production, and opens a new chapter in the pharmaceutical history of Ukraine.

May this book become a symbol of partnership, development, and confidence that Ukrainian medicines are not only about the health of our nation but also about our contribution to a shared European future.

Maryna Slobodnichenko,
Deputy Minister of Health for European Integration

FROM NATIONAL SECURITY TO GLOBAL COMPETITIVENESS

The modern pharmaceutical industry of Ukraine is gradually turning into one of the key elements of national security and international partnership. The focus of the state strategy is to ensure the country's pharmaceutical independence through the development of local production and strengthening export potential in cooperation with the European Union.

THE EUROPEAN CONTEXT: A NEW SECURITY OF SUPPLY ARCHITECTURE

In March 2025, the European Commission presented the Critical Medicines Act, aimed at increasing the availability, stability of supply, and development of the production of such drugs within the EU. This document was a reaction to the excessive dependence of European countries on the supply of active pharmaceutical ingredients from India and China. The new EU policy provides for the diversification of suppliers and creates a unique window of opportunity for Ukraine. Among the key provisions of the law are simplified access to finance and accelerated regulatory procedures for the production of critical medicines, public procurement to increase the resilience of supply chains, joint procurement between EU member states, and partnerships with regions outside the Union. It is in this context that Ukraine can become a strategic partner of the EU in the production and supply of critical medicines

STRATEGIC GOALS OF UKRAINE

Pharmaceutical independence is not only about the economy, but primarily about the sustainability of the health care system and the safety of citizens. The main tasks of the industry development include: development of the Ukrainian pharmaceutical industry as a guarantee of national security and availability of effective and safe medicines; strengthening export potential and ensuring access to the European Union market; development of local R&D capacities, which will create innovative drugs and increase the competitiveness of Ukrainian manufacturers. State support for pharmaceutical companies also remains a key area — from promoting the modernization of production to simplifying regulatory procedures and participating in joint programs with the EU.

EXPECTED BENEFITS

For the state, the strategic development of the pharmaceutical industry means an increase in GDP and tax revenues, the creation of new jobs, an increase in exports and foreign exchange earnings, as well as a strengthening of Ukraine's role in global supply chains. For businesses, participation in European initiatives opens up new opportunities for partnership, allows them to present their capacities at an early stage of the critical medicines project and expand the sales market to the European Union.

Today, the Ukrainian pharmaceutical industry is on the verge of a new stage — from local production to an active player in the global market of critical drugs. This is the path not only to economic sustainability, but also to full pharmaceutical independence of Ukraine, which is the foundation of its national security and international trust.

TABLE OF CONTENTS

1. Macroeconomic Context **23**

1.1. General Characteristics of the Country 24

2. Ukrainian Market **27**

2.1. Production Volume, Consumption Structure 28

2.2. General Information on Market Participants 32

3. Ukraine in the Global Pharmaceutical Market **35**

3.1. Ukrainian Pharmaceutical Market: Strong Position and Resilience 38

4. Regulatory System of Ukraine and Key Reforms **43**

4.1. Regulatory System of Ukraine 44

4.2. Reform of the Regulatory System 46

4.3. Healthcare System and Key Reforms 50

4.4. Reimbursement Programme “Affordable Medicines” 51

5. Tax and Investment Climate of Ukraine **55**

5.1. Tax System and Business Taxation in Ukraine 56

5.2. Customs System and Import Requirements in Ukraine 63

6. Ukraine: A Key Market in Central and Eastern Europe **69**

6.1. Unique Assets Powering Ukraine’s Pharmaceutical Sector 70

6.2. Market Insights in CEE Region 71

6.3. Ukrainian Pharmaceutical Market Overview 72

6.4. Regional Players (CEE) 73

7. Human Resources **75**

7.1. Opportunities of Ukrainian Education in the Field of Pharmaceuticals 76

8. Leading Ukrainian Manufacturers of Medicines and APIs **79**

8.1. Farmak (Ukraine, Kyiv) 85

8.2. Darnytsia Pharmaceutical Company (Ukraine, Kyiv) 95

8.3. InterChem (Ukraine, Odesa) 107

8.4. Pharmhim (Ukraine, Shostka) 117

8.5. Kyivmedpreparat (Ukraine, Kyiv) 125

8.6. Viola Pharmaceutical Factrory (Ukraine, Zaporizhzhia) 135

8.7. Biopharma Plasma (Ukraine, Bila Tserkva) 145

8.8. Lubnypharm (Ukraine, Lubny) 155

8.9. Borshchahivskiy Chemical-Pharmaceutical Plant (Ukraine, Kyiv) 163

8.10. Lekhim (Ukraine, Kyiv) 173

8.11. Yuria-Pharm (Ukraine, Kyiv) 181

8.12. Valartin Pharma (Ukraine, Kyiv) 189

8.13. Indar (Ukraine, Kyiv) 197



UKRAINE A MODERN PHARMACEUTICAL POWERHOUSE

Key Figures That Shape the Industry

50+

LARGE AND MEDIUM PHARMACEUTICAL MANUFACTURING SITES ACROSS UKRAINE

50+

LARGE AND MEDIUM GMP-CERTIFIED MANUFACTURING SITES

10

LEADING UKRAINIAN MANUFACTURERS REPRESENTED GLOBALLY

4

CORE UNIVERSITIES IN PHARMACY, CHEMISTRY AND BIOTECH

National University of Pharmacy (Kharkiv)

Danylo Halytsky Lviv National Medical University

Ternopil National Medical University

Taras Shevchenko National University of Kyiv (Faculty of Chemistry)

Bukovinian State Medical University (Chernivtsi)

50+

COUNTRIES IMPORT UKRAINIAN PHARMACEUTICAL PRODUCTS

35

UNIQUE EXPORT MARKETS IDENTIFIED

5 000+

NEW SPECIALISTS GRADUATED ANNUALLY

Pharmacy, chemical technologies, biotechnology, laboratory sciences

30

YEARS OF BIOTECHNOLOGY EXPERTISE

Indar — insulin production
Biopharma — plasma-derived products
Yuria-Pharm — recombinant proteins & RNA platform

3

INTERNATIONAL PRODUCTION SITES OPERATED BY UKRAINIAN COMPANIES

Barberà del Vallès, Spain - **Farmak**
Trieste, Italy — **DIACO (YURiA-PHARM)**
Vilnius, Lithuania — **LEKHIM**
Uzbekistan — **REKA-MED FARM / Lekhim & YURiA-PHARM facilities**

3

LARGEST MANUFACTURERS API

Farmak's API production site has an annual capacity of 100 tonnes

PHARMHIM — full-cycle API & intermediates manufacturing

INTERCHEM — portfolio includes 10 original active substances


EMERGENCY

1 | MACROECONOMIC CONTEXT

1.1. GENERAL CHARACTERISTICS OF THE COUNTRY

Ukraine is the second-largest country in Europe, with a total area of 603.700 square kilometers. It occupies a strategically important geographical position and has access to the Black Sea and the Sea of Azov. This location gives Ukraine a significant logistical advantage for trade and industrial cooperation. Ukraine is administratively divided into 24 regions (oblasts), the Autonomous Republic of Crimea, and two cities with special status — Kyiv, the capital, and Sevastopol. Crimea and parts of the Donetsk, Luhansk, Zaporizhzhia, and Kherson regions are temporarily occupied, but remain integral parts of Ukraine under international law. Kyiv serves as the political, cultural, and economic center of the country.

Ukraine's population before the full-scale war in 2022 was about 41 million people. The number of refugees from Ukraine as of 31.12.2024 amounted to 6.8 million according to the United Nations High Commissioner for Refugees (UNHCR), including:

- 6.3 million — in Europe, russia and belarus;
- 0.5 million — in other countries.

In other words, the population with access to Ukrainian pharmaceutical market has significantly decreased, and as of the end of 2024, according to various institutions, it became approximately 30 million people. Despite migration and temporary displacement caused by the war, the country continues to demonstrate demographic and social resilience. Ukrainians are known for their high level of education, adaptability, and entrepreneurial spirit.

Despite the war, Ukraine's economy and businesses have demonstrated remarkable resilience, recovering faster than forecasted and attracting international investment

The Ukrainian economy has undergone a profound transformation over the past three decades. The main sectors include agriculture, metallurgy, machinery, IT services, and pharmaceuticals.

During the war, Ukraine's economy has demonstrated resilience and is recovering faster than forecasted by various institutions, which is a positive signal for investors. Macroeconomic stability during the full-scale war has been reinforced by reforms in fiscal policy, banking supervision, and transparency in public finance. The Ukrainian national currency, the hryvnia (UAH), has remained relatively stable, supported by prudent monetary policy and strong backing from international financial institutions such as the IMF, World Bank, and EU.

Before full-scale invasion, the country's economy was developing, and in 2021 its Gross domestic product (GDP) reached its highest ever level of € 169 billion. The full-scale war and related factors remain the main constraints on Ukraine's economic growth, including temporary occupation of territories, destruction of infrastructure, loss of a significant part of the population due to migration abroad, and people remaining in the temporarily occupied territories. However, the country's economy demonstrates resilience. At the beginning of the full-scale invasion, the International Monetary Fund (IMF) predicted a 45% decline in Ukraine's GDP by the end of the year, but economy and business quickly adapted to the martial law. The resilience of Ukraine's economy and business has demonstrated positive signals for foreign investors to invest in Ukraine. One of such signals is Horizon Capital's closure of USD 350 million Ukraine-focused investment fund in Tokyo on February 19, 2024. The fund was 40% larger than the initial target size of $250 million. This shows

that investors are ready to invest in Ukrainian businesses despite the war, and their number will increase once the war is over. Investors who have supported the fund have a capital base of about $700 billion. These are international financial institutions such as International Finance Corporation, European Bank for Reconstruction and Development, European Investment Bank through the EU for Ukraine Fund, U.S. International Development Finance Corporation, Deutsche Investitions- und Entwicklungsgesellschaft, Dutch entrepreneurial development bank (FMO), Japan International Cooperation Agency, Proparco (a subsidiary of Agence Française de Développement Group), Swiss Investment Fund for Emerging Markets, Swedfund, Finnfund, Western NIS Enterprise Fund, Investment Fund for Developing Countries (IFU).

The closure of a USD 350 million Ukraine-focused investment fund — 40% above its initial target — shows strong global investor confidence in Ukrainian companies even during wartime

Despite the ongoing war, Ukraine continues to function as a democratic state with robust institutions. The government ensures uninterrupted operation of key services, maintains macroeconomic stability, and actively implements reforms aligned with EU standards. The resilience of Ukrainian society — demonstrated by businesses adapting to wartime conditions, volunteers supporting the army, and communities rebuilding infrastructure — is a defining feature of the nation's strength.

In summary, Ukraine remains a country with substantial economic potential, a skilled workforce, and strategic geographic advantages. Its ability to sustain growth, preserve democratic values, and maintain production capacity under extreme pressure highlights the resilience and determination that define modern Ukraine.

2 | UKRAINIAN MARKET

2.1. PRODUCTION VOLUME, CONSUMPTION STRUCTURE

Over the past years, the Ukrainian pharmaceutical market (retail+hospital) has been growing steadily in national currency. Between 2008 and 2024, the volume of retail sales and supplies to the hospital of medicines increased almost 11 times from UAH 16 billion in 2008 to UAH 170 billion in 2024. Following the full-scale invasion of Ukraine by russia in 2022, the pharmaceutical market suffered losses, as did many other industries. However, the market recovered quickly and exceeds the figures for 2021 in national currency as before the full-scale invasion. Since 2008, the market has also been growing rapidly in foreign currency, but russian aggression in 2014 caused the national currency to devalue and, as a result, the market to decline. It was only in 2019 that pharmacy sales and hospital supplies of medicines in euros reached the levels of 2013 and continued growing. However, russia's full-scale invasion of Ukraine in February 2022 caused the economy to downturn and the hryvnia to devalue, which again resulted in a significant decline in the pharmaceutical market in currency terms.

Between 2008 and 2024, the Ukrainian pharmaceutical market in national currency grew almost 11 times — from UAH 16 billion to UAH 170 billion

In 2023, the market volume reached 3.7 billion euros, up to +8% compared to 2022. The war caused the hryvnia to increase in value against the euro from around UAH 31 per EUR 1 in early 2022 to UAH 37 per EUR 1 after the full-scale invasion. As of the end of 2023, the official exchange rate of the hryvnia to the euro was around UAH 42 per EUR 1. As a result, the market in euros is developing less actively than in national currency, and in 2023 remained at the level of 2020. In other words, russia's full-scale invasion of Ukraine set the market back by 3 years. As a result of these constant fluctuations, the pharmaceutical market (retail+hospital) in euros has grown less than twice over the past 17 years, from €2.1 billion in 2008 to €3.9 billion in 2024.

The pharmaceutical market in Ukraine is almost entirely financed by consumers, as the retail segment accounts for the lion's share of medicines consumption. The share of hospital supplies in the overall market structure remains quite low and, by the end of 2024, amounts to about 10% in value and 13% by volume. If we compare the annual per capita retail and hospital consumption of medicines in Ukraine with other countries in 2023, we can note a rather low level, which is significantly lower than in developed European countries. However, as already mentioned, the Ukrainian market is highly potential for growth and in the absence of external factors and Ukraine's accession to the EU in the future, per capita consumption of medicines will continue growing.


After the full-scale invasion, the market recovered quickly and already exceeds 2021 levels in national currency

Consumption of medicinal products in packages shows similar trend to the currency equivalent. During the periods of russian aggression, consumption volumes are significantly reduced. In 2014, the decline reached 13%, and in 2022 — 22%. In 2022, consumption of medicines in packages decreased by 22% compared to the previous year, and in 2023 it increased by only 4%. During these 2 years, the lowest consumption of medicines in packages was recorded in the entire history of observations. One of the reasons for the lack of growth in packages was the significant loss of the population that had access to the market. As of the end of 2024, there were 6.8 million refugees. A significant part

of the population is also in the temporarily occupied territories. The number of people available for the market is about 30 million. In general, over the past 17 years, consumption of medicines in packages has decreased by 30% from 1.4 billion in 2008 to 970 million packs in 2024 (retail+hospital). The main reason for this decrease is the russian aggression.


As already stated, the retail segment accumulates 89% of the total volume of the drug market. Therefore, long-term trends are similar to those for the entire market. This is a stable development in the national currency over the past 16 years and a decline in pharmacy sales and euros, and packages after the Russian aggression in 2014 and a full-scale invasion in 2022. After a significant decline caused by full-scale invasion in 2022, the market started recovering from March 2023, showing a significant

Fig. 2.1.1 Dynamics of retail sales of medicines



Source: PharmXplorer Market Research System Proxima Research International.


Fig. 2.1.2 Changes in retail consumption of medicines in national currency



Source: PharmXplorer Market Research System Proxima Research International.


growth rate in the national currency (more than 60% in the middle of the year), but at the end of the year this indicator slowed down due to low base exhaustion comparing to 2022. Following the results of 2023, the volume of pharmacy sales amounted to UAH 130 billion and increased by 25.1% compared to the volumes of 2022. The number of packages sold amounted to 848.6 million, which is higher by 0.5%. In euros, sales increased by 7.7% and amounted to 3.3 billion euros. The market started operating quite confidently, showing an increase in retail sales in hryvnia by 18% in 2024 compared to 2023 and in euros by 7%. By volume, pharmacy sales decreased by 1% (Fig. 2.1.1). In 2022, due to a significant decrease in physical consumption of medicines, a deeper decline in hryvnia was constrained by high inflation rates. In 2023–2024, the market developed

Fig. 2.1.3 Structure of retail sales of "pharmacy basket" in monetary terms



Source: PharmXplorer Market Research System Proxima Research International.

Fig. 2.1.4 Structure of pharmacy sales of medicines of domestic and foreign production




Source: PharmXplorer Market Research System Proxima Research International.

mainly due to inflationary component, as well as an increase in sales in packages and a redistribution of consumption towards more expensive drugs, as evidenced by high indicator of substitution index (Fig. 2.1.2).


Among the products of the "pharmacy basket" there are 4 main groups of products: medicines, dietary supplements, medical devices, and cosmetics. Over the past 10 years, one of the trends in the pharmaceutical market of Ukraine became dietary supplements share growth in the total structure of pharmacy basket items sale. This can be explained by the fact that some medicines are re-registered as dietary supplements, as they are easier to register and enter the market, as well as less regulatory requirements when registering promotions aimed at healthcare professionals and advertising for the end user.

Fig. 2.1.5 Structure of pharmacy sales by prescription status



Source: PharmXplorer Market Research System Proxima Research International.

Fig. 2.1.6 Structure of medicines consumption in Ukraine in 2024 by sources of financing



Source: PharmXplorer Market Research System Proxima Research International.

In 2024, dietary supplements share amounted to 11.2% in monetary terms and 8.9% in physical volume (Fig. 2.1.3).

Another trend in the pharmacy retail market is the development of private label (PL) products. A private label is a brand owned by any company that markets it — either an individual retailer or a cooperation of pharmacy chains and distributors. Against the background of expanding pharmacy chains, the share of private label products has also been growing, reaching 5.2% in monetary terms and 11.1% in physical volume of the total sales of pharmacy basket goods in December 2024.

The structure of medicines consumption by production place is very dependent on external factors. The economic crisis or military aggression contributes to share of medicines produced in Ukraine increase in the overall market structure. However, the structure quickly recovers to the indicators recorded before the influence of external factors. In general, over the past 17 years, domestic producers have significantly increased their share in the total volume of retail sales of medicines in hryvnia. Moreover, by volume the share of domestic producers remained the almost same as 17 years ago (Fig. 2.1.4). In the structure of pharmacy sales, there is a long-term tendency towards prescription drugs share increase in the overall market structure (Fig. 2.1.5).

Domestic manufacturers have significantly increased their share in pharmacy retail sales over the past 17 years

Ukrainian pharmaceutical market development is almost entirely dependent on consumer welfare. In 2024, public spending covered about 13% of total consumption of medicines (Fig. 2.1.6). If we consider public spending on medicines, the supply of medicines procured under centralised programmes of MoH of Ukraine covers 2.5% of the total market. Medicines procured at the expense of the local and departmental budgets account for 7.5%. Another 3.3% is covered by the reimbursement programme. Supplies to private clinics are estimated at 0.8%, but such purchases can be attributed to retail segment, since these medicines are paid for by the patient, not the state. In terms of the number of tenders held, 32.6 thousand tenders were accepted in 2024 (excluding tenders for procurement under centralised programmes of the Ministry of Health) for the procurement of medicines for a total amount of UAH 13.1 billion (EUR 297.8 million at the exchange rate as of 31.12.2024). Moreover, the number of tenders in regional procurement increased by 15% in 2024 compared to 2023, while the volume of procurement increased by 31%. The lion's share of procurements fell on the first half of the year (Fig. 2.1.7).

2.2. GENERAL INFORMATION ON MARKET PARTICIPANTS


As of November 10, 2025, 15.199 trade names of medicinal products were registered in Ukraine, including 12.017 finished pharmaceutical products, 2.379 active pharmaceutical ingredients (APIs), 625 *in-bulk* medicines, and 174 medicines that are packaged or repackaged from *in bulk*.

The dynamics of pharmacy sales of medicines from the top 10 pharmaceutical companies over the past 17 years indicates the active domestic pharma development. Most Ukrainian companies have significantly increased their market share. In the structure of pharmacy sales in the context of pharmaceutical companies at the beginning of the war, high volatility was recorded. The war affected manufacturers in different ways. Panic, bombed warehouses, lack of advertising and promotion affected each of the market participants in different ways. Geographic location also had an essential role to play. Companies which production facilities or warehouses were located

in the temporarily occupied territories or in war zones were more affected. However, the situation quickly stabilized, the companies were able to adapt to the war conditions, to relocate their business from these territories, and to switch to contract production at production sites of Ukrainian and foreign manufacturers.


As for producer segment consolidation, it has become quite stable and has not changed significantly in recent years. Over the past 6 years, the share of top 5 manufacturers in the total structure of pharmacy sales has increased from 18% in 2019 to 20% in 2024. By volume, this indicator changed from 32% to 33% (Fig. 2.2.1). For the top 10 producers over the same period, the share increased from 26% to 28% in monetary terms and did not change by volume (39%).

Fig. 2.1.7 Amount and number of tenders accepted from January 2021 to December 2024, excluding centralised procurement by MoH



Sources: PharmXplorer Market Research System Proxima Research International; prozorro.gov.ua/uk.

Fig. 2.2.1 Dynamics of top-100, top-10, top-5, and top-3 manufacturers share by volume of pharmacy sales of medicines



3 | UKRAINE IN THE GLOBAL PHARMACEUTICAL MARKET

Global Export Map of Ukrainian Pharmaceuticals



3.1. UKRAINIAN PHARMACEUTICAL MARKET: STRONG POSITION AND RESILIENCE

The pharmaceutical market of Ukraine holds a significant position among the countries of Central and Eastern Europe, demonstrating dynamic growth even under extremely challenging political and economic conditions. Despite the losses caused by russia's armed aggression, Ukraine's pharmaceutical industry has preserved its production potential, innovative capacity, and domestic demand. It remains one of the most resilient components of the national economy, playing a strategic role in both the healthcare system and state security.

For many years, the Ukrainian pharmaceutical market has shown double-digit growth rates, allowing the country to enter the pharmerging markets segment. According to the IQVIA classification, this group includes countries with a per capita income below USD 30.000 per year and a projected increase in prescription drug sales of more than USD 1 billion over five years. This segment is considered one of the most attractive for international investors due to its high potential for further growth.

Ukraine's pharmaceutical industry has preserved its production potential, innovative capacity, and domestic demand — remaining one of the most resilient components of the national economy


However, following the annexation of Crimea and the partial occupation of the Donetsk and Luhansk regions, Ukraine's share in the global pharmaceutical market declined. At the beginning of 2022, the country managed to regain its position in the pharmerging markets segment. Yet, the full-scale russian invasion in February 2022 prevented Ukraine from maintaining this position (Fig. 3.1.1). As a result of the hostilities, some market players lost their manufacturing facilities, warehouses, and pharmacies. Nevertheless, despite the severe challenges, the Ukrainian pharmaceutical sector continued to operate, quickly restoring logistics, ensuring the supply of medicines to the population, and resuming production. This demonstrates a high level of resilience, adaptability, and an unbreakable potential for recovery and growth, which can be realized with economic stabilization and investment inflow.

Despite wartime challenges related to the occupation of certain territories and the migration of part of the population abroad, the Ukrainian pharmaceutical market shows gradual recovery of both retail and hospital consumption of medicines in monetary terms (Fig. 3.1.2).

Six Ukrainian manufacturers joined the EU Critical Medicines Alliance — a key step toward strengthening Europe's security of supply


An important trend in recent years (2023-2024) is the gradual increase in the share of imported medicines, driven by the expansion of the product range, including innovative products that are not yet manufactured in Ukraine. At the same time, in the structure of the retail market, the share of Ukrainian manufacturers is only slightly lower in volume terms but remains smaller in monetary value. This reflects the higher affordability of domestic medicines and their key role in providing the population with essential drugs. Some Ukrainian companies are gradually expanding their presence

Fig. 3.1.1 Ukraine's share in the global pharmaceutical market




Source: PharmXplorer Market Research System Proxima Research International; IQVIA Market Prognosis, 2021–2024.

Fig. 3.1.2 Dynamics of retail sales and hospital supplies of medicines



Source: PharmXplorer Market Research System Proxima Research International.

Fig. 3.1.3 Annual per capita consumption of medicines (retail + hospital segment) in 2023 compared to other countries



Source: Statista, 2023.

in foreign markets, developing export activities — a result of years of harmonizing national standards with European ones and implementing Good Manufacturing Practices (GMP) and other quality systems.

In 2022, Ukraine exported $228.7 million worth of pharmaceutical products — a 20.6% increase from the previous year.

Six Ukrainian manufacturers joined the EU Critical Medicines Alliance. This integration marks an important step toward strengthening Europe's security of supply. Ukraine is ready to contribute to preventing shortages of essential medicines through production capacities, technological expertise, and strategic partnership within the EU framework.

Despite these positive trends, the per capita consumption of medicines in Ukraine remains significantly lower compared to other countries (Fig. 3.1.3). This may be due to lower income levels and unequal access to medical services. However, this gap indicates a substantial potential for further growth. As living standards improve, the reimbursement system develops, and healthcare services expand, the demand for medicines will naturally increase.

With the stabilization of the political situation, economic recovery, reform of the reimbursement system, and digitalization of regulatory processes, Ukraine has the potential to strengthen its position in the global pharmaceutical market.



4 REGULATORY SYSTEM OF UKRAINE AND KEY REFORMS

4.1. REGULATORY SYSTEM OF UKRAINE

Healthcare in general, and the pharmaceutical sector in particular, have always been among the priority areas of state policy in Ukraine (Fig. 4.1.1). Considering the country's strong pharmaceutical industry, significant human and investment potential, population living standards, and security challenges, the following principles of state policy — officially declared in the new Law of Ukraine "On Medicinal Products" — serve as guidance for competent national regulatory authorities:

- Protection of patients' rights, ensuring the population's access to medicinal products to uphold citizens' right to healthcare;
- Development of professional market self-regulation and limitation of state regulation of business activities;
- Integration into the European Union medicinal products market, including the adaptation of Ukrainian legislation to the normative acts of the European Union;
- Support for research and clinical trials, particularly clinical trials of innovative medicinal products, the creation and implementation of new technologies to ensure patient access to innovative treatment methods;
- Promotion of self-sufficiency in Ukraine with a sufficient supply of human donor blood, blood components, and blood-derived products;
- Broad public awareness of the dangers posed by falsified medicinal products.

Ukraine is integrating into the EU medicinal products market, aligning national legislation with the regulatory framework of the European Union

The main state institutions regulating the pharmaceutical sector in Ukraine are the Ministry of Health (MoH), the State Enterprise "State Expert Centre of the MoH of Ukraine" (SEC), and the State Service of Ukraine on Medicines and Drugs Control (State Drug Service). Their activities are aimed at creating a transparent, reliable, and safe pharmaceutical market in line with EU standards (Fig. 4.1.2).


The MoH is the central executive authority responsible for shaping state policy in healthcare, including the pharmaceutical sector. Its key role lies in regulatory oversight and strategic management of all processes related to the life cycle of medicinal products — from preclinical research to medical use.

The SEC is a specialized expert organization authorized by the MoH of Ukraine to conduct preclinical studies, clinical trials, and state registration of medicinal products (including the examination of registration dossiers and clinical trial materials). It also serves as the principal body in pharmacovigilance, standardization of medical care, and pharmaceutical services, including the development of relevant medical-technical documents and draft regulatory acts. It operates under the governance of the MoH.

The State Drug Service is a member of PIC/S, a voting member of the European Pharmacopoeia, and part of the EDQM OMCL network — confirming compliance with high European quality standards

The State Drug Service is a central executive authority whose activities are directed and coordinated by the Cabinet of Ministers of Ukraine through the Minister of Health, who implements state

Fig. 4.1.1 Growth of Ukraine's Pharmaceutical Sector



Sources: Pharmaphorum, Farmak, Darnytsia, Proxima Research.

policy in the fields of quality and safety control of medicinal products, including medical immunobiological products, medical devices, and controlled substances. This includes the circulation of narcotic drugs, psychotropic substances, and precursors, combating their illegal distribution, overseeing blood and blood components, and managing the national blood system.

Key areas of the State Drug Service's activity in the pharmaceutical sector include licensing, GMP and GDP certification, quality control of medicinal products, and state supervision. The State Drug Service has been a member of PIC/S since 2011, a voting member of the European Pharmacopoeia since 2013, and a party to the MEDICRIME Convention since 2012. Additionally, it is a member of the European Directorate for the Quality of Medicines & HealthCare (EDQM), with one of its laboratories joining the OMCL network of official control laboratories for medicines and the OCCL network for cosmetic products in 2013.

Details of the existing regulatory system are presented in Table 4.1.1.

4.2. REFORM OF THE REGULATORY SYSTEM

Ukraine's integration into the European Union (EU) entails harmonisation of the main elements of legal systems. For medicinal products, this requires alignment between the regulatory frameworks of the EU, its member states, and Ukraine, based on best European practice. Consequently, Ukrainian and EU legislation on medicinal products must use consistent terminology and incorporate uniform pharmaceutical market regulatory rules.

Reducing regulatory burden and providing a flexible legal framework to support innovation and competitiveness are continuously implemented in EU authorisation procedures, including the supervision of human-use medicinal products.

To gradually introduce current and updated EU pharmaceutical regulation, Ukraine initiated a reform of its state regulatory authorities for the pharmaceutical sector, relying on continuous dialogue between the Ministry of Health of Ukraine and European partners — the European Commission, the European Medicines Agency, and their working bodies.

To achieve this goal, revise regulatory principles in the medicinal products sector, shift focus toward patient rights, and enhance quality, efficacy, safety, and accessibility of medicinal products, the Law of Ukraine "On Medicinal Products" was adopted in 2022. The law comprehensively incorporates Directive 2001/83/EC of the European Parliament and of the Council — "Community Code Relating to Medicinal Products for Human Use." Due to the Russian Federation's armed aggression and the need to adapt the Ukrainian pharmaceutical sector to both war conditions and new regulatory procedures, the law's entry into force has been postponed until 2027.

The MoH of Ukraine is actively preparing for the law's implementation, developing subordinate regulatory acts on clinical and preclinical studies, state registration, pharmacovigilance, quality control, licensing, state supervision, etc., fully aligned with relevant EU legislation.

A key reform element is the creation of a single supervisory and control authority in the pharmaceutical sector (hereinafter — the State Control Authority), which will enhance regulatory

efficiency and ensure proper allocation of powers among state bodies (Fig. 4.2.1).

Thus, powers related to state policy formation in the pharmaceutical sector will remain with the MoH, while functions for policy implementation and related areas (Table 4.2.1) will transfer to the newly established State Control Authority, ensuring proper oversight throughout the entire life cycle of medicinal products (development, market authorisation, quality control in circulation, safety, and efficacy) by a single controlling authority.

The new Law of Ukraine 'On Medicinal Products' fully incorporates Directive 2001/83/EC, aligning Ukraine's pharmaceutical regulation with EU standards

Overall objectives of the reform, to be achieved by the State Control Authority:

- Foster competitive conditions in the medicinal products market to improve quality, safety, efficacy, economic accessibility, and treatment effectiveness;
- Promote competitiveness of the pharmaceutical industry and alignment of Ukrainian and EU markets;
- Create a favourable investment climate, remove technical barriers to international trade in medicinal products through harmonisation with EU legislation and standards;
- Ensure proper pharmacovigilance and quality control, including for imported products;
- Prevent the circulation of substandard and falsified medicinal products;
- Conduct registration and market authorisation based on comprehensive assessment of quality, efficacy, safety, and benefit-risk balance;
- Protect the rights and legal interests of market participants;

Fig. 4.1.2 Institutional structure of the pharmaceutical regulation system in Ukraine



Sources: treasury.gov.ua, nszu.gov.ua.

- Conduct transparent and proper licensing of manufacturing, import, wholesale, and retail of medicinal products to protect public health;
- Implement justified restrictions on marketing and promotion of medicinal products;
- Ensure accessibility of medicinal products and points of sale.

The EU Twinning project, implemented jointly with Lithuania, Poland, and Germany, supports the establishment of Ukraine's new pharmaceutical State Control Authority

Table 4.1.1 The life cycle of a medicinal product in Ukraine

Life Cycle Stage	Authorisation Document	Regulatory Act	Functions of State Authorities
Preclinical studies	No separate authorisation required, but must follow an approved study protocol/ plan	• Law of Ukraine "On Medicinal Products" • MoH Order No. 944, 14.12.2009 • Good Laboratory Practice (GLP), MoH Order No. 95, 16.02.2009	• MoH defines requirements for preclinical studies • SEC conducts examination of preclinical study materials and audits
Clinical trials	MoH authorisation for clinical trials	• Law of Ukraine "On Medicinal Products" • MoH Order No. 690, 23.09.2009 • Good Clinical Practice (GCP), MoH Order No. 95, 16.02.2009	• SEC examines materials for clinical trials • MoH issues clinical trial authorisations based on SEC expert conclusions
State registration of medicinal products	Registration certificate (valid 5 years)	• Law of Ukraine "On Medicinal Products" • CMU Resolution No. 376, 26.05.2005	• SEC examines registration materials • MoH makes registration decisions and issues registration certificates
Production of medicinal products	Manufacturing licence	• Law of Ukraine "On Medicinal Products" • Law of Ukraine "On Licensing of Types of Economic Activity" • CMU Resolution No. 929, 30.11.2016 • GMP, MoH Order No. 95, 16.02.2009	State Drug Service: • issues manufacturing licences and GMP certificates • inspects compliance with licence conditions and conducts GMP inspections
Circulation (wholesale, retail, import)	Licences for import, wholesale, and retail	• Law of Ukraine "On Medicinal Products" • Law of Ukraine "On Licensing of Types of Economic Activity" • CMU Resolution No. 929, 30.11.2016 • GDP, MoH Order No. 95, 16.02.2009	State Drug Service: • issues licences and GDP certificates • inspects compliance with licence conditions and GDP inspections
Medical use	No separate authorisation required (use based on product registration)	• Law of Ukraine "On Medicinal Products" • MoH Order No. 360, 19.07.2005 • National Formulary	MoH regulates medical use of medicinal products
Pharmacovigilance	No authorisation required (ongoing)	• Law of Ukraine "On Medicinal Products" • MoH Order No. 898, 27.12.2006	• SEC conducts pharmacovigilance • State Drug Service may impose temporary bans on products if unexpected adverse reactions/ deaths occur • MoH may impose full or temporary bans by suspending registration certificates
Re-registration / termination of registration	MoH order on continuation or termination of registration	• Law of Ukraine "On Medicinal Products" • CMU Resolution No. 376, 26.05.2005 • MoH Order No. 1801, 05.08.2020	• SEC conducts re-examination of registration materials • MoH decides on re-registration or refusal

These objectives will also be pursued through institutional self-assessment of Ukrainian authorities according to EMA methodology during 2025–2027, with KPIs including:

1. Strategy & planning.
2. Leadership & culture.
3. Stakeholders.
4. Quality management.
5. Risk management.
6. Crisis management.
7. Human resource management.

Fig. 4.2.1 Ukraine's regulatory system from 2027




Table 4.2.1 Transfer of functions and responsibilities in pharmaceutical regulation under the new governance model

No.	Regulatory Area	Competence of the State Control Authority (Main Functions)
1	Medicinal products	• Clinical trials (authorisation) • Registration of medicinal products • Pharmacovigilance • Licensing • State supervision (control) • Maintaining registries
2	Medical devices	• Market surveillance • Maintaining registries
3	Blood and blood components	• Licensing • State supervision (control)
4	Narcotic drugs, psychotropic substances, and precursors	• Licensing • Import/export authorisations • State supervision
5	Cosmetics	• Market surveillance • Maintaining registries
6	SoHo	• Maintaining enterprise registries • Authorisations for business entities • Product authorisation • Monitoring clinical trials • State supervision • Market surveillance

8. Operational management.
9. Information management.
10. Interfaces.
11. Scientific decision-making.
12. Regulatory impact/effectiveness.

The benchmarking aims to evaluate the contribution of medicines control bodies and other national health authorities, and determine whether national health policy is evidence-based. This process supports the establishment of an effective quality management system to enable the future single control authority to achieve its policy and strategic goals.

Given the ambitious objectives of Ukraine's pharmaceutical sector reform and the creation of the State Control Authority, the EU Twinning instrument has been involved to harmonise legislation, standards, and management practices with EU standards. The project "Support for Establishing the State Control Authority in the Pharmaceutical Sector of Ukraine" will run for 21 months (2025–2027) (Fig. 4.2.2).

The project is implemented on Ukraine's side by the MoH and on the EU side by a consortium of Lithuania, Poland, and Germany, including:

- State Medicines Control Agency (SMCA), Lithuania — project coordinator;
- Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL), Poland;
- Federal Ministry of Health (BMG), Germany.

4.3. HEALTHCARE SYSTEM AND KEY REFORMS

Over the past decades, Ukraine has undergone a profound transformation of its healthcare system, gradually shifting from the Semashko model to a patient-centered and financially transparent system. The Ministry of Health of Ukraine (MoH) acts as the main policymaker and regulator in the sector. Significant institutional changes began after 2017, marking the start of a new era in healthcare financing and management.

OIn 2017, the National Health Service of Ukraine (NHSU) was established as a single national purchaser of healthcare services. This reform introduced the "money follows the patient" principle, replacing outdated budgeting practices with direct contracting between the NHSU and healthcare providers. One year later, in 2018, the State-Owned Enterprise "Medical Procurement of Ukraine" (MPU) was founded as a centralized procurement agency. Starting from 2023, MPU became the sole agency responsible for centralized procurement of medicines and medical devices in the healthcare sector, ensuring transparency, competition, and efficient use of public funds.

> ***In 2017, the National Health Service of Ukraine (NHSU) was established as a single national purchaser of healthcare services, introducing the 'money follows the patient' principle***

A key digital instrument of reform is the electronic healthcare system (eHealth) — a national digital platform that underpins all NHSU operations. The strategic goals of eHealth include ensuring transparency in healthcare financing, introducing electronic medical records (e-prescription, e-referral, e-patient card), expanding digital services for citizens, and opening new business opportunities in health

tech. Despite the challenges of full-scale war, the reform continues. In the second year of the invasion, electronic prescriptions for all categories of prescription medicines were introduced. Initially launched as part of the reimbursement programme "Affordable Medicines", the e-prescription became available for all medicines on April 1, 2023.

In particular, in 2024, a new List of medicinal products prohibited from advertising was approved (Order No. 457 of March 18, 2024), which expanded the number to 407 trade names of over-the-counter medicines whose advertising is prohibited.

4.4. REIMBURSEMENT PROGRAMME "AFFORDABLE MEDICINES"

The "Affordable Medicines" reimbursement programme was launched in April 2017 as a key component of Ukraine's healthcare guarantees. Initially administered by the MoH, in 2019 it was transferred under the management of the National Health Service of Ukraine. The NHSU is a central executive body directed by the Cabinet of Ministers through the Minister of Health, responsible for implementing state financial guarantees of healthcare for the population. Its main functions include administering the medical guarantees programme, contracting healthcare providers, and ensuring reimbursement for priority diseases.

By the end of 2024, the reimbursement list covers more than 70 INNs and 596 SKUs — more than double the scope of five years ago

Within the framework of the Programme of Medical Guarantees, NHSU provides reimbursement for medicines used in outpatient treatment of cardiovascular and cerebrovascular diseases, diabetes mellitus and diabetes insipidus, chronic respiratory conditions, mental and behavioural disorders, epilepsy, Parkinson's disease,

Fig. 4.2.2 EU Twinning project "Support for Establishing the State Control Authority in the Pharmaceutical Sector of Ukraine" (2025–2027)



post-transplant therapy, endocrine disorders, metabolic, autoimmune and inflammatory diseases, migraines, certain pediatric conditions, treatment of oncological diseases for patients with hormone-dependent breast cancer and patients with non-hormone-dependent breast cancer, as well as treatment of pregnant and postpartum women and palliative care. Since October 2023, the programme has also included medical devices, such as blood glucose test strips.

By the end of 2024, the reimbursement list covers over 70 international nonproprietary names (INNs) and fixed combinations of active substances. The programme's scale has more than doubled over five years:

- 2019 — 258 SKU;
- 2024 — 596 SKU.

In 2024, doctors issued an average of 1.3 million electronic prescriptions per month, with over 1.1 million fulfilled in pharmacies (an 85.8% redemption rate). Over six years, more than 5.8 million patients have benefited from the programme. In 2024 alone, the NHSU compensated pharmacies nearly UAH 5.6 billion (≈ €127 million), of which UAH 2.6 billion covered insulin reimbursement (Fig. 4.4.1). The total allocation for the programme in 2024 amounted to UAH 5.6 billion, increasing to UAH 6.6 billion in 2025 (≈ €150 million).


In 2024, the NHSU compensated pharmacies nearly UAH 5.6 billion, increasing to UAH 6.6 billion in 2025

Future plans include expanding reimbursement for medicines treating mental and behavioural disorders, ensuring access to essential therapies free of charge or with minimal co-payment.

Future expansion plans for the program are as follows:

- 2026 — combination cardiovascular medicines (further expansion), anticoagulants, type 2 diabetes (oral therapy) — expansion of the National Essential Medicines List;

Fig. 4.4.1 Dynamics of funds compensated to pharmacies for drugs released under reimbursement program



Sources: treasury.gov.ua, nszu.gov.ua.

- 2026–2027 — review of the pricing model for insulin products and originator medicines (potentially starting in 2025);
- 2027 — expansion of the list of pain management medicines, reimbursement of medical devices (self-monitoring tools for patients with diabetes, etc.), inclusion of medicines from centralized procurement programs (oncology), and provision of treatment for patients with human immunodeficiency virus (HIV) and hepatitis.

5 TAX AND INVESTMENT CLIMATE OF UKRAINE

5.1. TAX SYSTEM AND BUSINESS TAXATION IN UKRAINE

5.1.1. TAX REGULATION

The key priorities defining Ukraine's tax policy include:

- harmonisation of Ukrainian tax legislation with EU law;
- support for the Armed Forces and taxpayers under martial law;
- digitalisation of tax services.

Both the legislative and executive branches are involved in the formation and implementation of tax policy. The Ministry of Finance of Ukraine is responsible for developing tax policy and coordinating its implementation, while the State Tax Service of Ukraine (STS) directly implements this policy through the administration of taxes and fees.

Ukraine's tax legislation is fully codified and consolidated within the Tax Code of Ukraine, which defines the country's tax system and regulates tax administration matters. With respect to taxation of operations involving the movement of goods across the customs border of Ukraine, the Tax Code of Ukraine (TCU) is supplemented by the Customs Code of Ukraine (CCU) and other customs-related laws. In addition, international treaties ratified by the Verkhovna Rada of Ukraine, particularly those on the avoidance of double taxation, constitute an integral part of the tax legislation.

The government promptly responds to the current needs of taxpayers by reducing the tax burden, including through temporary tax relief measures during martial law

The current Ukrainian tax system includes 12 taxes and fees, among which are:

- National direct taxes: corporate income tax (CIT), personal income tax (PIT), and military levy (ML) [1];
- National indirect taxes: value-added tax (VAT) and excise tax;
- Customs duties;
- Environmental tax and rent payments;
- Local taxes: property tax, unified tax, parking fee, and tourist tax.

An important component of the fiscal system is the single social contribution (SSC) to the compulsory state social insurance, which has an insurance nature and finances extrabudgetary social insurance funds (such as the Pension Fund and others) [2].

The SSC is paid by employers on behalf of their employees and by self-employed individuals.

Since the beginning of the full-scale invasion on 24 February 2022, Ukraine has not introduced any new taxes. The government promptly responds to the current needs of taxpayers by reducing the tax burden, including through temporary tax relief measures during martial law. The only significant change during this period for a wide category of taxpayers was the increase of the military levy rate from 1.5% to 5%.

At the same time, attracting large-scale private investment necessary for post-war recovery requires a transparent, stable, and business-oriented fiscal policy. The Government of Ukraine has already demonstrated a strategic long-term approach by adopting the National Revenue Strategy until 2030 [3], which provides for comprehensive alignment of tax and customs legislation with EU standards. This document ensures the predictability of fiscal policy, essential for both domestic and international investors.

5.1.2. GENERAL OVERVIEW OF THE TAX ENVIRONMENT FOR BUSINESS

Depending on the form of business organisation, a taxpayer (economic entity) may carry out entrepreneurial activity either as an individual entrepreneur

or as a legal entity. The following table illustrates various business models from the perspective of tax burden and highlights the differences between the general and simplified taxation systems (Table 5.1.2.1).

5.1.3. CORPORATE INCOME TAX

The standard corporate income tax (CIT) rate is 18%. Taxable profit is determined based on financial reporting prepared either under

- National Accounting Standards (NAS) or
- International Financial Reporting Standards (IFRS).

These indicators are subsequently adjusted by so-called tax differences, as provided in Articles 138–141 of the Tax Code of Ukraine (TCU), to increase or decrease the financial result. Such adjustments are necessary to avoid double taxation and prevent tax evasion.

For instance, depreciation is calculated in accordance with accounting standards, but for tax purposes, taxpayers applying tax differences must make specific adjustments regarding the definition of fixed assets, minimum useful lives, and other parameters. However, taxpayers whose annual income from any activity does not exceed UAH 40 million are entitled not to apply such tax differences.

The standard corporate income tax (CIT) rate is 18%

CIT payers are allowed to carry forward losses to subsequent periods following the period in which tax losses were incurred. However, large taxpayers [4] may reduce their taxable profit by no more than 50% of the unutilised loss amount from previous periods (until fully offset).

An increase in share capital does not affect income and/or expenses of either the shareholder or the recipient company for CIT purposes. Submission of consolidated tax reporting is not required.

The tax legislation does not provide for industry-specific CIT incentives for the pharmaceutical sector. Nevertheless, general tax incentive mechanisms that may be used for investment in this industry are discussed in a subsequent subsection.

5.1.4. VALUE-ADDED TAX

The standard VAT rate is 20%. Reduced VAT rates apply as follows:

- 14% — for certain types of agricultural products (raw materials);
- 7% — for the supply of medicinal products, cultural and sports services, and hotel accommodation services.

Table 5.1.2.1 Overview of Taxation Regimes for Individual Entrepreneurs and Legal Entities

Legal Entity	Individual Entrepreneur	System of Taxation
General Taxation System	PIT — 18% of net income ML — 5% of net income SSC — 22% of net income + VAT	CIT — 18% of profit + VAT
Simplified Taxation System (Group 2, Unified Tax)	Unified Tax — up to 20% of the minimum monthly wageML — 10% of the minimum monthly wageSSC — 22% of the minimum contribution baseVAT — not applicable	Not applicable
Simplified Taxation System (Group 3, Unified Tax)	Unified Tax — 5% of income (without VAT) or 3% of income (+ VAT) ML — 1% of income SSC — 22% of the minimum contribution base	Unified Tax — 5% of income (without VAT) or 3% of income (+ VAT) ML — 1% of income

Exports of goods are subject to a 0% rate.

Operations taxed at 7% VAT include the supply and importation into Ukraine of medicinal products and medical devices, provided that:

- the medicinal products are authorised for manufacture and use in Ukraine and listed in the State Register of Medicinal Products;
- the medical devices are authorised for placement on the market and/or for use in Ukraine and are listed in the State Register of Medical Equipment and Medical Devices, or comply with the relevant technical regulations, as confirmed by a conformity certificate.

Additionally, operations taxed at the 7% rate include:

- the supply and importation of medicinal products, medical devices, and/or medical equipment authorised for use in clinical trials approved by the Ministry of Health of Ukraine (MoH);
- the importation of unregistered medicinal products within expanded access programmes for patients and/or post-trial access programmes to investigational medicinal products.

The amount of VAT payable to the state budget or refundable to the taxpayer is calculated as the difference between output VAT and input VAT.

The standard VAT rate is 20%. A reduced VAT rate of 7% applies to the supply of medicinal products

If the result is positive (output VAT exceeds input VAT), the difference is payable to the budget.

If the result is negative (input VAT exceeds output VAT), the difference may be:

(a) offset against VAT arrears;

(b) refunded from the budget upon the taxpayer's request; or

(c) carried forward to the next reporting period as input VAT.

The VAT refund mechanism is available to all VAT payers. A VAT payer has the right to claim a budget refund if it has opted for reimbursement and submits a tax return together with a refund application, both of which are reflected in the declaration. Upon submission of a return claiming VAT reimbursement, a desk audit (and, in some cases, a documentary audit) is carried out.

Ukraine has achieved significant progress in combating VAT-related corruption and fraud, particularly through digitalisation. The country has introduced the Electronic VAT Administration System (EVAS) and the System for Suspension of Tax Invoice Registration (SSITIR), which are interconnected and designed to ensure the timely reimbursement of VAT from the budget.

Ukraine has achieved significant progress in combating VAT-related corruption and fraud, particularly through digitalisation

SSITIR monitors the movement of tax invoices issued for every VAT-taxable good or service and functions as a preventive control mechanism, detecting potential abuse and preventing unjustified formation of tax credit even before the VAT declaration is submitted, at the stage of invoice registration.

5.1.5. EXCISE TAX

As the production of certain medicinal products involves the use of alcohol, it should be noted that ethyl alcohol is classified as an excisable good. The excise tax rate for ethyl alcohol under codes 2207 and 2208 of the Ukrainian Classification of Foreign Economic Activities (UCFEA) is UAH 133.31 per litre of 100% alcohol.

However, a special administration mechanism applies to pharmaceutical manufacturers through the use of tax promissory notes.

To obtain ethyl alcohol from an excise warehouse at a preferential rate of UAH 0 per litre of 100% alcohol, a manufacturer of medicinal products intending to use ethyl alcohol for the production of medicines (including blood components and derivatives thereof, but excluding medicines in the form of balms and elixirs) must issue a tax promissory note for the amount of tax calculated on the volume of alcohol received, based on the standard excise tax rate of UAH 133.31 per litre of 100% alcohol. Such a tax promissory note is issued for a period of up to 180 calendar days. The distribution of ethyl alcohol for the manufacture of medicinal products is regulated by Government-established quotas [5].

To ensure control over the intended use of alcohol, tax posts are established at enterprises that use alcohol under the zero-rate regime, providing continuous direct oversight. In cases of misuse of ethyl alcohol obtained as raw material for the production of medicinal products, the enterprise is subject to a penalty calculated based on the volume of misused alcohol and the excise tax rate, increased by a factor of 1.5.

Accordingly, a manufacturer of medicinal products acquires the status of an excise taxpayer only in the event of misuse of ethyl alcohol.

5.1.6. TAXATION OF PASSIVE INCOME OF NON-RESIDENT COMPANIES AND AVOIDANCE OF DOUBLE TAXATION

The taxation of passive income such as interest, royalties, and dividends received by non-residents from Ukrainian sources is governed by Article 141 of the Tax Code of Ukraine (TCU).

A resident making a payment of income to a non-resident or its authorised representative must withhold tax from such income at a rate of 15% of the amount paid (at the expense of the recipient) and remit it to the state budget at the time of payment, unless otherwise provided by an international double taxation treaty between Ukraine and the country of residence of the recipient.

As of 2025, Ukraine has concluded 70 bilateral double taxation treaties with other states, including all EU Member States

As of 2025, Ukraine has concluded 70 bilateral double taxation treaties with other states, including all EU Member States.

Some of these treaties establish reduced withholding tax rates on income derived by non-residents from Ukrainian sources — for example, 2%, 5%, 7%, or 10%, depending on the treaty.

Thus, subject to the requirements set out in the TCU and the relevant international treaty, interest, royalties, and dividends paid to non-residents are subject to taxation either at the statutory rate of 15% or at a reduced rate provided for by the applicable treaty.

5.1.7. TRANSFER PRICING AND COOPERATION WITH NON-RESIDENTS

As a member of the OECD/G20 Inclusive Framework, Ukraine has undertaken commitments to implement the BEPS Action Plan. Although Ukraine has made significant progress in implementing BEPS measures, further refinement of transfer pricing (TP) rules in line with the latest OECD Guidelines is needed to ensure full BEPS alignment.

Transfer pricing rules have been in force in Ukraine since 1 September 2013 and apply exclusively for determining the taxable profit base for corporate income tax (CIT) purposes.

Transactions that qualify as controlled transactions for TP purposes, and where the pricing does not comply with the arm's length principle, result in increasing tax adjustments.

A transaction is considered controlled if it simultaneously meets all of the following criteria:

- It affects the taxpayer's CIT base;
- One of the parties to the transaction is a non-resident meeting certain criteria (e.g., a related non-resident entity, intermediary, resident of a non-cooperative jurisdiction, or an entity not subject to corporate income tax in its home country);
- The taxpayer's annual revenue from any activity exceeds UAH 150 million (net of indirect taxes) for the relevant year;
- The total volume of transactions with each counterparty exceeds UAH 10 million (net of indirect taxes) per year.

Additionally, transactions between a non-resident and its permanent establishment in Ukraine are considered controlled if their annual volume exceeds UAH 10 million. The Ukrainian definition of a permanent establishment aligns broadly with that found in double taxation treaties.

As a member of the OECD/G20 Inclusive Framework, Ukraine has undertaken commitments to implement the BEPS Action Plan

Moreover, thin capitalisation rules apply to loans obtained from non-residents. Specifically, if a taxpayer's debt liabilities to non-residents exceed its equity by more than 3.5 times, the taxpayer must increase its taxable profit by the amount of interest accrued under such debt obligations exceeding 30% of the sum of the taxable profit (before interest and depreciation), financial expenses, and depreciation according to financial statements.

Ukraine has also implemented Controlled Foreign Company (CFC) rules. A CFC is any legal entity registered abroad that is controlled by a Ukrainian resident (individual or legal entity). Legislative amendments to harmonise Ukrainian CFC rules with the EU Anti-Tax Avoidance Directive (ATAD) are expected by 2026.

5.1.8. INTERNATIONAL COOPERATION IN TAX MATTERS AND AUTOMATIC EXCHANGE OF TAX INFORMATION

Ukraine is a party to the Convention on Mutual Administrative Assistance in Tax Matters, ratified by the Law of Ukraine No. 677-VI of 17 December 2008.

In 2018, Ukraine also acceded to the Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting (MLI), extending its application to all double taxation treaties in force at the time of accession [6].

Ukraine participates in the automatic exchange of financial account information in accordance with the OECD Common Reporting Standard (CRS)

Ukraine participates in the automatic exchange of financial account information in accordance with the OECD Common Reporting Standard (CRS). On 19 August 2022, the State Tax Service of Ukraine (STS), acting as the competent authority, signed the Multilateral Competent Authority Agreement (MCAA) on the Automatic Exchange of Financial Account Information and conducted its first international exchange in 2024.

Furthermore, on 3 November 2022, Ukraine joined the Multilateral Competent Authority Agreement on the Automatic Exchange of Country-by-Country Reports (CbCR), with the first exchange scheduled for 2026.

5.1.9. SPECIAL REGIMES AND INVESTMENT INCENTIVES

To stimulate investment activity in Ukraine, several special regimes and incentive mechanisms are in place, which may be used for investment in the pharmaceutical and R&D sectors (Table 5.1.9.1).

Here are several successful examples of investment projects involving significant capital investments.

To stimulate investment activity in Ukraine, several special regimes and incentive mechanisms are in place, which may be used for investment in the pharmaceutical and R&D sectors

One such project is LLC "ASTARTA Agro Protein", with a total investment volume exceeding UAH 3.3 billion (EUR 76.6 million). The project envisages the creation of a modern facility for the advanced processing of soybeans, enabling the production of a new high-quality product and increasing added value in the agro-industrial sector. To implement the project, a special

Table 5.1.9.1 Special Investment Regimes and Incentive Mechanisms Applicable to the Pharmaceutical and R&D Sectors in Ukraine

Comparison Criteria	Diia City	Industrial Parks	Significant Investment Projects
Legal Framework	Law of Ukraine "On Stimulating the Development of the Digital Economy in Ukraine"	Law of Ukraine "On Industrial Parks"	Law of Ukraine "On State Support for Investment Projects with Significant Investments in Ukraine"
Eligibility Criteria	Conduct of eligible activities generating >90% of total income; ≥9 employees or gig specialists; average salary > EUR 1,200	Resident entity registered within an Industrial Park; ownership rights to real estate within the Park; activity limited to manufacturing industry	Investment project in the manufacturing sector involving construction, modernisation, or re-equipment of facilities with investment > EUR 12 million over 5 years and creation of new jobs
Duration	At least until 2047	Unlimited	Until 1 January 2035
Applicable to the Pharma Sector	R&D in pharmaceuticals and MedTech (e.g., production of bionic prostheses) [7]	Manufacture of basic pharmaceutical products and preparations	Manufacture of basic pharmaceutical products and preparations
CIT Incentives	Replacement of CIT with a 9% tax on withdrawn capital	Exemption from CIT on income derived from manufacturing activities within the Park for 10 years; prohibition on dividend distribution	CIT exemption for 5 years under a special investment agreement
Customs and VAT Incentives	None [10]	Exemption from import VAT and customs duties on new (≤3 years old) equipment and components imported for own use [8]	Exemption from import VAT and customs duties on new equipment and components imported under an investment agreement [9]
PIT and SSC Incentives	PIT at 5% (instead of 18%) for employees and gig specialists; SSC 22% of minimum base	None	None
Land Tax Incentives	None	Local authorities may reduce or exempt land tax and property tax on non-land assets	Same as for Industrial Parks
Other Non-Tax Incentives	Gig contracts, elements of English law (convertible loans, options, indemnities, etc.)	Interest rate compensation, financing for park infrastructure, reimbursement of utility connection costs	Priority access to land and reimbursement or state funding for infrastructure construction

investment agreement was concluded between the Cabinet of Ministers of Ukraine, LLC "Astarta-Kyiv," and LLC "Astarta Agro Protein" (Resolution of the CMU dated 04.10.2024 No. 945-r).

The state provided support in the form of exemptions from corporate income tax, import duties, and value-added tax. The total amount of state support is estimated at UAH 945.7 million (EUR 19.4 million).

It is expected that by 2032, revenues to budgets of all levels will amount to UAH 3.8 billion (EUR 77.9 million), while the agreement is valid until 31 December 2034.

Another example is the investment project of LLC "AQUAPARK," implemented at the Bukovel tourist resort. Its goal is to promote and develop domestic tourism in Ukraine through the construction of a modern water park. The total investment volume amounts to UAH 883.4 million (EUR 21.4 million). According to CMU Resolution dated 04.10.2024 No. 946-r, a special investment agreement was also concluded between the Cabinet of Ministers of Ukraine, LLC "Bukovel," and LLC "Aquapark."

State support was provided in the form of corporate income tax exemption totaling UAH 224.5 million (EUR 4.6 million). According to projections, between 2024 and 2033, revenues to budgets of all levels will reach UAH 1.66 billion (EUR 34 million), and the agreement is valid until 31 December 2031.

Successful examples are also demonstrated by the industrial parks mechanism.

Participants of the "Fastindustry" Industrial Park in Kyiv Region have received the following benefits throughout the operation of the park:

- UAH 3.2 million (EUR 65,000) in land lease reductions;
- UAH 6.42 million (EUR 131,000) in customs duty exemptions;
- UAH 42.7 million (EUR 875,000) in VAT exemptions.

During the same period, total investments amounted to UAH 306 million (EUR 6.3 million).

It is noteworthy that the industrial park hosts manufacturers producing food-grade packaging for numerous Ukrainian companies, as well as paper cups supplied to fast-food chains across the European Union.

Another strong example is the "Friendly Wind Technology" Industrial Park in Zakarpattia Region, which not only became a shelter for a relocated enterprise from Donbas — a manufacturer of wind turbine blades — but also actively utilizes tax and customs incentives, including an import duty exemption of UAH 58.2 million (EUR 1.2 million). The total investment volume in the enterprise has reached UAH 1.76 billion (EUR 36 million).

5.1.10. PROSPECTS AND RECOMMENDATIONS FOR INVESTORS IN TAX POLICY

Ukraine's tax legislation is evolving in line with the directions and priorities defined in the National Revenue Strategy until 2030. The upcoming amendments to the Tax Code of Ukraine will focus on updating transfer pricing rules in accordance with the OECD Guidelines and implementing Council Directive (EU) 2016/1164 of 12 July 2016, which lays down rules against tax avoidance practices that directly affect the functioning of the internal market (ATAD).

Prospective foreign investors in the pharmaceutical industry are advised to verify whether a valid double taxation avoidance treaty exists between Ukraine and the investor's country of residence [10], as well as to determine the appropriate structure of related entities and supply chains.

In addition, investors should assess the advantages and potential limitations of Ukraine's existing special regimes and investment

incentives in terms of their applicability to the planned business activities.

The National Revenue Strategy until 2030 provides for the use of tax incentives to support post-war recovery, as well as balanced incentives to promote the development of the processing industry

It is also essential to monitor ongoing legislative developments in Ukraine. In particular, it should be noted that on 14 November 2025, the Verkhovna Rada of Ukraine adopted at first reading a package of draft laws amending Ukraine's tax and customs legislation to introduce investment compensation through tax mechanisms, aiming to stimulate the development of the processing industry (which includes the production of pharmaceutical products and preparations [11].

However, given the negative assessment of these initiatives by the IMF, it is currently difficult to predict their further legislative prospects.

At the same time, the National Revenue Strategy until 2030 provides for the use of tax incentives to support post-war recovery, as well as balanced incentives to promote the development of the processing industry. Therefore, it can be argued that these legislative initiatives indicate the Government's continued focus on identifying an optimal model for stimulating investment, and that this search remains ongoing.

5.2. CUSTOMS SYSTEM AND IMPORT REQUIREMENTS IN UKRAINE

5.2.1. CUSTOMS REGULATION

Despite the serious challenges caused by Russian aggression, Ukraine is actively working to create favourable conditions for facilitating international trade, increasing the volume of goods crossing its customs border, and aligning national legislation with EU law. This includes simplifying customs procedures, developing customs infrastructure, and improving the qualifications of customs officers.

Ukraine is a member of the World Trade Organization (WTO). In 2015, Ukraine ratified the Trade Facilitation Agreement, confirming its strong commitment to improving its trade and investment climate.

Ukraine is also a member of the World Customs Organization (WCO) and a contracting party to several WCO conventions, including the Convention Establishing the Customs Cooperation Council, the International Convention on the Harmonized Commodity Description and Coding System, and the Convention on Temporary Admission (Istanbul, 1990), among others.

Ukraine is actively working to create favourable conditions for facilitating international trade, increasing the volume of goods crossing its customs border, and aligning national legislation with EU law

Since 1 October 2022, Ukraine has been a member of the Convention on the Simplification of Formalities in Trade in Goods and the Common Transit Convention (NCTS). This membership allows Ukrainian businesses to transport goods in transit through the territories of 37 member countries (including the EU Member States, the United Kingdom, Turkey, Serbia, North Macedonia, Iceland, Norway, Liechtenstein, Switzerland, and Georgia) using a single transit document and without intermediate customs control by the customs administrations of those countries. This system reduces customs clearance costs, shortens processing time, and accelerates delivery from sender to recipient.

5.2.2. GENERAL PROVISIONS

Ukraine's customs legislation consists of the Customs Code of Ukraine (CCU), the Tax Code of Ukraine (TCU), other Ukrainian laws, international treaties, and regulatory acts issued under and in execution of these laws.

Goods crossing the customs border of Ukraine are subject to customs control and clearance, performed by the customs authorities.

Under Ukrainian customs law, customs authorities include the State Customs Service of Ukraine (SCS), customs offices, and customs posts.

The SCS is the central executive body implementing state customs policy, directing, coordinating, and overseeing the activities of customs offices, and exercising other powers defined by customs legislation. Customs offices and posts apply customs law within their designated areas of operation.

Contact information for Ukrainian customs authorities is available at: https://customs.gov.ua/contacts.

Any person intending to engage in activities governed by Ukrainian customs law must be registered with the customs authorities. Registration involves assigning a unique identification number, automatically generated in the relevant register after all necessary data are entered [12].

Failure to register persons engaged in operations with goods constitutes grounds for refusal of customs clearance.

5.2.3. PLACE OF CUSTOMS CLEARANCE

Customs clearance of goods is carried out at any customs authority upon presentation of the goods, unless otherwise provided by law.

Clearance is performed at the locations of the respective customs units during their established working hours.

Ukrainian law permits customs control and clearance outside the location or working hours of customs authorities in specific cases defined by Articles 247 and 249[1] of the CCU.

5.2.4. CUSTOMS PAYMENTS

Goods imported into Ukraine for free circulation are subject to customs payments, which include import duty, value-added tax (VAT), and excise tax on imported goods.

Import duty is levied on goods brought into Ukraine's customs territory, with rates established in the Customs Tariff of Ukraine.

The rules for imposing VAT and excise tax on goods crossing the customs border are defined in the Tax Code of Ukraine.

There is no export duty imposed on the export of pharmaceutical products from Ukraine.

> ***Goods imported into Ukraine for free circulation are subject to customs payments, which include import duty, value-added tax (VAT), and excise tax on imported goods***

Goods placed under customs regimes such as transit, customs warehouse, free customs zone, duty-free trade, or processing in the customs territory benefit from conditional full exemption from customs payments.

Goods may be placed under the temporary importation regime with full or partial exemption from customs duties.

5.2.5. CLASSIFICATION AND ORIGIN OF GOODS

To calculate customs payments due upon importation, three key factors must be considered:

- The value of the goods;
- The commodity code;

- The country of origin.

Classification of goods for customs purposes is carried out according to the Ukrainian Classification of Goods for Foreign Economic Activity (UCGFEA), which forms the commodity nomenclature of the Customs Tariff of Ukraine. This classification follows the General Rules for the Interpretation of the UCGFEA and relies on the defining characteristics of the product. To ensure uniform interpretation and application, Ukraine has introduced official Explanatory Notes to the UCGFEA [13].

Rules of origin determine the country where a product was either wholly obtained or underwent sufficient processing. There are two types of origin rules: non-preferential and preferential.

The Customs Code of Ukraine sets out non-preferential rules of origin, used to determine the country of origin of goods crossing the customs border for the purpose of applying duty rates, granting most-favoured-nation (MFN) treatment, and implementing non-tariff measures in line with WTo requirements.

5.2.6. CUSTOMS PREFERENCES

Preferential rules of origin determine whether a product qualifies as originating from a country with which a preferential trade agreement exists.

If all agreement conditions are met, goods with preferential origin may be imported into Ukraine duty-free, at reduced duty rates, or within tariff quotas, depending on the applicable agreement.

Ukraine, like the European Union, is a party to the Regional Convention on Pan-Euro-Mediterranean Preferential Rules of Origin (PEM Convention), which has applied to bilateral trade between Ukraine and the EU since 2019.

As Ukraine's international trade relations are continually evolving, it is recommended to consult official sources for up-to-date information on preferential agreements in force.

In addition, importers may benefit from other customs exemptions.

Pharmaceutical products and substances used for their manufacture — not produced in Ukraine and classified under Chapters 28, 29, and 30 of the UCGFEA — are exempt from import duty according to a list approved by the Cabinet of Ministers of Ukraine [14].

5.2.7. TRADE DEFENCE INSTRUMENTS

To protect Ukraine's economic interests and domestic producers, the following special types of duties may be imposed on imported goods, independently of other duties:

- Special duty;
- Anti-dumping duty;
- Countervailing duty;
- Additional import levy.

5.2.8. IMPORT REQUIREMENTS FOR MEDICINAL PRODUCTS FOR HUMAN USE

Medicinal products registered in Ukraine may be imported in accordance with national legislation, subject to the availability of:

- A certificate of quality for the batch issued by the manufacturer;
- An import licence for medicinal products (excluding APIs) issued to the importer (the manufacturer or its authorised representative in Ukraine).

The shelf life of imported medicines must be at least half of that set by the manufacturer (if the total shelf life is under one year), or at least six months (if the total shelf life exceeds one year).

All medicinal products imported for sale or for use in the manufacture of finished medicines are subject to state quality control [15].

All medicinal products imported for sale or for use in the manufacture of finished medicines are subject to state quality control

Unregistered medicinal products may be imported into Ukraine for:

- Transit through Ukraine or placement under the customs warehouse regime for subsequent re-export, provided they are registered in the country of manufacture, accompanied by a quality certificate, and do not violate the Council of Europe Convention on Counterfeiting of Medical Products and Similar Crimes (MEDICRIME Convention). Such products must be re-exported at least six months before their expiry date;
- Preclinical studies and clinical trials;
- Registration of medicinal products in Ukraine (samples in finished dosage forms);
- Exhibition at fairs, conferences, etc. (without the right of sale);
- Medical supply (without the right of sale) for foreign military units legally admitted to Ukraine;
- Treatment of rare (orphan) diseases upon decision of the central health authority, applicable only to medicines developed exclusively for such conditions and authorised for use in the US or EU Member States, regardless of registration status in those jurisdictions;
- Personal use by individuals;
- Procurement by authorised healthcare purchasing agencies for national health programmes or managed access agreements, regardless of funding source, as defined by the Law of Ukraine "On Medicinal Products" [16].

5.2.9. PROSPECTS FOR THE DEVELOPMENT OF CUSTOMS REGULATION IN UKRAINE

Ukraine is actively implementing the norms of EU customs legislation into its national framework.

In April 2025, amendments to the Customs Code of Ukraine (Law No. 3926-IX of 22 August 2024) came into effect, introducing EU-aligned provisions, including:

- The concept of customs representation;
- New types of customs warehouses and storage periods;
- Authorisations for customs regimes such as temporary importation and processing (both within and outside Ukraine's customs territory).

Ukraine is actively implementing the norms of EU customs legislation into its national framework

By the end of 2027, a new Customs Code of Ukraine is expected to enter into force, fully aligning national customs law with the EU Customs Code and establishing the legislative basis for all customs IT systems Ukraine will need upon EU accession.

5.2.10. CHALLENGES IN THE FIELD OF CUSTOMS REGULATION

Due to the Russian aggression, 3 of 26 regional customs offices are currently non-operational, and 13 operate partially.

The Government has also temporarily closed several border crossing points, including all air checkpoints, as Ukraine's airspace remains closed to civil aviation.

Up-to-date information on active border crossing points is available on the official website of the State Border Guard Service of Ukraine: https://dpsu.gov.ua/uk/map.

References

1. A temporary tax introduced in 2014 under paragraph 16-1 of Subsection 10, Section XX of the Tax Code of Ukraine.
2. Since the Unified Social Contribution (USC) is not part of Ukraine's tax system, its collection procedure is regulated not by the Tax Code but by the Law of Ukraine "On Collection and Accounting of the Unified Contribution for Mandatory State Social Insurance."
3. National Revenue Strategy until 2030, approved by the Order of the Cabinet of Ministers of Ukraine dated December 27, 2023, No. 1218-r. Available: https://mof.gov.ua/storage/files/National%20revenue%20strategy%20.pdf.
4. A large taxpayer is a legal entity or a permanent establishment of a non-resident in Ukraine whose total income from all activities over the last four consecutive quarters exceeds the equivalent of EUR 50 million, or whose total payments to the State Budget of Ukraine during the same period exceed the equivalent of EUR 1.5 million.
5. Resolution of the Cabinet of Ministers of Ukraine dated January 5, 2011, No. 19 "Issues of the Use of Ethyl Alcohol for the Production of Medicinal Products." Available: https://zakon.rada.gov.ua/laws/show/19-2011-%D0%BF#n16.
6. Consolidated texts on the application of Ukraine's international treaties on the avoidance of double taxation. Available: https://mof.gov.ua/uk/mli-441.
7. Types of activities according to the Resolution of the Cabinet of Ministers of Ukraine dated April 19, 2022, No. 467 "On Determining the Types of Activities Stimulated by the Creation of the Legal Regime Diia City." Available: https://zakon.rada.gov.ua/laws/show/467-2022-%D0%BF#n8.
8. The benefit applies to goods under the codes of the Ukrainian Classification of Foreign Economic Activity (UCC FEA) in accordance with part six of Article 287 of the Customs Code of Ukraine.
9. The benefit applies to goods under the codes of the Ukrainian Classification of Foreign Economic Activity (UCC FEA) pursuant to subparagraph 15 of paragraph 4, Section XXI of the Customs Code of Ukraine.
10. Texts of Ukraine's international treaties on the avoidance of double taxation are available on the website of the Ministry of Finance of Ukraine. Available: https://mof.gov.ua/uk/international_agreements_of_ukraine_on_avoidance_double_taxation-543.
11. Draft Law No. 13415 (available: https://itd.rada.gov.ua/billinfo/Bills/Card/56646) and Draft Law No. 13414 (available: https://itd.rada.gov.ua/billinfo/Bills/Card/56645).
12. Procedure for the registration of persons participating in customs-related legal relations, approved by the Order of the Ministry of Finance of Ukraine dated June 15, 2015, No. 552. Available: https://zakon.rada.gov.ua/laws/show/z0807-15#Text.
13. Explanatory Notes to the Ukrainian Classification of Foreign Economic Activity (UCC FEA), approved by the Order of the State Customs Service of Ukraine dated December 14, 2022, No. 543. Available: https://customs.gov.ua/documents/pro-zatverdzhennia-poiasnen-do-ukrayinskoyi-klasifikatsiyi-tovariv-zovnishnoekonomichnoyi-diialnosti-321.
14. Resolution of the Cabinet of Ministers of Ukraine dated November 17, 2004, No. 1568 "Issues of Exemption from Import Duty on Pharmaceutical Products and Compounds Used for Their Manufacture Not Produced in Ukraine." Available: https://zakon.rada.gov.ua/rada/show/1568-2004-%D0%BF#n9.
15. Resolution of the Cabinet of Ministers of Ukraine dated September 14, 2005, No. 902 "On Approval of the Procedure for State Quality Control of Medicinal Products Imported into Ukraine." Available: https://zakon.rada.gov.ua/rada/show/902-2005-%D0%BF#Text.
16. As of the date of preparation, the effective law is the Law of Ukraine "On Medicinal Products" dated April 4, 1996, No. 123/96-VR. Available: https://zakon.rada.gov.ua/laws/show/123/96-%D0%B2%D1%80#Text.

6 UKRAINE: A KEY MARKET IN CENTRAL AND EASTERN EUROPE

6.1. UNIQUE ASSETS POWERING UKRAINE'S PHARMACEUTICAL SECTOR

1. **Scalable Production** — 100+ manufactures, GMP compliant, strong domestic champions, modern production lines, export ready infrastructure reaching 70+ global markets reach.
2. **Skilled Talents** — > 40 leading universities and higher-education institutions with modern laboratories, co-operation with pharma industry, digital educational platforms in place.
3. **Strong Chemical Base** — EUCI (Energy, Utility, and Infrastructure) backed industry with in-house APIs.
4. **Resilience** — unique war-related crisis management know-how, regulatory agility and diversified logistics networks.
5. **Energy Stabilization** — nuclear energy sourcing and emergency backup, integration with EU energy networks for reliability.
6. **EU Integration** — regulatory alignment and VAT harmonization in place, supply chain advantages for European market access.

Fig. 6.1.1 Ukraine in the CEE Pharma Landscape: Scale, Market Value, and Growth Potential

Region	Country	Pharma market value (mEUR)	% of total CEE pharma market	% of total CEE GDP
CEE	Total CEE	42212	100.0%	100.0%
	POLAND	12697	30.1%	31.1%
	ROMANIA	6040	14.3%	13.7%
	CZECHIA	4706	11.1%	12.4%
	HUNGARY	3333	7.9%	8.2%
	UKRAINE	3142	7.4%	6.6%
	BULGARIA	2593	6.1%	3.9%
	SLOVAKIA	2078	4.9%	5.1%
	CROATIA	1585	3.8%	3.2%
	SERBIA	1510	3.6%	3.0%
	LITHUANIA	1166	2.8%	3.0%
	SLOVENIA	1003	2.4%	2.6%
	LATVIA	542	1.3%	1.6%
	BOSNIA	502	1.2%	1.0%
	ESTONIA	436	1.1%	1.6%
	MOLDOVA*	287	0.7%	0.7%
	MACEDONIA*	217	0.5%	0.6%
	ALBANIA*	209	0.5%	0.9%
	MONTENEGRO*	109	0.3%	0.3%
	KOSOVO*	57	0.1%	0.4%

*Source: IQVIA Pharma Prognosis, World Bank, IMF, *Countries with no MIDAS coverage excluded from detailed analysis on following pages, Ukraine = Proxima data.*

Pharmaceutical Market Position: Ukraine ranks 5th in CEE by market value, with an estimated €3.1 billion, representing 7.4% of the region (Fig. 6.1.1).


Population Scale: Ukraine is the second-largest country by population in CEE, with approximately 30 million residents and an additional 7 million living abroad (22% of total CEE population).

Economic Context: GDP per capita stands at €5,900, nearly four times lower than the CEE average (€19,500), highlighting significant growth potential.

6.2. MARKET INSIGHTS IN CEE REGION

Protected Rx Products: Nearly 56% of prescription (Rx) products in Central and Eastern Europe (CEE) are protected drugs. Ukraine has the lowest share of protected Rx products at 34%, followed by Serbia (31%) and Bosnia (17%), indicating significant growth potential

Fig. 6.2.1 Pharma market structure (FY 2024, bn LCEUR)



Protected — Rx with market exclusivity (protected) in time-period in-scope, 2024, IQVIA MIDAS
CEE includes Poland, Romania, Czechia, Hungary, Bulgaria, Slovakia, Croatia, Serbia, Lithuania, Slovenia, Latvia, Bosna, Estonia & Ukraine. DATA for Ukraine= MAT09/2024

Source: IQVIA MIDAS, Pharma market includes Retail and Hospital sales. Ukraine = Proxima data.

for innovation—strongly dependent on increased reimbursement budgets (Fig. 6.2.1).

Consumer Health Leadership: Ukraine leads the CEE region in Consumer Health sales value, accounting for 40% of the pharmaceutical market share, followed by the Baltic states:


- **Latvia:** 29%
- **Lithuania:** 26%
- **Estonia:** 24%

6.3. UKRAINIAN PHARMACEUTICAL MARKET OVERVIEW

Local Market Share: Ukrainian companies account for 39% of the total market value share (Fig. 6.3.1).

Top 5 Ukrainian Companies: Farmak, Darnytsia, Arterium, Kyiv Vitamin Factory and Medical Center M.T.K collectively represent over 18% of total sales value.

Fig. 6.3.1 Market share by manufactures presence (2024, bn LCEUR)



Local — with global HQ in the given country from CEE region, Regional — global HQ in the CEE region, International — with global HQ outside CEE
CEE: Poland, Romania, Czechia, Hungary, Bulgaria, Slovakia, Croatia, Serbia, Lithuania, Slovenia, Latvia, Bosna, Estonia, Ukraine.
DATA for Ukraine = MAT09/2024

Source: IQVIA MIDAS, market includes hospital and parmacy sales. Ukraine = Proxima data.

6.4. REGIONAL PLAYERS (CEE)

Primarily generic (Gx) manufacturers and OTC medication experts:

- CEE: 6% share
- Ukraine: 7% share

International Players (CEE) have 54% share.

7 | HUMAN RESOURCES

7.1. OPPORTUNITIES OF UKRAINIAN EDUCATION IN THE FIELD OF PHARMACEUTICALS

Pharmaceutical education is not merely an academic process — it is a strategic investment in the nation's human capital. It develops competent specialists capable of ensuring the rational use of medicines, effective communication with patients, and the advancement of pharmaceutical care and services. Graduates can work in various sectors — from production and quality control to regulatory affairs, clinical practice, or scientific research.

Ukraine has one of the most robust pharmaceutical education systems in Central and Eastern Europe. More than 30 higher education institutions deliver pharmaceutical training, including three key universities that form the core of the country's human capital in this field:

- National University of Pharmacy (Kharkiv) – the largest specialized pharmaceutical institution;
- Danylo Halytsky Lviv National Medical University;
- I. Horbachevsky Ternopil National Medical University.

Pharmaceutical education in Ukraine is aligned with European standards and includes: five years of study in "Pharmacy, Industrial Pharmacy" at the master's level; two to three years of internship for selected clinical and specialized tracks and postgraduate professional education.

Ukraine's pharmaceutical education integrates academic training with practical experience through dual education formats and partnerships with pharmaceutical enterprises

In the modern context of Ukraine's integration into the European pharmaceutical and educational space, the human factor becomes decisive — above all, knowledge, critical thinking, flexibility, and readiness for continuous professional development. The training and development of human resources are among the key factors ensuring the sustainability, efficiency, and adaptability of the national healthcare system. In Ukraine, this aspect gains special significance — both due to the challenges of wartime and in the context of European integration.

Ukraine's system of pharmaceutical education has a number of important advantages and solid foundations. First of all, its regulatory framework is aligned with European standards. The training of pharmacists in Ukraine meets the requirements of Directive 2005/36/EC of the European Parliament and of the Council on the recognition of professional qualifications, harmonised with European qualification criteria in terms of duration of study, mandatory educational components, and competency framework. The specialty 226 "Pharmacy, Industrial Pharmacy" is strictly regulated. Unified national standards govern access to professional practice for educational institutions preparing specialists in this field. At the same time, within the framework of academic autonomy, universities may implement their own educational projects, maintaining individual approaches and unique academic traditions.

Moreover, a comparative analysis of pharmacy education programmes in Ukrainian and several EU universities (Poland, Italy, Sweden, and Germany) — "The Comparative Analysis of Components of Pharmacy Education Programs in Universities of EU Countries and Ukraine" (A. Krychkovska et al., 2024) — confirmed their similarity and demonstrated the possibility for

Ukrainian students to continue studies abroad and integrate into international educational systems.

It is also important that all professional standards in the field of pharmacy have already been developed or are nearing completion, while educational standards have been approved for all levels of pharmaceutical education. The "Strategic Directions for the Development of Pharmaceutical Education in Ukraine", defined within the framework of the Healthcare System Development Strategy until 2030, outline key systemic goals and measures aimed at training competent, socially oriented professionals capable of addressing complex challenges in the healthcare sector.

One of the main strengths of the Ukrainian educational system is its integration of education with practical experience — through the development of dual education formats and active partnerships between higher education institutions and pharmaceutical enterprises or pharmacy chains. This approach allows students to combine theoretical learning with the acquisition of practical skills and gain insights into production, management, and clinical activities.

Ukraine's pharmaceutical education integrates academic training with practical experience through dual education formats and partnerships with pharmaceutical enterprises


In this context, an important step forward is the establishment of Ukraine's first Pharmaceutical Cluster in Kharkiv. It brings together leading scientific institutions and universities to conduct joint research in pharmaceutical chemistry, biotechnology, molecular biology, and pharmacology; to develop active pharmaceutical ingredients; to create domestic test systems; to introduce technologies for manufacturing essential medicines; and to advance quality control systems in accordance with international standards. The pharmaceutical cluster is a working model of cooperation between science, education, and industry that helps to more effectively transform scientific ideas into practical solutions for people. However, the system also faces serious challenges. Martial law, the destruction of infrastructure, and instability of human resources impose additional burdens. Strengthening the educational infrastructure, renewing academic staff, and improving digital competencies remain urgent priorities.

In 2027 Ukraine will launch a new regulatory authority aligned with EU standards. Its mission is to protect public health by ensuring access to high quality, effective and safe medicines, and to support innovation in the sector. To bring this mission to life, Ukrainian universities are already at work, training thousands of professionals ready to scale solutions and collaborate internationally.

The human capital of pharmacists is not merely a workforce — it is a strategic asset of the state, determining its capacity to provide the population with medicines, implement modern pharmaceutical practices, and integrate into the European and global professional community. A systematic, modernised, practice-oriented education that reflects current educational trends, labour market needs, regulatory requirements, and internal national challenges forms the foundation on which the competitiveness, development, and quality of pharmaceutical care in Ukraine are built.

8 LEADING UKRAINIAN MANUFACTURERS OF MEDICINES AND APIS

Pharmaceutical Manufacturing
Map of Ukraine




Farmak



FARMAK

DRIVING QUALITY MEDICINES WORLDWIDE

Farmak is the leading pharmaceutical manufacturer in Ukraine and one of the country's largest exporters. Established in 1925, the company marks its 100th anniversary this year, standing as a cornerstone of Ukraine's modern pharmaceutical industry.

Farmak's portfolio comprises more than 450 medicinal products across all major therapeutic categories. Key areas include endocrinology, gastroenterology, cardiology, respiratory care, neurology, ophthalmology, intensive care, and anaesthesia. The company manufactures medicines in all core dosage forms, including tablets, capsules, sachets, ampoules, vials, nebulas, suppositories, and sprays. Each year, Farmak introduces approximately 20 new products to the market.

The company's R&D infrastructure includes 13 state-of-the-art laboratories staffed by 150 highly qualified specialists, among them 40 PhD holders. Farmak collaborates with over 50 leading scientific institutions and companies worldwide, strengthening its global research capabilities.

Farmak's production footprint includes a high-tech facility for finished dosage forms in Kyiv and an API manufacturing plant in Shostka, Sumy region. In 2026, Farmak will expand its international presence with the launch of a new manufacturing site in Spain, focused on complex generics such as anaesthetics, antithrombotic agents, systemic hormones, psycholeptics, and cardiovascular medicines.

Quality control is ensured through seven specialized laboratories certified to conduct 144 test methods in line with the State Pharmacopoeia of Ukraine, harmonized with the European Pharmacopoeia, British Pharmacopoeia, and US Pharmacopeia. The company consistently reinvests up to 90% of its profits into development, maintaining production and laboratory facilities that comply with stringent EU GMP standards.

Farmak exports its products to 60 countries across the EU, Asia, Central and South America, the Middle East, and Australia. The Farmak Group operates 11 representative, marketing, and distribution companies in Poland, the UAE, Switzerland, the United Kingdom, the Czech Republic, Slovakia, Moldova, Vietnam, Uzbekistan, Kazakhstan and Kyrgyzstan, employing approximately 3,500 people.

Despite the challenges of the full-scale war, Farmak continues to invest in Ukraine. The company is constructing an innovation centre in Kyiv with advanced laboratories, modern production lines, and office spaces. Farmak has also invested nearly €8 million in energy autonomy to ensure uninterrupted manufacturing of essential medicines under any circumstances.

Farmak's mission is to ensure access to modern, effective medicines, enabling people to maintain their health and quality of life. The company remains fully committed to this mission as Ukraine continues to face unprecedented challenges.



We are the leader of Ukrainian pharmaceutical industry, actively transforming into a fully-fledged international company, with the production sites, R&D and laboratories both in Ukraine and the EU; as well as the subsidiaries in the EU, Middle East, Caucasus & Asia. Our daily operations are built upon resilience, innovation and global expansion policy.

Since the full-scale war in Ukraine, we have ensured the uninterrupted manufacturing of critical medicines for the frontline, hospitals and civil people. However, being committed to prioritizing the needs of the domestic market, we still manage to increase our global footprint, already supplying products to 60 countries around the world, including the EU member-states, Latin America, Caucasus, Middle East and Asia. This demonstrates the global recognition of our quality, which adheres to GMP standards.

Farmak focuses on the production of high-quality complex generic drugs – such as anesthesia, MRI Contrast Agents, Intensive Care Medicines, hormones etc.

We believe that strong local pharmaceutical sector is an essential aspect of national security and people's welfare. We have proven our reliability in critical conditions and invite you to join a partnership where resilience meets global ambition.

Volodymyr Kostiuk, CEO





Farmak

A Century-long heritage

Farmak Group is a global pharmaceutical business with deep Ukrainian roots dating back to 1925.

Today the company operates 2 state-of-the-art manufacturing facilities for the ready-to use medicines in Ukraine and Spain; 1 manufacturing site for API's (active pharmaceutical ingredients); as well as subsidiaries and representative offices across 11 countries around the world.

Company's products are produced in compliance with the EU GMP standards.
90% of **Farmak's** profits are annually reinvested in the growth and development of the business, which enables to strengthen position in the international arena.

*by sales of medicines in monetary terms, according to Proxima Research in 2024







Annual production capacity (Ukraine & Spain)

1900 MIO tablets	240 MIO capsules	235 MIO dragees	160 tons of APIs	150 MIO ampoules	155 MIO glass vials	57 MIO plastic bottles
55 MIO soft-shell gelatine capsules	50 MIO sachets	50 MIO syringes	36 MIO nebuls	5 MIO suppositories	4,8 MIO tubes	4,5 MIO catridges

Farmak's Portfolio

We manufacture a wide range of quality generics, with the focus on complex pharmaceuticals & injectables:

- Anesthesia
- MRI Contrast Agents
- Intensive Care Medicines
- Hormones
- Antithrombotic Drugs
- Medicines for the Endocrine System etc.

Across all the therapeutic groups, including:

- Endocrinology
- Gastroenterology
- Cardiology
- Ophthalmology
- Gynecology
- Neurology etc.



Farmak's capacities to manufacture API's and medicines in a full production cycle

- **At the moment, Farmak** manufactures finished medicinal products in a full cycle (using own API's) for 21 INNs
- Current capacities for the production of API's make 200 ton per year
- The company is capable of manufacturing APIs that require complex chemical reactions (e.g. **esterification, bromation, alkylation, nitration, hydrogenation** etc.)
- To focus on API's and full-cycle medicines production, possible investments in the new equipment might require around 300 000 Euro



Farmak's Quality Control

6 laboratories: input quality control of raw materials, output control, microbiological, chromatographic and 2 analytical* laboratories

Stability Testing Zone

Specifications and Method Transfer Department

Control Organization Department

Laboratory Equipment Department

Farmak controls and ensures quality at every stage of production: from incoming raw materials and packaging to finished products and pharmaceuticals shelf-life stability testing.

Medicines go through at least 5 stages of quality control

*Ukraine, Spain









Farmak's Quality Control

- Certified to conduct 144 test methods of the State Pharmacopoeia of Ukraine, which are also listed in the leading pharmacopoeias of the world: European Pharmacopoeia, British Pharmacopoeia, US Pharmacopoeia.
- Laboratories go through up to 10 Ukrainian and foreign inspections per year



Farmak's R&D

€14 MIO of annual investment in R&D

≈20 new medicines launched annually

The R&D* complex includes

- **1** API Synthesis Laboratory
- **1** Biotechnological API Synthesis Laboratory
- **1** Pilot-Scale Unit with the state-of-the-art equipment for production of biotechnological APIs and finished dosage forms

More than 450 units of high-precision equipment

* Ukraine, Spain

5 analytical laboratories
- **2** analytical laboratories for solid dosage forms
- **2** analytical laboratories for liquid dosage forms
- **1** laboratory for special test methods

6 technological laboratories
- **2** laboratories for the development of solid dosage forms
- **4** laboratories for the development of liquid dosage forms

Farmak's R&D




- Development of new medicines and current technology improvements are carried out by **150** highly qualified specialists, **40** of them have doctoral scientific degrees
- Scientific partnerships with more than **50** companies and R&D institutions over the world
- Cooperation with **6** leading Ukrainian universities and Junior Academy of Sciences of Ukraine

Full cycle production – from traditional and biotech APIs to wide range of various finished dosage forms


Global Presence & Distribution

The company's products are exported to over **60 countries** around the world, including EU countries (**Great Britain, Switzerland, Poland, Czech Republic, Slovakia, Bulgaria, Hungary, Portugal, Lithuania, Latvia**), countries in **Central and South America, the Middle East, Asia, Africa, and Australia**.



60 countries worldwide

Around 25% **of the products** manufactured by Farmak in Kyiv are sold outside Ukraine


Farmak
Farmak: Key Takeaways
Farmak may serve a strategic partner that combines a comprehensive portfolio, uncompromising European quality and competitive logistics efficiency
Key competitive advantages:
1. Portfolio including both basic needs generics for hospital and retail sector, as well as complex and hard-to-replicate generics, injectables etc.
2. Experience of developing and manufacturing own API's and medicines in a full production cycle
3. EU GMP certification for all production lines & laboratories
4. Own R&D team
5. State-of-arts manufacturing sites in Ukraine & Spain, digitalized and equipped with the top machinery
6. Robust and extensive distribution chains developed over many years of successful operations in the region.


Farmak
Farmak's options for cooperation include:
• Joint R&R and manufacturing of API's and medicines (including those produced in a full cycle) both, for the needs of private sector and state procurement
• Transfer of technologies / licensing / localization of products, with the focus on innovative and technologically complex medicines (specialization in the manufacture of complex generic dosage forms that require high expertise)
• Distribution of medicines via the company's distribution chains in Ukraine, Caucasus, Middle East & Asia
• Contract manufacturing both, for the needs of private sector and state procurement


DARNYTSIA



DARNYTSIA PHARMACEUTICAL COMPANY

COMPANY OVERVIEW

Darnytsia Pharmaceutical Company is one of Ukraine's most established and resilient pharmaceutical manufacturers, with its heritage dating back to 1930. For nearly a century, Darnytsia has remained unwavering in its mission to protect public health by providing widespread and affordable access to high-quality generic medicines. Today, amidst full-scale war, economic instability, and a shortage of qualified personnel, the company's mission goes far beyond business objectives: it reflects a profound responsibility to its employees, society, and the nation as a whole. The stability of its production and the strength of its leadership form the foundation upon which Darnytsia continues to demonstrate the resilience and enduring spirit of Ukraine's pharmaceutical sector.

Located in Kyiv, Darnytsia produces more than 180 brands of medicines, leveraging decades of expertise and a commitment to continuous innovation. Its state-of-the-art manufacturing complex is certified to GMP standards, ensuring the flexibility and capacity required for rapid expansion into the European market. Darnytsia is prepared to more than triple its tablet production and increase the output of soft dosage forms tenfold, relying solely on its existing designed capacity. The company also possesses significant potential for localizing European partners' products — including injectable dosage forms (small- and large-format ampoules), tablets, capsules, and infusion solutions.

Darnytsia's strategic development plan includes preparations for future investments, notably the potential establishment of an mRNA vaccine production facility, which would require an estimated €50 million. Although the company does not manufacture active pharmaceutical ingredients (APIs) directly, it specializes in high-quality generics—including several products based on Ukrainian-origin APIs, such as Miramistin, Glycine, and Umifenovir. This strategic focus, combined with robust operational capacity, positions Darnytsia as a reliable and scalable partner for European markets.

Internationally, Darnytsia continues to expand its presence. The company's GMP-compliant products are registered and supplied in more than 20 countries across Europe, Asia, Oceania, and the Middle East. Darnytsia has established strong market positions in Lithuania, Latvia, Estonia, Poland, Moldova, and Bosnia and Herzegovina. Its products are also available in highly regulated markets such as Australia, New Zealand, Singapore, Malaysia, and Vietnam. Additionally, Darnytsia supports essential supply chains in countries where access to quality medicines is critically important, including Iraq, Libya, Georgia, Azerbaijan, Armenia, Kyrgyzstan, and Mongolia.

Uncompromising quality is the cornerstone of Darnytsia's operations. All manufacturing sites fully comply with GMP standards, with quality recognized by some of the world's strictest regulatory agencies. Certifications from the Therapeutic Goods Administration (TGA) of Australia and EU GMP approval by the State Medicines Control Agency of Lithuania demonstrate Darnytsia's ability to consistently meet the highest global requirements. All four Ukrainian production sites — for hard, soft, ampoule, and infusion dosage forms — hold valid national GMP certificates.

Darnytsia is actively strengthening its international compliance, with an EU Chief Pharmaceutical Inspectorate audit anticipated in 2025 and preparations underway for inspections by the Saudi FDA and Central Asian regulatory authorities. Sustainability principles underpin the company's responsible approach to operations, supported by ISO 22000 and ISO 14001 certifications.

A robust in-house Quality Control Department reinforces Darnytsia's reputation for reliability. The company operates two certified laboratories — the Laboratory of Chemical and Biological Analysis and the Microbiological Laboratory — which provide multi-level oversight across all stages of production. With certificates of unlimited validity, these laboratories guarantee comprehensive safety and quality control, while also supporting the development of new, competitive products that meet ICH standards.

Darnytsia is fully prepared to provide full-cycle contract manufacturing and rapid localization for EU partners, supported by robust logistics and its strategic proximity to the European market. With six INNs already registered in the EU — and the capacity to register up to 50 more with relatively low investment — the company offers both regulatory readiness and a broad therapeutic portfolio tailored to European needs. Darnytsia's involvement in international initiatives, including the WHO mRNA Technology Transfer Programme, further underscores its strategic ambitions and commitment to technological advancement.

Darnytsia is more than just a pharmaceutical manufacturer — it is a cornerstone of Ukraine's healthcare system: resilient, innovative, and committed to responsible partnership. The company stands ready for deep cooperation with Europe, further strengthening the region's healthcare landscape.

Darnytsia Pharmaceutical Company

DARNYTSIA

Today, amid the challenges of full-scale war, economic instability, and personnel shortages, our mission extends far beyond achieving business results. It encompasses a profound responsibility to our team, society, and the nation.

We believe that true leaders — those who ensure business continuity and inspire their teams toward new accomplishments — are the driving force behind real progress.

Every day, we work diligently to uphold the stability of both our production and management, demonstrating the unwavering resilience of the Ukrainian spirit and our relentless commitment to progress.

Our foremost priority is providing Ukrainians with high-quality, affordable medicines — an essential element in safeguarding the nation's health.

We deeply value our employees, ensuring they have decent working conditions and robust social support, even in the most challenging of times.

Darnytsia is more than just a pharmaceutical company. It is a cornerstone of Ukraine's healthcare system and an ambitious, innovative partner, ready to collaborate at the European level.

Andrii Obrizan,
Darnytsia Company CEO



Production Facilities




DARNYTSIA
Production Facilities
Darnytsia stands as a symbol of the resilience and reliability of Ukrainian pharmaceuticals, with a history dating back to 1930. For nearly a century, we have been steadfast in safeguarding health, specializing in the production of generic medicines. Our strategy is to ensure broad access to effective therapies, making treatment both affordable and cost-effective.


Production Facilities
Darnytsia's portfolio encompasses key therapeutic areas critical to modern medicine, including:
• Cardiology
• Medications for the treatment of neurological disorders
• Pain management
• Hospital medicines (a wide range of injectables essential for inpatient care), including antibiotics and treatments for type 2 diabetes mellitus.
DARNYTSIA


DARNYTSIA
Production Facilities
Located in the heart of Ukraine, in Kyiv, Darnytsia draws on many years of experience and innovative approaches every day to create more than 180 brands of medicines that save and improve lives.
180+
brands

DARNYTSIA

Product Range

Darnytsia Pharmaceutical Company features a modern manufacturing complex certified according to GMP standards, which is key to our reliability and our ability to localize European orders.

Our manufacturing facilities have significant capacity reserves, ensuring flexibility and readiness for expansion into the EU market.





DARNYTSIA

Product Range

We are prepared to more than triple our tablet production and increase the output of soft dosage forms (ointments and creams) over tenfold, all by leveraging our existing designed capacity.





DOSAGE FORM	ACTUAL PRODUCTION VOLUMES (UNITS PER YEAR)	DESIGN CAPACITY (UNITS PER YEAR)
Pills	105 670 697	329 694 891
Capsules	4 810 479	14 282 609
Injection	14 911 220	46 000 000
Ointments/ creams	3 897 638	50 000 000
Granules	876 257	6 022 500
Drops/ solutions	8 101 960	15 000 000
Sterile powders	4 435 434	40 000 000

DARNYTSIA

Strategic Flexibility and Development

Localization for the EU

Our facilities are ideally suited for the rapid localization of European partners' production, particularly for injectable forms (small- and large-format ampoules), tablets, capsules, and infusion dosage forms.


Innovation Horizon

We are considering strategic investments for the future, with €50 million required for the potential development of mRNA technology-based vaccine production.




DARNYTSIA
Strategic Flexibility and Growth
Specialization
While we do not manufacture APIs, we specialize in producing high-quality generic medicines (GMs), nine of which utilize APIs of Ukrainian origin (such as Miramistin, Glycine, Umifenovir, and others).
Our manufacturing capacity represents a reliable, certified, and scalable resource, ready to support European partners in providing access to high-quality medicines.
EUROPEAN PARTNERSHIP
IN PHARMACEUTICALS


DARNYTSIA
Distribution
Darnytsia Pharmaceutical Company is also actively expanding its international presence, consistently confirming the quality of its products and their compliance with global standards.
Our GMP-compliant products are supplied to and registered in more than 20 countries across four continents. This demonstrates the trust that international partners place in the Darnytsia brand.
20+
countries
worldwide


DARNYTSIA
Distribution
We have a strong foothold in EU countries and neighboring European states, including Lithuania, Latvia, Estonia, Poland, Moldova, and Bosnia and Herzegovina.
The quality of our products is recognized in highly regulated markets, as demonstrated by registrations in Australia, New Zealand, Singapore, Malaysia, and Vietnam.
We are a reliable supplier to regions where access to quality medicines is critically important, notably Iraq and Libya.
Our strong, long-standing relationships ensure regular supplies to Georgia, Azerbaijan, Armenia, Kyrgyzstan, and Mongolia.
Active deliveries
Planned
20+
countries
worldwide



Quality Control

Every country where Darnytsia Pharmaceutical Company's products are registered and supplied stands as a testament to our resilience, international recognition, and ability to meet the highest regulatory standards.





Quality Control

Uncompromising quality is the cornerstone of Darnytsia Pharmaceutical Company.

Our production operates in full accordance with the highest international standards of Good Manufacturing Practice (GMP), ensuring the reliability of every medicine we produce.



Quality Control

Our quality is recognized by the world's leading regulatory authorities, reaffirming our ability to operate in highly regulated markets:

Australia (TGA)

A valid certificate from the Therapeutic Goods Administration (TGA) serves as a mark of trust from one of the world's most stringent regulatory bodies.

European Union (Lithuania)

Certification by the State Medicines Control Agency (SMCA) in Lithuania is clear evidence of our full compliance with EU GMP requirements, paving the way for fruitful European cooperation.

Four Production Sites

All key production facilities in Ukraine — including hard, soft, ampoule, and infusion dosage forms — are certified according to national standards, guaranteeing stability and quality control at every stage of the manufacturing process.



Quality Control

We are continuously deepening our integration into the international community:

1. In September 2025, we expect an inspection from the **EU Chief Pharmaceutical Inspectorate (Poland),** which will provide further confirmation of our readiness for an expanded presence in the EU.
2. We are also preparing for inspections by the **Saudi Food and Drug Administration (SFDA) and regulatory authorities in Central Asia,** reaffirming our global ambitions.

In addition to GMP standards, our activities are guided by the principles of sustainability and responsibility, including compliance with:

- ISO 22000 (Food Safety Management System)
- ISO 14001 (Environmental Management)





Quality Control Department

The success of Darnytsia is inextricably linked to its own powerful laboratories, which serve as the heart of innovative development and impeccable quality control.

The quality control department includes two key certified laboratories that provide multi-level oversight of all products:

- **Laboratory of Chemical and Biological Analysis**
- **Microbiological Analysis Laboratory**

These laboratories are certified by the State Service of Ukraine on Medicines and possess certificates of unlimited validity (No. 128, issued on 11.07.2012). This is official confirmation of our right and capability to conduct comprehensive quality and safety control of medicines, covering a wide range of analyses.

Quality Control Department

Darnytsia's in-house laboratory and R&D base provide a double guarantee for our partners: not only do they offer the potential for developing new, competitive products, but they also ensure consistent, officially confirmed quality at every stage of production.





DARNYTSIA

Key Takeaways: Positioning and Strategic Advantages

Darnytsia is positioned as a partner capable of delivering flexibility, quality, and speed of delivery.

Key Points of Interest for Partners:

Production and Logistics Efficiency
We are fully prepared for contract manufacturing and the potential localization of a wide range of dosage forms for the EU market — including injections (small- and large-format ampoules), tablets, capsules, soft and infusion forms.

Our substantial production capacity allows for rapid scaling of manufacturing close to the EU, enabling fast and efficient delivery.



DARNYTSIA

Key Takeaways: Positioning and Strategic Advantages



Quality, Product Assortment, and Regulatory Readiness
We offer European-level quality control and have proven experience exporting to EU countries (Lithuania, Latvia, Estonia). Our focus is on the production of generic medicines in key therapeutic areas that are in demand in Europe.

We have a strong track record of product registration in the EU, with six INNs already approved (including Fluconazole, Furosemide, and Magnesium sulfate), underscoring our regulatory competence.

There is the potential to register up to 50 INNs from our current portfolio in the EU, with relatively low investment (from €10,000 to €50,000 per SKU).

Additionally, our in-house R&D laboratory enables the development of new products in accordance with ICH requirements.

Strategic Advantages
Darnytsia Pharmaceutical Company offers a full cycle of finished pharmaceutical production and possesses proven experience in international projects and tender supply, including participation in the WHO mRNA Technology Transfer Programme.


InterChem



INTERCHEM

COMPANY OVERVIEW

INTERCHEM SLC is one of Ukraine's most technologically advanced and innovation-driven pharmaceutical manufacturers, distinguished by its strategic focus on original drug development. From its inception, the company pursued the challenging path of creating new molecules rather than duplicating existing ones — a philosophy that has become its key competitive advantage. INTERCHEM has successfully developed and commercialized four proprietary original molecules, an exceptional achievement for Eastern Europe, demonstrating strong scientific capacity and long-term commitment to pharmaceutical innovation.

The company operates on a full-cycle model that integrates research, synthesis of active pharmaceutical ingredients (APIs), and finished dosage form production. Its manufacturing facilities comply with international GMP standards, ensuring consistency, transparency, and high quality.

In-house R&D laboratories support the entire product lifecycle — from molecule design and synthesis to analytical testing and quality control — providing complete oversight of innovation and manufacturing processes. INTERCHEM positions itself not only as a business but as a socially responsible Ukrainian manufacturer that has severed all ties with the aggressor state and actively supports the Armed Forces of Ukraine and the national economy. The company is widely recognized for its impactful charitable projects.

INTERCHEM's production capacity reflects both current scale and future growth potential. The company produces approximately 4,500 kg of APIs annually, with reserve capacity up to 10,000 kg per year. Its manufacturing lines output 600 million tablets and capsules annually, with installed capacity for upscaling to 1 billion units. In 2026, INTERCHEM will launch a new high-tech site for injectable dosage forms, designed to produce 7.25 million nebulas per year — a strategic expansion that will significantly strengthen its position in the global supply chain.

The product portfolio includes essential APIs, finished dosage forms, and proprietary developments. Key substances include anxiolytics, hypnotics, and antivirals such as Phenazepam®, Gidazepam®, Levana®, and Amixin® (tilorone), as well as clonidine, diazepam, and others. In-house synthesis of critical APIs ensures supply reliability, quality control, and resilience to global market fluctuations — an important advantage for international partners.

INTERCHEM supplies products to Azerbaijan, Kazakhstan, Georgia, Tajikistan, and Uzbekistan and has experience exporting APIs to the EU (Lithuania). The company has successfully participated in major international tenders with organizations including the Global Fund, Crown Agents, and UNICEF.

Quality assurance underpins every stage of manufacturing. INTERCHEM's operations are aligned with GMP requirements and supported by rigorous documentation, risk management, raw-material control, and validated analytical methods. The Quality Control Department includes certified analytical and microbiological laboratories equipped with advanced instrumentation. Every batch undergoes multi-level testing and certification by a qualified person, ensuring full compliance with the registration dossier. Regular self-inspections and audits reinforce quality system performance and ensure product stability throughout shelf life.

INTERCHEM offers strong strategic advantages for European partners. The company is prepared to localize production in the EU, offering an alternative to products previously manufactured in Asia, thereby strengthening supply chain security. With proven R&D capacity for developing new APIs, INTERCHEM is ready to invest €2–5 million in expanding in this direction. Localization of raw material sourcing from Ukrainian suppliers further enhances supply resilience. To meet EU market requirements, the company is ready to invest €1–5 million in EU GMP inspections, bioequivalence studies, and dossier preparation.

INTERCHEM stands as a symbol of trust, innovation, and resilience. Combining proprietary molecule development, high production capacity, and rigorous quality systems, the company is fully prepared for deep cooperation with European partners — offering not only ready-made pharmaceuticals but also reliable supply, technology transfer, and a long-term strategic vision.



When we began our work, we consciously chose the most challenging, yet only correct path: the development of original drugs. This is our key competitive advantage and our core philosophy. Instead of merely duplicating existing treatments, we invest in our own scientific research, creating new molecules and bringing innovative medicines to the market that Ukraine and the world require. We have developed and commercialized four proprietary original molecules — a rare achievement for Eastern Europe.

Our production facilities fully comply with international GMP standards, and process transparency and unquestionable quality are our highest priorities. Thanks to our in-house R&D laboratories, we ensure a full cycle of product development and quality control.

We are more than just a business; we are a socially responsible Ukrainian company. We have decisively severed all ties with the aggressor country and actively support the Armed Forces of Ukraine and the economy. As Churchill once said, "If you're going through hell — keep going". Despite the challenges our country and our people have faced, we continue to work.

«INTERCHEM» is a synonym for trust, innovation, and resilience. We are ready for fruitful European cooperation, ensuring that our original developments serve patients across the globe.

CEO & Co-owner, PhD in Chemistry, Honorary Professor Anatoliy Reder





InterChem

Production facilities



«INTERCHEM» does not just produce medicines, but creates them, controlling the entire cycle:

Pharmaceutical Substances (APIs)

Our fine organic synthesis capacity reaches 4,500 kg/year, with a growth plan of up to 10,000 kg/year. We produce the basis of medicines.

Finished Dosage Forms

Our actual annual output of tablets and capsules is 600 million units, but we are ready to scale to 1 billion units!

New Horizon

In 2026, we are opening a new high-tech site for the production of injection solutions in nebulas, with a design capacity of 7.250 billion nebulas per year.







InterChem

Product range

INTERCHEM demonstrates significant production capacities that cover the full cycle of drug development — from the synthesis of active ingredients to finished forms, with a focus on future growth.

Heart of Production
Active Pharmaceutical Ingredients (APIs)

Actual capacity
4,500 kg/year (products of fine organic synthesis).

Project growth
an increase to 10,000 kg/year is planned, confirming significant ambitions in the field of chemical synthesis.











InterChem

Product range

INTERCHEM offers its partners not just ready-made medicines, but quality control and reliability of supply, which begins with its own synthesis of critical substances.

The main attention of the company is focused on critical areas, including anxiolytic, hypnotics and antiviral substances: **phenazepam®, gidazepam®, levana®, amixin® (tilorone), clonidine, diazepam** and others.




The company's current capacities are ready to meet significant demand, and the project volumes make it easy to scale cooperation:

DOSAGE FORM	ACTUAL VOLUME (PER YEAR)	PROJECT POTENTIAL (PER YEAR)
Tablets /capsules	**600 mln.** dosage units	**Up to 1 billion.** dosage units
Powders (Sachets)	**90 million** sachet	**Up to 150 million** sachet


Distribution
MEDICAL


InterChem
Distribution
The export potential of Interchem is based on proven quality and experience:
Certification
Production meets national GMP requirements (valid until 23.12.2025). Quality control laboratories (Analytical and Microbiological) have industry certification (Certificate No. 294).
Markets
The company's products are already supplied to Azerbaijan, Kazakhstan, Georgia, Tajikistan and Uzbekistan.
EU experience
The company has a past experience of exporting APIs to Lithuania (an EU country), which confirms its ability to work with regulated markets.
Participation in Tenders
Successful participation in international projects and tenders (Global Fund, Crown Agents, UNICEF) for the supply of substitution maintenance therapy (SMT) drugs.


InterChem
Quality Control
To ensure the current quality standards, the company clearly and harmoniously works a whole system – GMP, quality control at all levels of production, risk management to ensure the highest degree of safety, identity and effectiveness of medicines.



Quality Control

The InterChem quality system is about:

- medicines are developed and researched in accordance with **GMP** requirements;
- production operations and control methods are documented and comply with **GMP** requirements;
- incoming raw materials, auxiliary and packaging materials, intermediates and production processes that are subject to strict incoming controls;
- finished products manufactured in accordance with **GMP** requirements and tested in accordance with approved **ICC**;
- more internal measures that guarantee the quality of finished products throughout the entire shelf life;
- Regular self-inspections and audits assess the effectiveness of the quality assurance system at all levels.

Quality Control Department

Interchem has its own certified laboratories of the quality control department of Interchem:

- Analytical Laboratory of the Quality Control Department of INTERCHEM SLC
- Microbiological Laboratory of the Quality Control Department of INTERCHEM SLC.

The laboratories are equipped with modern equipment and measuring instruments necessary for quality control of medicines, in accordance with the field of accreditation.
In addition, each batch of finished products is certified for compliance with the requirements of the registration dossier of the medicinal product by an authorized person of the enterprise. A set of these measures makes it possible to guarantee the exceptional, stable and undoubted quality of all **InterChem** products.



Competitive advantages of the company

Interchem is ready to become a strategic partner for the EU thanks to the following options:

Localization

There is an opportunity to localize the production of drugs previously imported from Asia, increasing the reliability of supplies in Europe.

API expansion

We have the proper **R&D** base for the development and production of new APIs, ready for an additional investment of **€2-5 million**. euros in this direction.

Chain Resilience

There is an opportunity to use localized raw materials from Ukrainian suppliers, which increases the resilience of the supply chain.




InterChem
Investment Potential
Interchem medicines have a high potential for registration in the EU. To do this, the company is ready to invest 1-5 million. euro in:
• Passing an inspection to confirm compliance with GMP EU.
• Carrying out the necessary studies, including bioequivalence.
INTERCHEM offers European partners not just ready-made medicines, but quality control and reliability of supply, which begins with its own synthesis of critical substances.


PHARMHIM



PHARMHIM

COMPANY OVERVIEW

PHARMHIM is the leading and largest manufacturer of active pharmaceutical ingredients (APIs) in Ukraine, as well as a strategically important element of the pharmaceutical supply chain. By ensuring stable supplies of critically important substances, PHARMHIM plays a key role in maintaining pharmaceutical security and in the production of essential medicines across various therapeutic categories.

The company operates a fully vertically integrated production model that covers the manufacturing of specialized chemical raw materials, intermediates, and finished APIs. This approach ensures high autonomy, supply stability, and strict quality control at every stage.

The production complex in Shostka includes 24 manufacturing units, 8 cleanroom units, and over 120 reactors of various volumes, enabling multi-stage chemical synthesis under controlled conditions and across a wide temperature range. The infrastructure provides opportunities for production scale-up according to the needs of international partners. In the Kyiv region, the company operates pharmaceutical warehouses that ensure efficient logistics and fast distribution.

The company's design production capacity exceeds 300 tons of APIs and 490 tons of bulk solutions per year, while actual output already surpasses 100 tons of APIs and 120 tons of bulk solutions. PHARMHIM specializes in the synthesis of generic APIs for nootropic, sedative, antioxidant, immunomodulatory, antibacterial medicines, and emergency care products. The company also has the capability to manufacture customized intermediates for specific synthetic routes and offers contract manufacturing (CMO) and technology transfer services.

For all APIs, DMFs in CTD format and Written Confirmations are available, meeting EU requirements and simplifying regulatory procedures for partners. The quality system complies with GMP PIC/S and ISO 9001:2015 standards. The laboratory network includes analytical, microbiological, and R&D units that perform method validation, synthetic route optimization, and new product development.

PHARMHIM exports its products to 12 countries across Europe and Asia and supplies more than 40 pharmaceutical companies in Ukraine. The company is steadily expanding its API portfolio in line with global market needs and maintains flexibility in adapting production processes to partner requirements. With its modern technological base, vertical integration, strong quality standards, and scalable production capabilities, PHARMHIM is a reliable and strategically important partner for international manufacturers of APIs and finished pharmaceutical products.



Medicine starts with active pharmaceutical ingredients. The production and quality of finished dosage forms rely entirely on the availability and quality of APIs.

PHARMHIM is the largest API producer in Ukraine and provides a critically important link in the supply chain.

Our advantage lies in our vertical integration: the company's production complex carries out multi-stage chemical synthesis and manufactures raw materials, intermediates and final APIs, which minimizes external dependency and ensures reliable quality control.



CEO *Mykola Fedko*

PHARMHIM

Manufacturing and Distribution Facility



PHARMHIM

Vertically Integrated Production Complex



LLC «TSH-KHIMREAKTIV»

PRODUCTION OF SPECIALIZED RAW MATERIALS FOR FURTHER CHEMICAL SYNTHESIS

LLC «SHOSTKA- HIMPRODUCT»

PRODUCTION OF PHARMACEUTICAL INTERMEDIATES

LTD «PHARMHIM»

PRODUCTION OF ACTIVE PHARMACEUTICAL INGREDIENTS

PHARMHIM



Production Facilities

Design capacity:

- API production > 300 tons/year
- Production of solutions in bulk 490 tons/year
- Production of intermediates > 150 tons/year

Actual Power:

- API production > 100 tons/year
- Production of solutions in bulk 120 tons/year
- Production of intermediates > 80 tons/year

PHARMHIM

Production Facilities

- **24 production sites**
- **8 cleanroom sites**
- **120 multifunctional chemical synthesis reactors** with capacities ranging from 0.05 to 4,000 liters, operating within a temperature range of –25 °C to +240 °C
- Ion exchange columns
- Rectification columns of both plate and nozzle types
- Absorption columns designed for saturating liquids (solvents) with gases
- Dryers equipped with heating, rotation, and vacuum capability
- Specialized centrifuges
- Ultrafine filtration units
- Mixers of various types
- Vacuum distillation systems and other equipment



Product Range

Specializes in multi-stage organic synthesis of APIs. Portfolio of generic APIs for finished dosage forms, including:

- **Nootropic**
- **Sedative**
- **Antioxidant**
- **Cerebroprotective**
- **Immunostimulant**
- **Antibacterial**
- **Emergency medicines**





Distribution

PHARMHIM

The company exports its products to 12 countries across Europe and Asia.

Europe: Bulgaria, Italy, Moldova, Poland, Romania

Asia: Armenia, Georgia, India, Kazakhstan, Pakistan, Turkey, Uzbekistan

Main market: Ukraine — 43 buyers



PHARMHIM

Quality System, Certifications & Laboratory Network

PHARMHIM ensures a high level of quality control and continuous development through a comprehensive quality management system, which includes:

- GMP PIC/S certification
- ISO 9001:2015 certification

- Analytical and Microbiological Laboratories within the Department of Quality Control
- Industrial and Sanitary Laboratory

- Technology R&D Laboratory



PHARMHIM

Competitive Advantages of PHARMHIM



- Manufacturing, processes, and documentation aligned with European standards
- The robust and technologically advanced industrial base
- An in-house R&D department specializing in chemical synthesis technologies
- Independent production of raw materials and intermediates for internal use and for other API manufacturers
- Highly cost-effective manufacturing operations
- Proximity to clients and a high level of adaptability to their specific needs

КИЇВМЕДПРЕПАРАТ

АКЦІОНЕРНЕ ТОВАРИСТВО



KYIVMEDPREPARAT

COMPANY OVERVIEW

JSC Kyivmedpreparat is one of the largest and oldest pharmaceutical manufacturers in Ukraine, with advanced technological capabilities. It has played a defining role in the country's pharmaceutical industry, becoming the first enterprise in Ukraine to produce an antimicrobial medicine — penicillin — in 1949. This laid the foundation for national antibacterial therapy. Today, Kyivmedpreparat remains a leading producer of antimicrobials and other essential medicines, offering a diverse portfolio of almost 190 generic drugs in various dosage forms, as well as several original medicinal products.

Kyivmedpreparat provides the entire production process, from developing technological documentation to manufacturing, packaging, quality control and logistics. This integrated approach ensures stability, flexibility, and full control over every stage of pharmaceutical production. The company's facilities are equipped with modern machinery from leading European manufacturers and are certified according to Good Manufacturing Practice (GMP), guaranteeing compliance with strict international quality standards.

The enterprise's R&D centre is a major driver of innovation. Over the past three years alone, Kyivmedpreparat has developed more than 80 new medicines for domestic and international markets alike. Its scientific teams are focused on expanding the portfolio of modern generics, strengthening therapeutic coverage and responding quickly to market needs. The company's main therapeutic areas include medicines for the nervous and digestive systems, dermatology, urology, endocrinology and cardiology, reflecting a balanced range of in-demand products.

Kyivmedpreparat also stands out for its unique production versatility. It manufactures products in all major dosage forms and sources high-quality imported APIs, enabling it to adapt rapidly to global pharmaceutical trends while ensuring long-term supply reliability. This flexibility is crucial for international partners seeking stable, compliant and scalable manufacturing.

Quality lies at the heart of the company's values. Kyivmedpreparat is certified with both national GMP and Eurasian Economic Union (EAEU GMP), demonstrating its ability to adapt production to different regulatory environments. The company also upholds international management standards, including ISO 14001:2015 and ISO 22000:2018. This confirms its commitment to environmental safety, responsible resource management and strict health and safety protocols. Kyivmedpreparat's quality system is supported by fully equipped chemical and biological laboratories that conduct comprehensive testing at every stage of production, guaranteeing the safety and effectiveness of all medicines produced.

Kyivmedpreparat is also actively moving towards deeper integration into the European pharmaceutical market. It has successfully registered dietary supplements in Poland, and plans to extend this practice to other EU countries. Given Ukraine's proximity to the European Union, Kyivmedpreparat offers clear logistical advantages, enabling fast delivery times and optimised transportation costs.For European partners, Kyivmedpreparat offers a powerful blend of heritage, scientific expertise and contemporary industrial performance. Its portfolio includes high-demand generic products that can fulfil critical therapeutic needs in Europe, particularly in the areas of antibiotics, herbal medicines, and neuro- and cardiovascular drugs. Kyivmedpreparat pairs its production strength with marketing expertise grounded in scientific rigour and creativity.

Kyivmedpreparat is open to all forms of cooperation, including contract manufacturing, and offers a full range of services: documentation development, production, quality control, packaging, labelling, warehousing and logistics. With its decades of experience, strong regulatory foundation and reliable team of professionals, the company is well positioned to support European partners seeking stable, high-quality pharmaceutical manufacturing.

Kyivmedpreparat is a trusted and forward-looking enterprise, ready to collaborate, integrate, and contribute meaningfully to the European pharmaceutical market.



Kyivmedpreparat is one of the largest and most experienced pharmaceutical enterprises in Ukraine. It was Kyivmedpreparat that was the first in Ukraine in 1949 to start the production of an antimicrobial drug - penicillin.

We've been a major player in the national market for antibacterial drugs for a long time. We produce nearly 190 generic drugs, considering the forms and dosage, as well as several original medicines.

We provide a full production cycle — from the development of technological documentation, production and quality control to packaging and logistics, and offer contract manufacturing services.

Our production sites are GMP-certified and equipped with modern machinery from leading European manufacturers, enabling us to produce medicines in various forms.

Our R&D center develops new medicines for the Ukrainian and international markets. Over the past three years, we have developed more than 80 new drugs.

Kyivmedpreparat is an experienced pharmaceutical enterprise with modern facilities and a strong team of specialists ready to face the challenges of the global market. We strive to provide European partners looking for new opportunities with reliable support through our expertise, technological base, and quality requirements. We believe that collaborating with Ukrainian manufacturers is an effective business solution and a contribution to developing the European pharmaceutical market."

Vice President of JSC Kyivmedpreparat,
Oleksandr Yatsyuk





КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Production facilities



КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Production facilities of the company

The main therapeutic areas of Kyivmedpreparat are drugs for the nervous and digestive systems, as well as dermatological, urological, endocrinological, etc.



КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Production Overview

DOSAGE FORM	ACTUAL PRODUCTION VOLUMES (UNITS/YR)	DESIGN CAPACITY FOR 2024 (UNITS/YR)	POTENTIAL CAPACITY (SUBJECT TO INVESTMENT/ MODERNIZATION)	ESTIMATED INVESTMENT REQUIRED
Tablets	21 210	486 129	100 milion unts	12 million USD
Capsules	3 469	96 812	10 milion unts	3 million USD
Injection	22 450	22 450	100 milion unts	20 million USD
Ointments/ Creams	2 254	2 254	10 milion unts	7 million USD
Suspension	230	230	0.5 milion unts	3 million USD
Sachet	273	1 598	5 milion unts	2 million USD

КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Production Overview

JSC Kyivmedpreparat has a unique strategic position: it is a high-tech plant that produces products in all major dosage forms, using imported APIs. This enables the company to adapt to global pharmaceutical trends quickly.







КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Distribution



JSC Kyivmedpreparat operates in ten markets worldwide, indicating stable development and the ability to work flexibly with international partners.
In Central Asia and the CIS: Kazakhstan, Uzbekistan, Kyrgyzstan, Tajikistan, and Turkmenistan are key sales markets with high demand for the company's products.
The Caucasus region includes: Armenia, Azerbaijan, and Georgia are regions with established partnerships.
In Eastern Europe, the company is developing a consistent presence, particularly in **Moldova.**
In Asia: Vietnam is an example of a successful entry into a remote market.

КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО


Quality Control

Kyivmedpreparat's commitment to uncompromising quality is confirmed by multi-level certification covering production processes and management systems, such as **Good Manufacturing Practice (GMP)** status
The availability of **Eurasian Union (EAEU GMP)** certificates emphasizes the ability to adapt production processes to regional requirements, which is an advantage for international trade.
In addition to production quality, **Kyivmedpreparat** has implemented international management systems covering ecology and safety **(ISO 14001:2015, ISO 22000:2018).**





КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО



Quality Control

The heart of the quality management system of **Kyivmedpreparat** is its fully equipped chemical and biological laboratories. They contribute to ensuring a complete and continuous cycle of quality control of medicines at each stage of production, guaranteeing the compliance of products with the highest standards.









КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО



Key Takeaways

Kyivmedpreparat is actively paving the way for integration into the EU pharmaceutical market. In particular, the company has already successfully notified dietary supplements in Latvia and Poland, and plans to expand this practice to other EU countries.

КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО



Why Kyivmedpreparat?

The company's portfolio includes modern generics that can fill critical niches in the European market, in particular:

- Antibiotics
- Herbal medicines
- Drugs of neuro- and cardio groups.

Proximity to the EU ensures the prompt delivery of products and optimized transport costs.

КИЇВМЕДПРЕПАРАТ
АКЦІОНЕРНЕ ТОВАРИСТВО

Why Kyivmedpreparat?

Marketing Expertise, combining a scientific approach and creativity.

Contract Manufacturing (CMO): the company is open to cooperation in the format of contract manufacturing.

Our **GMP-certified** production facilities are equipped with state-of-the-art equipment for the production of a wide range of dosage forms, from solid to injectable.

A full cycle of services: from the development of documentation and quality control to packaging and logistics.






VIOLa
Pharmaceutical
factory



VIOLA PHARMACEUTICAL FACTORY

COMPANY OVERVIEW

PJSC “Viola Pharmaceutical Factory” is one of Ukraine’s oldest and most reputable pharmaceutical manufacturers, with a legacy dating back to 1945. Today, the company employs 449 specialists and maintains a strong market position thanks to its deep expertise in traditional, well-studied, and generic medicines, as well as its expanding portfolio of medical devices, cosmetics, and dietary supplements. Viola’s long-standing specialization in liquid dosage forms and herbal-based products — including tinctures, syrups, extracts, and herbal teas — makes the company a particularly relevant partner for the European market, where demand for natural and plant-derived therapeutics continues to grow.

The company operates a modern pharmaceutical complex in Zaporizhzhia, Ukraine, designed to provide patients with high-quality, safe, and affordable medicines. Viola’s mission is rooted in technological excellence and continuous innovation, combining decades of pharmaceutical tradition with modern industrial capabilities. Its full production cycle covers research and development, manufacturing, quality control, packaging, and distribution, ensuring complete regulatory and process transparency.

Viola’s product portfolio includes more than 100 items across a wide range of dosage forms: syrups, solutions, liniments, ointments, gels, pastes, capsules, tinctures, powders, oils, and packaged herbal raw materials. The company holds a particularly strong leadership position in herbal pharmaceuticals, with 46 INNs based on medicinal plant materials. This extensive expertise in botanical processing allows Viola to transform natural raw materials into consistent, high-quality medicinal forms, offering unique value for partners seeking herbal-origin generics and para-pharmaceutical products.

Production capacity is another strategic advantage. With a design capacity exceeding 87 million units per year, Viola is well positioned for both large-scale manufacturing and agile production of small or specialized batches. This flexibility, combined with geographical proximity to the EU, enables fast delivery times, reduced logistics costs, and enhanced resilience in the face of global supply chain disruptions. For European partners, such logistical advantages significantly strengthen supply reliability and competitiveness.

Quality and regulatory compliance form the foundation of Viola’s operations. The company has implemented an integrated quality management system certified to international standards: ISO 9001:2015, ISO 13485:2016 for medical devices, ISO 45001:2019 for occupational health and safety, and ISO 22000:2018 (HACCP) for dietary supplements. Viola adheres to Good Manufacturing Practice (GMP) requirements — fully aligned with the Ukrainian MoH Guideline 42-4.0:2020 — ensuring that every stage of production meets strict controls for safety, purity, and consistency.

Viola’s quality assurance is supported by its own modernized and certified laboratory complex. The Physicochemical and Microbiological Laboratories are equipped with advanced systems from Agilent, Esco, Systec, and Sartorius, enabling sophisticated chromatographic and microbiological analysis compliant with pharmacopeial standards. Certification from the State Service of Ukraine on Medicines (Certificates No. 311 and No. 338) confirms the laboratories’ full technical competence and regulatory compliance.

The company’s export history includes deliveries to EU countries such as Estonia and Poland, demonstrating its regulatory readiness and familiarity with European requirements. Viola is actively expanding its strategic international presence and is fully prepared for contract manufacturing collaborations with European partners — offering GMP-compliant production, strong documentation practices, scalable capacity, and competitive pricing.

Viola’s commitment to future development includes investment readiness for expanding product lines and introducing new dosage forms. The company combines nearly 80 years of pharmaceutical experience with modern production technologies, delivering a balance of tradition, innovation, and reliability.

With its strong specialization in natural and herbal medicines, diverse dosage forms, robust quality systems, and strategic location near the EU, PJSC “Viola Pharmaceutical Factory” stands out as a trusted, flexible, and competitive partner for European companies seeking high-quality generics, herbal products, and contract manufacturing solutions.


Private Joint Stock Company"VIOLA"
PHARMACEUTICAL FACTORY" (PJSC PF "Viola")
VIOLa
Pharmaceutical factory


I am pleased to introduce our company, whose history dates back to 1945, and where a team of 449 specialists currently works.
We specialize in the production of generic, well-studied, traditional medicines, as well as medical devices, cosmetics, and dietary supplements. The leading direction of our work is the production of liquid dosage forms and products based on medicinal herbal raw materials (tinctures, syrups, extracts, herbal teas), which may be of particular interest to the European market.
Our quality is ensured by a full technological cycle and multifaceted certification, we comply with GMP and ISO requirements, which in turn allows us to guarantee control at every stage of production. Thanks to our geographical proximity to the EU, we offer shorter supply times, lower logistics costs, and higher flexibility, which is a critical advantage amidst global supply chain disruptions.
We possess significant reserves of production capacity (total design capacity exceeding 87 million units per year) and are ready for contract manufacturing of large and small batches for European partners, including para-pharmaceutical products.
«Viola» represents your competitive pricing, uncompromising quality, and reliable support in the pharmaceutical sector.
Chairman of the Board Oleksandr Chanchykov


Production facilities
VIOLa
Pharmaceutical factory
Zaporizhzhia, Ukraine



VIOLA Pharmaceutical factory

Production facilities

Viola Pharmaceutical Factory is a modern, dynamically growing enterprise that has been working on the creation of high-quality medicines since 1945.

The company's mission is to provide customers with high-quality and affordable drugs by using modern technologies and achievements of the pharmaceutical industry.

Viola's key specialization includes the production of generic, well-researched and traditional medicines, as well as medical devices, cosmetic products, antiseptics and dietary supplements.







VIOLA Pharmaceutical factory

Product range

The traditional priority of the company **"Viola"** is products from medicinal plant raw materials. The products are available in a wide range of convenient forms: syrups, solutions, ointments, gels, liniments, pastes, capsules, tinctures, powders, oils, as well as packaged plant raw materials, meals and herbal teas.





VIOLA Pharmaceutical factory

Product range



DOSAGE FORM	ACTUAL PRODUCTION VOLUMES (UNITS PER YEAR)	DESIGN CAPACITY (UNITS PER YEAR)
Capsules	503 360	1,373,000 packs of 2 blisters
Ointments / creams	7 296 704	8 000 000
Syrups	2 734 147	3 100 000
Alcohol drugs	14 615 130	30 320 000
Aqueous solutions, oils	10 285 761	15 000 000
Packaged plant materials / Herbal teas	3 673 268	9 400 000
Powders	3 057 721	5 500 000
External Contract Manufacturing (iodine solution, Cosmetic products)	140 369	15 000 000
Others (First aid kits, Gauze medical products)	648 985	87 693 000
Just		

Distribution

VIOLa Pharmaceutical factory



The main market for Viola TM products is Ukraine. In addition, the company carries out export deliveries to the following countries: **Estonia, Moldova, Poland, Georgia, Tajikistan, Lithuania.**

VIOLa Pharmaceutical factory

Quality Control

Viola has developed and implemented an integrated quality management system certified in accordance with the requirements of international standards **ISO 9001:2015, ISO 13485:2016, ISO 45001:2019** for medical devices and **ISO 22000:2018** for dietary supplements (HACCP).



VIOLa Pharmaceutical factory

Quality Control

Viola provides an appropriate level of quality control thanks to its own, modernized and certified laboratories that guarantee the safety and effectiveness of drugs.
Thus, the company's quality control department includes Physicochemical and Microbiological Laboratories equipped with modern high-tech equipment **(Agilent, Esco, Systec, Sartorius)** for the implementation of complex chromatographic and microbiological analysis methods in accordance with the requirements of the State Pharmacopoeia of Ukraine.







Quality Control

The activities of the laboratories are confirmed by the certification of the State Service of Ukraine on Medicines and Drug Control (Certificate No. 311 dated 22.09.2016 for the Physico-Chemical Laboratory and Certificate No. 338 dated 09.03.2017 for the Microbiological Laboratory).
The laboratory complex was reconstructed (2014-2016) and meets the requirements of GMP (Guideline of the Ministry of Health of Ukraine 42-4.0:2020), which ensures the purity and reliability of control.









Key Advantages of Cooperation with PJSC "Viola Pharmaceutical Factory"

PJSC "Viola" offers partners a combination of European quality, competitive pricing, strategic logistics, and deep specialization in traditional and herbal pharmaceuticals.

Portfolio and Specialization

Herbal Leadership
A strong position in the production of a line of products based on medicinal plant raw materials—a traditional priority that accounts for 46 INNs (International Nonproprietary Names) of the total portfolio.

Diverse Product Range
Production of generic, well-studied, and traditional medicinal products, medical devices, cosmetic products, and dietary supplements.

Wide Range of Forms
A broad spectrum of dosage forms, including ointments, gels, syrups, capsules, tinctures, oils, and herbal teas.



- **Logistics Competitiveness**
- **Strategic Proximity:**
  The primary logistical advantage is the geographical proximity to the EU borders, which ensures shorter transit times and greater flexibility in deliveries to European markets.
- **EU Experience:**
  Past export experience to EU countries (Estonia, Poland), confirming regulatory readiness and compliance.


VIOLa
Pharmaceutical factory
Manufacturing Flexibility and Development
• Full Cycle & GMP: Providing a full technological cycle—from proprietary research and development to certified mass production in accordance with GMP standards.
• Scalable Production: Manufacturing capacity allows for the effective combination of large industrial volumes with the agile production of small and specialized batches.
• Contract Manufacturing: Full readiness to cooperate with European partners in the format of contract manufacturing.
• Investment Readiness: Clear investment plans for future expansion (e.g., in new dosage forms).


biopharma



BIOPHARMA PLASMA

COMPANY OVERVIEW

JSC “Biopharma Plasma” is a leading Ukrainian biotechnology company specializing in the development and production of essential plasma-derived medicinal products. As the largest manufacturer of plasma-based therapies in Eastern Europe, the company plays a critical role in ensuring global access to life-saving immunobiological medicines. Its high-tech fractionation plant, located in Bila Tserkva, represents a $120 million investment and is capable of processing up to 1 million liters of donated plasma annually. This capacity enables Biopharma not only to fully meet domestic needs but also to supply specialized products to numerous international markets.

The company integrates plasma collection, R&D, production, and quality control within a unified system, creating a complete plasma-processing ecosystem. A nationwide network of modern plasma collection centers ensures the availability of high-quality raw materials, while 580 dedicated professionals support the full production cycle. Biopharma positions itself as a socially responsible business committed to the development of science, education, and talent within Ukraine, fostering long-term growth of the biotechnology sector.

At the core of Biopharma’s operations are its fractionation lines, where blood plasma is transformed into valuable medicinal products through complex, high-precision processes. Manufacturing is carried out using equipment from leading European and American suppliers, while production technologies are developed by the company’s own R&D team. This approach guarantees both technological excellence and full control over every stage of the production chain.

The company’s product specialization focuses on plasma-derived and immunobiological medicines, including albumin and immunoglobulins — products of high strategic importance for the European healthcare system. Biopharma maintains strong production volumes for hospital-use medicines and confirms its readiness to scale up manufacturing and ensure uninterrupted supplies to the EU. Its export geography spans 11 countries, demonstrating a stable international presence and the reliability of its global logistics system.

Quality, safety, and efficacy are the foundation of Biopharma’s work. The company operates an advanced Pharmaceutical Quality System (PQS) covering the entire product lifecycle — from development and registration to distribution. This system incorporates GMP requirements and international quality standards. The Quality Control Department includes certified biological, chemical, and microbiological laboratories equipped with modern technologies such as NAT, ELISA, UHPLC, GC, and AAS. These facilities support comprehensive multi-level testing of plasma, intermediates, and finished products, ensuring that every batch complies with the European Pharmacopoeia and the State Pharmacopoeia of Ukraine. Biopharma’s QC laboratories hold official accreditation (Certificate No. 473), further strengthening trust in its testing integrity.

The company’s strong laboratory base includes specialized virological, biological, and research laboratories, enabling deep scientific analysis and continuous product innovation. This infrastructure supports not only the control of transfusion-transmissible infections and functional assays for biological activity but also Biopharma’s long-term research in immunobiology.

On the international stage, Biopharma positions itself as a highly specialized and reliable manufacturer of critically important plasma-derived products, fully prepared for cooperation within the EU. Its advantages include a unique full production cycle based on in-house plasma, a robust PQS aligned with GMP and ISO standards, globally recognized GMP certifications (including TITCK, ANVISA, and ANMAT), competitive logistics, and readiness for contract manufacturing or product localization. By selecting Biopharma as a partner, European companies gain access to a dependable supplier capable of ensuring quality, speed, and cost-effectiveness — essential attributes in the global supply of plasma-based medicines.

JSC “Biopharma Plasma” continues to expand its capabilities and international footprint, driven by innovation, scientific excellence, and a mission to provide patients worldwide with safe, effective, and vital biological products.



«Biopharma Plasma» is a Ukrainian biotechnology company specializing in the development and production of essential medicines derived from donated blood plasma. We are the largest manufacturer of plasma-derived products in Eastern Europe. Our state-of-the-art, high-tech fractionation plant is located in Bila Tserkva, Ukraine. This facility, representing a $120 million investment, has a processing capacity of up to 1 million liters of plasma annually, enabling us not only to meet Ukraine's needs but also to export products to dozens of other countries. We utilize our own R&D potential, and the quality of our products is confirmed by international certificates, including those from European institutions.

We do more than just produce medicine; we create an ecosystem. We are developing a network of modern plasma centers across Ukraine, which are the foundation for safe and high-quality raw material. I believe that «Biopharma» is not just the 580 professionals who work in our production facilities every day. It is, first and foremost, a socially responsible business that actively invests in the development of science and education in Ukraine, because we are committed to nurturing qualified talent.


We are constantly moving forward and embracing innovation. We do not shy away from challenges, setting global ambitions to expand our presence in international markets. We are a leading player in plasma processing, and we are open to collaboration to jointly provide patients worldwide with vital, safe, and high-quality preparations.

CEO Konstantin Yefimenko



biopharma

Production facilities







biopharma

Production facilities

Biopharma is a Ukrainian biotechnology company that is engaged in plasma procurement, and also specializes in the production of plasma for the manufacture of blood products. The plant is capable of processing 1 million. liters of plasma per year, which can meet the need for drugs not only in Ukraine, but also in dozens of other countries, because the company produces competitive products of the international level in a complex biotechnological industry.









biopharma

Production facilities

Fractionator production lines are the heart of the Biopharma complex. A high-tech process of converting plasma into valuable medicines takes place here.

The production uses equipment from the best European and American companies, all production technologies developed by the specialists of the Biopharma R&D department.











biopharma

Product range

The company "Biopharma" possesses a unique high-tech specialization within the Eastern European market, focused on blood plasma fractionation and the manufacturing of immunobiological products.







biopharma

Product range





Core Competence: Blood Plasma Products
"Biopharma" ensures a full production cycle and has its own API (Active Pharmaceutical Ingredient) manufacturing, specifically plasma for fractionation. This capability allows the company to produce a range of vitally important medicines that have high potential for EU registration:

- Human Albumin
- Human Intravenous and Subcutaneous Immunoglobulin
- Human Anti-Rhesus Immunoglobulin








biopharma

Production Volumes

The production complex maintains significant output volumes for hospital products, including:

DOSAGE FORM	ACTUAL PRODUCTION VOLUMES	POTENTIAL CAPACITY (PER YEAR)
Infusion Solutions	800,000 units	1,200,000 units



"Biopharma" is prepared to increase volumes and confirms its ability to ensure the stable supply of highly specialized products to the European market.

biopharma

Export Geography



11
countries worldwide

Our export potential covers the markets of Eastern Europe, as well as key regions in Asia and Latin America:
Europe and Asia: Ukraine, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Azerbaijan, Bosnia and Herzegovina.
Latin America and the Middle East: Brazil, Argentina, Venezuela, Iraq.



biopharma

Export Geography

"Biopharma" maintains a broad and geographically diversified presence in the global market, confirming its status as a reliable international supplier of high-quality blood plasma products.

"Biopharma" is proud that its vital medicines are available to patients in these 11 countries, strengthening the global supply chains for immunobiological products.

11
countries worldwide

biopharma

Quality Control

"Biopharma" pays the utmost attention to the quality, safety, and efficacy of its products, which is critically important for the manufacturing of immunobiological products. The company has developed and implemented an effective Pharmaceutical Quality System (PQS) that covers the entire product lifecycle: from pharmaceutical development and registration to delivery to end-users.





biopharma

Quality Control

Quality Standards and Certification
Our Quality System is based on key international standards, ensuring maximum compliance with global requirements:

ISO 9001:2015
Certified Quality Management System.

GMP (Good Manufacturing Practice)
Adherence to stringent manufacturing standards.





biopharma

Quality Control

International Recognition (GMP Certificates)

The high level of our production is confirmed by GMP certificates issued by authoritative international and national regulators:

- UA GMP (Ukraine)
- TITCK GMP (Turkey)
- ANVISA GMP (Brazil)
- ANMAT GMP (Argentina)

These certificates demonstrate "Biopharma's" readiness to operate within regulated markets and guarantee stable quality of supply.

biopharma

Own Laboratory Facilities

To ensure continuous control and innovative development, the company has a strong laboratory base:

- Virological Laboratory
- Biological Laboratory
- Research Laboratory

This allows for profound quality control of raw materials (plasma) and finished products, as well as conducting our own scientific research in the field of immunobiological products.











biopharma

Own Laboratory Facilities



"Biopharma's" Modern Quality Control System

The Quality Control Department (QCD) at "Biopharma" ensures comprehensive laboratory testing — from incoming raw materials (plasma) and intermediates to finished products. The QCD operates in compliance with Good Manufacturing Practice (GMP) requirements and holds industry accreditation (Certificate No. 473 from the State Service of Ukraine on Medicines and Drugs Control).

The QCD, which maintains data integrity per GMP requirements, consists of three specialized laboratories:

Biological Laboratory:

Specializes in testing blood plasma for transfusion-transmissible infection markers (Hepatitis A, B, C, HIV, Parvovirus B19) using NAT and ELISA methods.Conducts complex functional tests (clotting factors, Anti-D antibodies, Immunoglobulin Fc-function, bacterial endotoxins), utilizing equipment from Qiagen, Thermo Fisher Scientific, and BioTeK.

Chemical Laboratory:

Performs all tests in accordance with current editions of the European Pharmacopoeia (EP) and the State Pharmacopoeia of Ukraine (SPU). Equipped with modern analytical instruments, including UHPLC, GC, and AAS.

Microbiological Laboratory:

Conducts microbiological monitoring of production environments and other controlled areas. "Biopharma's" QCD guarantees data integrity and quality assurance, serving as the foundation for ensuring the superior quality of its plasma-derived products.

biopharma

«Biopharma»: Key Advantages for European Partners

"Biopharma" is a highly specialized manufacturer of critically important blood/plasma products, ready for partnership in the EU.

Our Advantages:

Unique Specialization

Full production cycle of Albumin and Immunoglobulin from our own plasma, products of high interest to the European market.

Guaranteed Quality

A robust Pharmaceutical Quality System based on GMP and ISO standards.

Global Certification

Possession of international GMP certificates (including TITCK, ANVISA, ANMAT) confirms our readiness to operate in regulated markets.

Competitive Logistics

Our location in Ukraine ensures speed of production and logistical flexibility.

Readiness for Cooperation

Open to contract manufacturing and product localization.

By choosing "Biopharma," you are selecting a reliable partner that ensures quality, speed, and cost-effectiveness in the supply of blood products.




19
32
LUBNYPHARM



LUBNYPHARM

COMPANY OVERVIEW

JSC “Lubnypharm” is one of the oldest and most respected pharmaceutical manufacturers in Ukraine, combining nearly a century of heritage with modern technologies and GMP-certified production. Founded in 1932 as a plant for the primary processing of medicinal herbs, the company has developed into a diversified pharmaceutical enterprise with a portfolio of more than 100 medicinal products across multiple dosage forms. For decades, Lubnypharm has been a reliable partner in strengthening medical security, offering affordable generics of both synthetic and herbal origin to millions of patients.

Lubnypharm’s manufacturing complex consists of eight fully GMP-compliant production units located in the Poltava region. These facilities support the development and production of a wide variety of finished dosage forms, including tablets, tinctures, extracts, ointments, gels, liniments, injection solutions, and medical devices. This diversity allows the company to cover a broad spectrum of therapeutic needs, ranging from basic anti-inflammatory and cardiovascular medicines — such as Aspirin, Paracetamol, and Enalapril — to critically important hospital injectables and antibiotics.

A defining feature of Lubnypharm is its long-standing expertise in traditional herbal medicines. The company excels at transforming high-quality plant raw materials into effective pharmaceutical forms, producing dozens of natural tinctures, extracts, and oils that remain in high demand across multiple markets. At the same time, Lubnypharm is deeply committed to quality and invests in state-of-the-art European equipment to maintain stable and reproducible production processes.

Lubnypharm uses environmentally friendly raw materials, sourced domestically and internationally, ensuring both safety and consistency. While the company does not work with biotechnologies or plasma products, its strategic focus is on developing and expanding a broad generics portfolio — particularly in tablets, ampoules, topical forms, and liquid medicines. This positioning makes Lubnypharm a strong industrial partner for healthcare systems seeking proven, essential, and cost-effective treatments.

Looking ahead, the company plans to expand into domestic production of selected Active Pharmaceutical Ingredients (APIs), including paracetamol, dimethindene maleate, mefenamic acid, and ethonium (an antiseptic). Each API manufacturing line will require an estimated €3–4 million in investment, covering equipment, infrastructure, and regulatory preparation. This strategic initiative aims to strengthen supply chain resilience, reduce import dependence, and create new opportunities for international cooperation.

Lubnypharm has already built a strong export footprint, supplying key markets across Central Asia and Europe. The company is actively pursuing further expansion through deeper penetration of existing markets, entry into additional EU countries, and the creation of strategic alliances with distributors and manufacturers. These partnerships would support joint registration and promotion of new APIs and finished products, significantly accelerating market access and enhancing commercial outcomes.

Quality control is a cornerstone of Lubnypharm’s operations. The company holds valid GMP certificates (UA No. 040/2025/GMP and UA No. 039/2025/GMP), valid until 2027 and 2028 respectively. In addition, Lubnypharm maintains ISO 13485:2016 certification, confirming that its processes for designing, developing, producing, and supplying medical devices meet stringent international regulatory standards. Fully equipped chemical and biological laboratories ensure continuous, multi-stage testing of raw materials, intermediates, and finished products.

With its nearly 100-year history, modern GMP-certified facilities, and advantageous geographic location near the EU, Lubnypharm is ideally positioned to offer Europe a high-quality, reliable, and cost-effective alternative to Asian suppliers. The company is ready to fill critical therapeutic niches in the European pharmaceutical market — including antibiotics, anti-inflammatories, analgesics, antiseptics, and hospital injectables — supported by rapid road logistics, competitive pricing, and a strong record of contract manufacturing.

Lubnypharm is open to adapting its medicines to EMA requirements, pursuing EU GMP certification, and building long-term partnerships that combine quality, accessibility, and regulatory readiness. With its proven expertise and strategic vision, JSC Lubnypharm stands ready to contribute meaningfully to the strengthening of pharmaceutical supply chains across Europe.



I am proud to introduce a company that stands as a reliable partner for millions of consumers. For decades, we have made a systemic contribution to medical security, focusing on affordable generics of synthetic and herbal origin.

Our production facility is a blend of deep pharmaceutical traditions and modern technologies. Across eight production units, all of which fully comply with international GMP requirements, we manufacture over 100 product titles of medicines. Our portfolio is striking in its depth: from essential, basic anti-inflammatory and cardiovascular medications (such as Aspirin, Paracetamol, and Enalapril) to critically important hospital injectable solutions and antibiotics.

Our special pride is our expertise in creating traditional medicines based on medicinal plant raw materials. We are masters at transforming natural power into effective forms: our portfolio includes dozens of natural tinctures, extracts, and oils that are in high demand. We do not work with biotechnologies or blood/plasma products; our strategic focus is on a wide range of generic solutions in the forms of tablets, ampoules, ointments, gels, and liquids. We invest in European equipment to guarantee consistently high quality and are ready to provide the European market with these proven and necessary medical solutions.

CEO Svitlana Vashchuk



Production facilities





Production facilities

JSC "Lubnypharm" is a fairly well-known enterprise in the pharmaceutical market of Ukraine, the year of foundation of which is considered to be 1932, when a plant for the primary processing of medicinal herbs was organized. Today, JSC "Lubnypharm" is a pharmaceutical enterprise, the main activity of which is the development and production of finished medicines for external and internal use in the form of: tablets, tinctures, extracts, ointments, gels, liniments, injection solutions, medical devices. The nomenclature of the enterprise is more than 100 items and has a wide range of pharmacological action, a wide variety of dosage forms.







Product range

Medicines manufactured by Lubnypharm JSC are environmentally friendly, various raw materials are used for their manufacture, including those imported from abroad.







Production facilities of the company



The company plans to strategically invest in the domestic production of Active Pharmaceutical Ingredients (APIs) under the following International Nonproprietary Names (INNs): paracetamol, dimethindene maleate, mefenamic acid, ethonium (antiseptic).

The launch of production of each API will require an investment of between 3 and 4 million euros (taking into account all associated costs).

DOSAGE FORM	DESIGN CAPACITY (UNITS PER YEAR)	POTENTIAL CAPACITY (TAKING INTO ACCOUNT MODERNIZATION / INVESTMENT)	ESTIMATED AMOUNT OF INVESTMENT REQUIRED
	Approximately 45,000,000 blisters	60,000,000 blisters	1,800,000 EUR
	2000,000 ampoules	32,000,000 ampoules	3,200,000 EUR
Ointments / creams remedies	4,000,000 tubes	10,000,000 tubes	2 900,000 EUR





Distribution

Lubnypharm has successfully built a strong geography of presence, covering the key markets of Central Asia and Europe. However, the company strives for further strategic growth and expansion of partnerships, in particular, through:

- deepening of presence (strengthening of positions in existing markets);
- access to related markets, in particular, other EU countries;
- creating strategic alliances with distributors or manufacturers to jointly register and promote new APIs and finished dosage forms, reducing time to market.

Lubnypharm has all the prerequisites to turn its current success into international expansion.

Quality Control

Lubnypharm confirms its commitment to the highest quality standards, which is evidenced by leading international and national certificates. In particular, these are valid **GMP (Good Manufacturing Practice)** certificates: **CERTIFICATE OF GMP COMPLIANCE UA: No. 040/2025/GMP Valid till: 28.02.2027 and CERTIFICATE OF GMP COMPLIANCE UA: No. 039/2025/GMP Valid till: 28.02.2028.**
In addition to GMP, Lubnypharm demonstrates a high level of quality management in specialized industries, in particular in the production of medical devices. And the obtained **ISO 13485:2016** certificate confirms that the processes of design, development, production and supply of medical devices at the plant meet strict international requirements established for regulatory purposes.









Quality Control

To ensure proper control and quality assurance of medicines manufactured at JSC "Lubnypharm", the chemical-analytical and microbiological laboratories of the quality control department, production workshops, warehouses for storing raw materials and finished products in accordance with GMP principles were completely modernized and equipped with modern equipment.









Key Takeaways: JSC "Lubnypharm" Positioning and Strategic Advantages

JSC Lubnypharm is a combination of almost 100 years of experience in pharmaceutical production, confirmed by current **GMP certification**, and geographical advantages, which makes the company an almost ideal alternative to **Asian suppliers for the EU market**.

JSC Lubnypharm is ready to fill critical niches in the European pharmaceutical market by offering a range of generics such as antibiotics, anti-inflammatories, analgesics, antiseptics and hospital solutions.

This can be achieved by:

- logistical advantages (proximity to the EU, possible fast delivery by road, reasonable logistics costs and reduction of supply chains);
- readiness for contract manufacturing with European partners (the company has significant experience, including experience in the production of batches of drugs ordered by other companies, GMP certification, can be provided with generics at competitive prices).

Lubnypharm is open to discussing adapting its dossiers to EMA requirements and obtaining EU GMP certification and strives to become a bridge connecting quality and accessibility with the needs of the European market.




БХФЗ
bcpp



BORSHCHAHIVSKIY CHEMICAL-PHARMACEUTICAL PLANT

COMPANY OVERVIEW

PJSC SIC “Borshchahivskiy CPP” is one of Ukraine’s most established pharmaceutical manufacturers, continuously operating since 1947. With decades of scientific expertise, industrial capability, and a strong commitment to European-level quality, the company is now actively expanding its presence in the EU market. Leveraging its advanced production base, modern quality systems, and experience in international registrations, BCPP positions itself as a reliable partner for long-term cooperation, contract manufacturing, and supply of critical medicines.

The company holds valid EU GMP certificates issued by Latvia and Lithuania, confirming full compliance with high European regulatory standards. Its production complex in Kyiv supports a broad portfolio of dosage forms, including antibiotics, solid and liquid pharmaceuticals, and medicinal products using APIs of its own manufacture. This integration of API production ensures transparency in raw material origin, robust quality control, and supply chain resilience — a key competitive advantage for partners seeking reliability and full-cycle pharmaceutical expertise.

BCPP already exports its products to EU member states such as Croatia, Lithuania, Latvia, and Poland, demonstrating established operational experience within the European pharmaceutical environment. The company’s strategic location in Ukraine ensures rapid logistics to the EU and the ability to maintain stable deliveries. Future investments are aimed at scaling production capacity and expanding the list of authorized INNs to strengthen its presence in highly regulated markets.

The company offers a diversified product range across major therapeutic areas, including cardiology, neurology, gastroenterology, and antibiotic therapy. Alongside high-quality generics, BCPP develops original formulations, phytopharmaceuticals, veterinary medicines, and dietary supplements. Many products incorporate multicomponent herbal APIs produced in-house, while others serve as essential therapies for cardiovascular and neurological conditions, as well as broad-spectrum antibiotics across different classes.

Quality and safety are central pillars of the company’s operations. BCPP has implemented an Integrated Pharmaceutical Quality System (IPQS), which incorporates the requirements of GMP, GDP, GSP, G(Q)CLP, ISO 9001, ISO 14001, ISO 17025, ISO 50001, SA 8000, and EU hygiene regulations, including HACCP principles. This comprehensive system ensures consistent quality across all manufacturing stages. The Quality Control Department includes certified physicochemical and microbiological laboratories, performing multi-level testing and holding a perpetual Certificate of Attestation.

Research and development remain a strategic priority. With its own R&D divisions, the company has become one of Ukraine’s leading developers of original pharmaceutical products. Continuous innovation, adherence to strict scientific standards, and investment in laboratory capabilities allow BCPP to introduce new medicines and improve existing formulations in line with global pharmaceutical trends.

In the European market, PJSC SIC “Borshchahivskiy CPP” positions itself as a technologically advanced, flexible, and dependable partner. Its key strengths include European-certified quality standards, a wide range of dosage forms, large-scale production capacity, and readiness to provide full-cycle contract manufacturing — from API sourcing to finished product release. The company continues to expand its export geography, viewing international cooperation as a core component of its long-term development strategy.

PJSC SIC “Borshchahivskiy CPP” welcomes dialogue with partners seeking high-quality manufacturing, efficient logistics, and scientifically grounded pharmaceutical solutions. Its commitment to quality, reliability, and innovation makes it a valuable ally for companies aiming to strengthen their presence in the European market and beyond.



PJSC SIC "Borshchahivskiy CPP" has been a reliable manufacturer of pharmaceutical products since its foundation in 1947. Building on our extensive experience and robust production capabilities, we are actively seeking to expand our presence and foster new partnerships in the EU market.

However, we are seeking to expand our presence in the EU market. For our part, we offer:

European Quality: We hold current EU GMP Certificates, issued by Latvia and Lithuania, confirming that our processes meet the highest quality standards.

Powerful Production Complex: Our manufacturing lines, located in Kyiv, allow us to produce a wide range of dosage forms.

Antibiotic Expertise: We already have products registered in the EU, including cephalosporin and carbapenem antibiotics, which is our key advantage.

Strategic Logistics: Our location in Ukraine guarantees proximity to the EU and the possibility of fast deliveries. We have current export experience to EU countries, including Croatia, Lithuania, Latvia, and Poland.

Contract Manufacturing: We are ready to become your reliable partner for full-cycle contract manufacturing, utilising our GMP-certified facilities and scientific base.

We view PJSC SIC "Borshchahivskiy CPP" as a compelling investment in quality, speed, and reliability within the European pharmaceutical market.

We would welcome the opportunity to discuss how our manufacturing expertise and certified capabilities can support your strategic goals.

CEO Yevhen Mandziuk



Production Facilities





БХФЗ bcpp

Production Facilities

At the current production sites, PJSC SIC "Borshchahivskiy CPP" is focused on using active pharmaceutical ingredients (APIs) of its own production, as well as certified substances from trusted manufacturers that have already been successfully registered. This ensures the highest level of quality control, transparency in the origin of raw materials, and supply chain sustainability.

BCPP has a clear strategic development plan:

- Future investments: After attracting the necessary investments, the production capacity will be expanded to issue additional authorized INNs (international nonproprietary names).
- Strategic Planning: This development will be carried out taking into account the territorial location of the enterprise, ensuring optimal logistics and production safety.





БХФЗ bcpp

Product Range

PJSC SIC "Borshchahivskiy CPP" offers a wide and diversified portfolio covering critical therapeutic areas:

- **Cardiology**
- **Neurology**
- **Antibiotic therapy**
- **Gastroenterology.**

The company combines the production of high-quality generic drugs with innovative in-house developments.



БХФЗ bcpp

Product Range



ANNUAL PRODUCTION CAPACITY	
1,864,940,000	units
18,240,000	vials
11,000,000	vials
4,875,000	vials
1,350,000	tubes
5,000,000	tubes
5,000,000	packs
400,000	vials
2,862,750	vials
5,588,220	ampoules
11,386 kg	**API, EXTRACTS, SUBSTANCES**



The basis of the company's work is the focus on high quality, safety and efficiency of products, satisfaction of consumer needs, environmental protection, health and safety of personnel, social responsibility, energy efficiency. The company's policy and strategy takes into account the interests and is available to all stakeholders.

Product Range

The key directions of the company are the production of high-quality generic drugs and phytopharmaceuticals. Our portfolio also includes original proprietary formulations, dietary supplements, and veterinary medicinal products.


Company's portfolio covers wide range of finished medical products, including:

- Multi-component herbal preparations, including those with APIs of own production.
- Critically important drugs for the treatment of cardiovascular and neurological diseases.
- Generic and combination drugs providing a broad spectrum of pharmacological effects.
- Broad-spectrum antibiotics of different classes.





Distribution



BCPP is a recognized international supplier, which is confirmed by its wide presence in the world, exporting its products to the **EU countries (Lithuania, Latvia, Croatia, Poland)**, which makes us a reliable partner who understands the requirements of the **European** market. In addition, the company's products are supplied to key markets of the **CIS (Azerbaijan, Georgia, Kyrgyzstan, Moldova, Tajikistan, Kazakhstan, Turkmenistan).**

Quality Control

Production is one of the main activities of **PJSC SIC "Borshchahivsky CPP"** and is carried out in accordance with the requirements of international standards, which makes it possible to manufacture products meeting European quality standards.



Quality Control

The company has implemented an integrated pharmaceutical quality system (IPQS), which takes into account the requirements of GMP, GDP, GSP, G (Q) CLP, ISO 9001, ISO 14001, ISO 17025, ISO 50001, SA 8000, Regulation of the European Parliament and of the Council (EC) No. 852/2004 of 29.04.2004 on food hygiene, incl. HACCP principles, IMPAC 10000.



Research & Development

The introduction of new medicines has always been among the priorities of BCPP. The presence of its own R&D divisions allowed the plant to become one of the key manufacturers of original drugs of its own development.











Safety and Efficiency

The quality of products of **PJSC SIC "Borshchahivsky CPP"** is ensured by a reliable and independent laboratory control system. The quality control department is represented by two key laboratories — physicochemical and microbiological, that carry out multi-level control at all stages of production.
The laboratories of the company's quality control department have a perpetual **Certificate of Attestation** (issued on January 20, 2012).







Key Takeaways: Positioning and Strategic Advantages



In the European arena, PJSC SIC Borshchahivsky CPP positions itself as a reliable and flexible partner.

Its strengths are based on technological excellence and extensive production capabilities, and the foundation of reliability is:

- European Quality Standards: The company has implemented quality standards, confirmed by international certificates, that enable the production of products meeting European-level quality.
- Wide range of dosage forms.
- Large-scale production facilities.
- Full Cycle Contract Manufacturing: The enterprise offers the possibility of full-cycle contract manufacturing, ensuring quality control and efficiency at every stage. Considering the export component of the business to be one of the priority aspects of its activity, the company is actively working on expanding the geography of sales markets.


LEKHIM
Group of Pharmaceutical Companies



LEKHIM

GROUP OF PHARMACEUTICAL

1992 — establishment of LEKHIM.

LEKHIM Group of Pharmaceutical Companies is a powerful high-tech manufacturing pharmaceutical

company in the field of development, production, and sale of high-quality medicinal products.

LEKHIM is one of the top 10 leading Ukrainian pharmaceutical companies.

LEKHIM employs over 1,000 people and produces over 250 high-quality, affordable medications, which are supplied to 30 countries worldwide LEKHIM Group of Pharmaceutical Companies includes 6 companies: Managing Company LEKHIM, Kyiv, UA, Manufacturing site TECHNOLOG, Uman, UA, Manufacturing site LEKHIM-KHARKIV, Kharkiv, UA, Manufacturing site LEKHIM-OBUKHIV, Obukhiv, UA, Export-Import Company LEKHIM-VILNIUS, Vilnius, Lithuania, LEKHIM, Tashkent Region, Uzbekistan is under construction.

Main activities:

- Production of finished dosage forms (medicines, nutraceuticals, veterinary drugs);
- Medical devices;
- Export-import operations;
- Contract manufacturing;
- R&D;
- Management and marketing, distribution and sales.

Production facilities:

- Small volume injections in ampoules and pre-filled syringes;
- Solid dosage forms: tablets, capsules, dragees, pellets, powders;
- Soft dosage forms: suppositories;
- Medicinal products in the form of sachet;
- Powder in vials for solutions for injections;
- Liquid dosage forms: syrups, oral solutions, liquids for external use, drops, etc.

All manufacturing sites of LEKHIM Group of Pharmaceutical Companies conduct manufacturing and quality control operations in strict compliance with current requirements of EU GMP Guidelines.

High manufacturing standards are confirmed by the competent authorities from EU, Ukraine and other countries.

Export markets:


Our products are successfully supplied to the markets of **EU, CIS, MENA, Africa, and Southeast Asia**.

We are open for a new partnership in the field of pharmaceutical development, contract manufacturing and export of LEKHIM products.

LEKHIM — your reliable partner in health support with innovative best practices!


LEKHIM Group of Pharmaceutical Companies
LEKHIM
Group of Pharmaceutical Companies


LEKHIM Group of Pharmaceutical Companies is a modern manufacturing company in the field of development, production and sale of high quality, safe, effective and affordable medicines.
1992 – the establishment of LEKHIM Company. LEKHIM is among the top 10 leading Ukrainian pharmaceutical companies and exports its products to more than 30 countries around the world.
LEKHIM Group of Pharmaceutical Companies includes 6 companies:
LEKHIM Managing Company, Kyiv, Ukraine
TECHNOLOG Plant, Uman, Ukraine
LEKHIM-KHARKIV Plant, Kharkiv, Ukraine
LEKHIM-OBUKHIV Plant, Obukhiv, Ukraine
LEKHIM-VILNUS Export-Import Company, Vilnius, Lithuania
LEKHIM Plant, Tashkent Region, Uzbekistan – under construction
Main activities:
• Production of finished dosage forms (medicines, nutraceuticals, veterinary drugs)
• Medical devices
• Export-import operations
• Contract manufacturing
• R&D
• Management and marketing, distribution and sales
Our key features:
«LEKHIM Company is a team of like-minded people who are passionate about their work. Established 33 years ago, it currently employs over 1,000 people and produces over 250 high-quality, affordable medicines, supplied to 30 countries worldwide. The development of modern medicines, conquering new markets, expanding and growth of the production facilities are our top priorities today – LEKHIM never stops. Our partners value our company's reliability, sociability and high level of professionalism!
We are committed to working hard for achieving our goals and believe in success!»
CEO of LEKHIM Group of Pharmaceutical Companies
Tetiana Pechaeva


LEKHIM Group of Pharmaceutical Companies Allocation
LEKHIM
LLC LEKHIM-OBUKHIV
Manufacturing site
Obukhiv
JSC LEKHIM
HEAD OFFICE
Kyiv
LITHUANIA
UKRAINE
PJSC LEKHIM-KHARKIV
Manufacturing site
Kharkiv
UAB LEKHIM-VILNIUS
Export-import
enterprise
Vilnius
FP LEKHIM LLC
Manufacturing site
Tashkent Region
PJSC TECHNOLOG
Manufacturing site
Uman
UZBEKISTAN
Annual turnover over 70 million US Dollars
Number of employees over 1000



Production and Development

LEKHIM was founded in 1992 and became one of the market leaders, employing approximately 1000 of personnel. The technological versatility of our manufacturing sites allows us to produce a wide range of dosage forms.

LEKHIM carries out contract manufacturing of medicines and nutraceuticals in various forms for a number of customers.

LEKHIM continuously develops and improves the equipment, capabilities and the training of the personnel.

Engineering utilities of all our facilities are energy independent and are equipped with their own alternative power supply systems, heat supply and a water supply stations.
All our manufacturing sites have R&D centres that provide a full cycle of medicines development, covering almost all types of finished dosage forms.
The R&D centres are equipped with the modern pilot equipment and analytical instruments.
In 2025, the construction of a new additional R&D area of 1,000 m2 was completed.

The fields of activity:
- Finished dosage forms
- Nutraceuticals
- Medical devices
- Contract manufacturing/Private label
- Research & Development

Product Range

- Small volume injections in ampoules and pre-filled syringes
- Powders for injections in vials
- Solid dosage forms: tablets, capsules, dragees, pellets, powders
- Soft dosage forms: suppositories
- Liquid dosage forms: syrups, oral solutions, oral drops, liquids for external use
- Lyophilisate for solutions for injection – under development
- Sterile solutions in dropper bottles – under development

LEKHIM — Your reliable partner in health support with innovative best practices





Production Capacity



Production of small volume injections:
200 million ampoules per year
30 million pre-filled dosable syringes per year



Production of solid dosage forms:
over 2 billion tablets per year
over 500 million capsules per year
over 100 million dragees per year



Production of dosage forms in sachet:
over 15 million sachet per year



Production of liquid dosage forms (oral solutions, syrups, other):
over 15 million bottles per year



Production of soft dosage forms:
over 30 million suppositories per year



Production of powder for solution for injections:
over 10 million vials per year



Distribution




30 countries worldwide

LEKHIM Group of Pharmaceutical Companies is marketed in Ukraine and outside the country. We export our products to more than **30 countries** worldwide. Our products are successfully supplied to the markets of **EU, CIS, MENA, Africa and South-East Asia.**
We are open for a new partnership in the field of pharmaceutical development, contract manufacturing and export of **LEKHIM** products.

GMP Compliance

All manufacturing sites of LEKHIM Group of Pharmaceutical Companies conduct manufacturing and quality control operations in strict compliance with current requirements of EU GMP Guidelines.
High manufacturing standards are confirmed by the competent authorities from EU, Ukraine and other countries.

- State Medicines Control Agency, Lithuania (EU member)
- State Service of Ukraine on Medicines and Drugs Control, Ukraine (PIC/s member)
- WHO Prequalification Committee, (RPQ)
- Medical and Pharmaceutical Control Committee, Kazakhstan
- Center for Good Practices, Uzbekistan



Key Takeaways: Capabilities and Advantages of LEKHIM Group of Pharmaceutical Companies

1. Portfolio and Technological Versatility

- **Broad Portfolio:** Manufacturing over 250 items of different dosage forms, focusing mostly on generic medicines, some biosimilars, nutraceuticals and medical devices.
- **Key Groups:** Coverage of most major therapeutic areas (Cardiology, Neurology, Gastroenterology, Gynaecology, Urology, Pulmonology, Antituberculosis treatment, Anti-infective agents, Antibiotics, Analgesic, Hormons, Vitamins etc.) under ATC codes A, B, C, G, J, M, N, R.
- **Complex Forms:** Production of a wide range of dosage forms, including small volume injections in ampoules and PFS, powders for injection in vials, sachets, tablets, coated tablets, capsules, dragees, pellets, oral solutions, syrups and suppositories.



Key Takeaways: Capabilities and Advantages of LEKHIM Group of Pharmaceutical Companies

2. International Integration and Quality

- **Global Presence:** Export of products to a wide range of countries, including the EU (Lithuania, Latvia, Estonia, Germany), Middle East, Africa, CIS, APAC. Supply of the antituberculosis medicine for the tender of WHO.
- **European Certification:** Production sites are certified according to GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) standards.
- **Regulatory Success**: Holding marketing authorizations in Ukraine - 250+, EU – 3, CIS counties – 330 +, other countries - 49.
- **Contract Manufacturing:** Experience cooperating with well-known European manufacturers, including Stada.



Key Takeaways: Capabilities and Advantages of LEKHIM Group of Pharmaceutical Companies





3. Strategic Advantages for Partners

- **Production Localization:** Full cycle or partial of contract manufacturing.
- **Favourable Geographic Location**: Neighborship to the EU and the availability of established logistics routes for prompt deliveries, the availability of reliable freight forwarders with specialized vehicles for transporting medicines with specific storage conditions.
- **Cost Efficiency:** Reasonable value for money, providing a competitive advantage in markets.
- **Transparent Cooperation:** Adherence to ethical business practices, efficiency in decision-making and proven reliability (cooperation with UNDP, Global Fund, Medicines sans Frontiers, etc.), short lead time.


YURiA·PHARM



YURIA-PHARM

COMPANY OVERVIEW

YURiA-PHARM is a Ukrainian pharmaceutical group with a global outlook, dedicated for more than 30 years to developing solutions that improve patient outcomes and advance modern pharmaceutical technologies.

The company's purpose is to create unique solutions for improving health and treating patients in the countries where it operates, providing healthcare systems with medicines and medical devices that save lives, reduce pain, accelerate recovery, and minimize the signs of aging.

The company holds strong positions in hospital-oriented therapeutic areas: blood substitutes and perfusion solutions, multimodal analgesia, peritoneal dialysis, inhalation therapies, infusion antibacterials, iodine-containing contrast agents, and medical devices including syringes and infusion systems.

YURiA-PHARM's portfolio includes 100 medicinal products and 67 medical devices. The total number of registration certificates exceeds 1,000, driven by the company's presence in more than 50 international markets. Today, more than 30% of its revenue comes from exports produced at its Ukrainian facilities, demonstrating that the company's technologies and approaches are competitive not only locally but also globally.

The main manufacturing hub in Ukraine produces 290 million units annually, complemented by the DIACO manufacturing facility in Trieste, Italy (33 million units), and a production site in Uzbekistan (92 million units).

Together, these sites form an integrated supply chain capable of supporting both regional and global demand. YURiA-PHARM holds strong expertise in parenteral solutions and emulsions, powders for injections, inhalation therapies, and biopolymeric gels based on hyaluronic acid.

The company also has experience in the in-house production lines of Active Pharmaceutical Ingredients (APIs), including such key molecules as Edaravone (for the drug Xavron) and Methoxyflurane (for Yumerox), which enables it to maintain full control over the production cycle. Yumerox has clear potential for EU registration. Completing the dossier will require an investment of $5 million.

Looking ahead, YURiA-PHARM is targeting biotechnological products (biosimilars), which will require an investment of $50 million.

YURiA-PHARM operates under the highest international quality standards. Its production sites are certified by regulators in Ukraine, Kazakhstan (EAEU), Uzbekistan, Uganda, and Libya. The company maintains a broad portfolio of management system certifications: ISO 9001:2015, ISO 14001:2015, ISO 22000:2018, and ISO 13485:2016 — verified by Ukrainian and international bodies including TÜV Rheinland.

Following a successful audit in 2025, the company is preparing for EU MDR certification, opening new opportunities for European market expansion.

Currently, the company has several products registered in the EU, including medical devices based on hyaluronic acid (Diart, Artro Patch, Okistar) and the specialized food product Reo water. A substantial part of the portfolio — injectable solutions in 100–500 ml polypropylene containers (levofloxacin, moxifloxacin, ciprofloxacin, paracetamol, and base solutions) — has clear potential for EU registration. Achieving this will require an investment of $3.8 million directed towards ensuring full compliance with EU GMP standards and final dossier requirements.

The company's portfolio also includes a number of products that may be of interest to the EU market in line with the Union List of Critical Medicines. Their registration and market entry will require investments of $20–25 million.

One of the company's key development principles is reinvestment. YURiA-PHARM reinvests more than 75% of its profits into growth — from R&D and manufacturing technologies to international expansion. The company aims for annual growth of at least 20%, supported by the systems, capabilities, and infrastructure built to deliver this objective.

Since 2015, YURiA-PHARM has been developing the YP Biotech biotechnology R&D infrastructure, aiming to create the first center in Ukraine capable of performing a full cycle of biotechnological development for biomedical purposes.

With established international experience, production capacity within the EU, a strong R&D base, and readiness for contract manufacturing and co-development, the group positions itself as a reliable and strategic partner for Europe's pharmaceutical ecosystem.


UKRAINIAN PHARMACEUTICAL
GROUP WITH A GLOBAL OUTLOOK
YURiA·PHARM


YURiA-PHARM is a Ukrainian pharmaceutical group of companies developing with a global vision.
For more than 30 years, we have been committed to creating solutions that improve patient outcomes, strengthen hospital care, and advance modern pharmaceutical technologies. Our portfolio includes over 1,000 registration certificates, 20+ new products every year, and operations in more than 50 countries, with 30% of revenue coming from exports produced at our Ukrainian facilities.
Our long-term strategy is to establish ourselves among the Top 100 global pharmaceutical companies through the development of what we refer to as the International Product – a solution that addresses unmet clinical needs, is in demand, competitive, and accessible far beyond our domestic market.
A key principle that drives our progress is reinvestment. We reinvest more than 75% of our profits directly into development — from R&D and manufacturing technologies to international expansion. Our goal is at least 20% annual growth, supported by systems, capabilities, and infrastructure built to deliver this ambition.
Today, our priority areas include:
• manufacturing hospital medicines and medical devices;
• adopting, developing, and scaling biopharmaceutical technologies;
• creating products based on hyaluronic acid.
• developing innovative solutions that can be integrated into global healthcare ecosystems.
The past years have truly tested the resilience of the Ukrainian industry. Despite the challenges of wartime conditions, we have maintained uninterrupted production, protected our dedicated teams, and continued delivering essential hospital therapies both in Ukraine and abroad. This experience has strengthened our conviction that agility, innovation, and strong partnerships are fundamental to modern pharmaceutical leadership.
YURiA-PHARM is evolving into a company where innovation is continuous — not episodic. Where management is not about control, but about creating an environment in which value can emerge. And where collaboration — including with competitors — becomes a foundation for sustainable growth.
Today, we are open to partnerships in co-development, contract manufacturing, international distribution, scientific collaboration, and the creation of new pharmaceutical capacities for Europe, with Ukraine as an integral part of this ecosystem.
We invite you to collaborate with us to create value that addresses patients' needs worldwide.
CEO Dmytro Derkach


YURiA·PHARM
Production Facilities
Cherkasy,
Cherkasy Region

YURIA·PHARM

Production Facilities



The main production hub of **YURiA-PHARM** is located in Ukraine, where we manufacture 290 million units of products annually. Our capacity is strengthened by the facility in **Italy (33 million units)** and the production site in **Uzbekistan (92 million units),** forming an integrated system that ensures supply stability and supports our growth across key international markets.

- **Areas of strong expertise**:
Development of parenteral solutions and emulsions, parenteral powders, inhalation products, and biopolymeric gels/hyaluronic acid formulations.


- **Areas of growing expertise:**
Development of a therapeutic platform for RNA therapy and a full development cycle of therapeutic solutions based on recombinant proteins.

YURIA·PHARM

Product Range



ACTUAL PRODUCTION VOLUMES AND DESIGN CAPACITY IN UKRAINE



YURIA·PHARM


Quality Control

YURiA-PHARM demonstrates its adherence to the highest international quality standards through numerous GMP and management system certifications.

The company's manufacturing facilities hold valid GMP certificates issued by regulators in Ukraine, as well as Kazakhstan (EAEU), Uzbekistan, Uganda, and Libya, enabling the supply of products to the markets of Eastern Europe, Central Asia, and Africa.

Management systems and medical device certification:
ISO 9001:2015 and **ISO 14001:2015 —** confirm the effectiveness of business processes and environmental responsibility.
ISO 22000:2018 — for the production of specialized food products.
ISO 13485:2016 — multiple certificates issued by Ukrainian and international bodies, including **TÜV Rheinland**.

The company also holds globally recognized certification from **TÜV Rheinland of North America (USA)** and is awaiting an updated ISO 13485:2016 certificate and initial **EU MDR** certification following a successful audit in September 2025, which will open new export opportunities to the European Union.





YURiA·PHARM

Product range

We are inspired by the opportunity to create innovative medicines, medical devices and technologies that save lives, reduce pain, accelerate recovery and reduce the signs of aging.

YURiA-PHARM's portfolio includes **100 medicinal products and 67 medical devices.** The total number of registration certificates exceeds 1,000, driven by the company's presence in more than 50 international markets.

Therapeutic areas where we hold strong positions:

- Blood substitutes and perfusion solutions: correctors of water-electrolyte balance, complex hyperosmolar solutions, solutions for buffering and restoration of acid-base balance;
- Multimodal analgesia solutions;
- Peritoneal dialysis solutions;
- Infusion antibacterial drugs;
- Medical devices based on hyaluronic acid;
- Products for inhalation (nebulizer) therapy;
- Iodine-containing X-ray contrast agents;
- Medical devices (including syringes and infusion systems).

The company also has experience in the in-house production lies of Active Pharmaceutical Ingredients (APIs), including such key molecules as **Edaravone (for the drug Xavron) and Methoxyflurane (for Yumerox).** This allows us to control the full production cycle. We are actively working to expand our European presence, with the potential to register our drug Yumerox on the EU market. To finalize the dossier and comply with EU requirements, an investment of **$5 million** is needed.

Looking ahead, YURiA-PHARM is targeting biotechnological products (biosimilars), which will require an investment of **$50 million.**

YURiA·PHARM

Distribution

Our preparations and medical devices, manufactured in **Ukraine**, are registered and supplied to countries spanning **Europe** (e.g., Germany, France, Italy, the United Kingdom, Poland, Spain, Sweden), the **Balkans** (Croatia, Serbia, Albania), **North and South America** (Canada, Chile, Colombia), **Asia** (Uzbekistan, Kazakhstan, Kyrgyzstan, Azerbaijan), and **Africa** (Morocco, Namibia, Nigeria, Tanzania, Uganda)

1000
Registration certificates


50+
Countries



Ukraine 375
Asia 464
Europe 130
Africa 27
America 10

YURiA·PHARM

Distribution



YURiA-PHARM is strategically positioned to serve the EU market, not only through exports but also through established production presence.

The company boasts experience in localizing manufacturing within the EU, notably at the Diaco production site in Trieste, Italy. This facility significantly expands the group's capacity, contributing 33 million units annually, including 30 million medicines, 440 thousand medical devices, and 2.2 million cosmetic products, offering an immediate solution for pharmaceutical products previously sourced from Asia.

The company has successfully registered several products in the EU, showcasing its commitment to quality. **Currently registered products include** medical devices containing the INN hyaluronic acid (commercial names: **Diart, Artro Patch, Okistar**), alongside the specialized food product, Reo water.

Looking ahead, a **significant portion of YURiA- PHARM's portfolio**, specifically injectable solutions in 100-500 ml polypropylene containers—such as those containing **levofloxacin, moxifloxacin, ciprofloxacin, paracetamol, and 0.9% NaCL/5% glucose solutions**—hold strong potential for EU registration. Achieving this will require **an investment of $3.8 million** directed towards ensuring full compliance with EU GMP standards and final dossier requirements. This investment is key to positioning these essential hospital products within the EU supply chain.

YURiA·PHARM

Quality Control Department



The YURiA-PHARM Quality Control Department holds full attestation (Certificate No. 550 from the SSUCDM) to conduct comprehensive quality and safety control of medicinal products. Its specialization covers a wide range of physical-chemical, identification, quantitative, and biological methods according to the requirements of the State Pharmacopoeia of Ukraine (SPhU) and Ph. Eur., including tests for sterility, pyrogens, and bacterial endotoxins. This officially validates the company's internal capacity for all-round laboratory control of its pharmaceutical output.








YURiA·PHARM

YURiA-PHARM's POSITIONING AND STRATEGIC ADVANTAGES



- **Full production and supply cycle**

The company manages the entire chain: from R&D to final product delivery to the client.

- **Wide hospital product portfolio**
- **International expansion experience**

Products are present in 50+ countries globally

- **Localization Expertise**

Successful experience in localizing production in Italy (Diaco) and Uzbekistan (Reka-Med Farm).

- **Commitment to Innovation**

Active development of the YP Biotech R&D infrastructure and the launch of the BioGENext scientific platform, underscoring a focus on creating value-added products.

- **Readiness for Cooperation**

Openness to contract manufacturing with European partners.

- **Tender Success**

Proven experience in successful participation in international tenders/projects.

YURiA·PHARM

YURiA-PHARM's POSITIONING AND STRATEGIC ADVANTAGES



- **EU production localization**

Proven experience in localizing production at the Diaco facility in Trieste, Italy, with an annual capacity of 33 million products (including 30 million medicines).

- **Active EU registrations**

Currently registered medical devices based on hyaluronic acid (Diart, Artro Patch, Okistar) and a specialized food product (Reo water).

- **High registration potential**

A significant part of the portfolio, specifically infusion solutions (Levofloxacin, Moxifloxacin, Paracetamol, and basic solutions), can be registered in the EU subject to achieving EU GMP compliance.

- **Investment for EU Compliance**

An investment of $20–25 million is required for the full registration of critical molecules of interest to the EU, as per the Union list of critical medicines.

- **Proximity to the EU**

The key advantage is the geographical closeness of Ukrainian production to the European Union, facilitating rapid logistics.

- **Developed Logistics Network**

Established in-house logistics system and the presence of the Diaco production site in Italy allow for supply chain optimization and technology transfer.


Valartin
pharma



VALARTIN PHARMA

COMPANY OVERVIEW

VALARTIN PHARMA LLC is a modern Ukrainian pharmaceutical company specializing in the development, production, marketing and distribution of medicines and pharmacy products (dietary supplements and medical devices).

The name of the company takes its roots from the latin «Valeo artis» — the art of creating health. This is precisely the mission of our company — to ensure patient access to pharmaceutical care, which is one of the main components of the accessibility of healthcare.

The company "VALARTIN PHARMA" has been operating on the pharmaceutical market ofUkraine since 2013. Its staff includes more than 160 highly qualified professionals.

The company has its own licensed and certified manufacturing facilities and modern laboratory complex in the Kyiv region. Manufacturing, quality system, storage, and distribution processes are certified for compliance with European requirements of GMP (Good Manufacturing Practice), GDP (Good Distribution Practice), HACCP (for dietary supplements), ISO 9001:2015 (Quality Management System), and ISO 14001:2015 (Environmental Management System).

The company provides a highly specialized product portfolio (medicines and dietary supplements) for its customers: patients, medical professionals, and pharmacists.

The key competencies of "VALARTIN PHARMA" are focused on the manufacturing and marketing of medicines and dietary supplements for gastroenterology, gynecology, otorhinolaryngology, immunotherapy/prevention, treatment of vascular diseases.

The company also manufactures an API of Benzyldimethyl[3-(myristoylamino)propyl] ammonium chloride monohydrate.

The Company`s marketing strategy is focused on the branding and unique selling proposition that create added value for customers (patients, doctors and pharmacists) and ensures their loyalty to the Company`s products.

Ukraine is the main market of "VALARTIN PHARMA". The Company also exports some products (dietary supplements) to the EU — the Baltic States and Bulgaria.

"VALARTIN PHARMA" invests significantly in research and development, actively developing new generic drugs, active pharmaceutical ingredients (API) and dietary supplements. Its Pharmaceutical Development Center supports the full cycle of innovation in accordance with ICH and CTD requirements — from formulation development and analytical methods to registration dossiers. This ability allows the company to quickly respond to market needs and develop products adapted for both the Ukrainian and international markets.

The long-term strategy of "VALARTIN PHARMA" prioritizes sustainable development and adaptability, particularly in the context of martial law and the associated economic and humanitarian challenges. Even in difficult circumstances, the company maintains operational stability, invests in modern technologies and continues its expansion.

"VALARTIN PHARMA" offers clear strategic advantages for European partners. The company is ready to localize European production in Ukraine. The company is open for contract manufacturing, offering production facilities that comply to EU regulatory requirements and supported by a strong research and development base. Geographical proximity to the EU ensures fast logistics and reduced supply chain risks. The company also offers the contract marketing and distribution of European medicines in Ukraine.

VALARTIN PHARMA is an ambitious partner that is prepared to deliver high-quality pharmaceutical solutions and participate in joint European projects aimed at expanding access to reliable and affordable healthcare.



«Valeo artis» in latin—the "art of creating health"—became the foundation of our company's name «Valartin Pharma». This is more than just an eloquent phrase; it is our mission, which a team of over 160 highly qualified employees has been implementing since 2013.

«Valartin Pharma» is a highly specialized company offering generic medicines, dietary supplements, and medical devices, concentrating on critically important therapeutic areas such as gastroenterology, gynecology, and immunotherapy. Our main strength is our comprehensive Pharmaceutical Quality System (PQS), which guarantees compliance with all national and international standards: our manufacturing facilities are GMP certified, our warehouses comply with GDP, and all operations are managed under ISO 9001 and ISO 14001 (environmental management) standards.

We are investing in the future: our Centre for Pharmaceutical Development and accredited quality control laboratories allow us to carry out the full cycle of new product development in accordance with ICH and CTD requirements—from formulation to regulatory dossier. We already have experience exporting our products to EU countries, particularly the Baltics and Bulgaria, and we are actively implementing our expansion strategy. We are open to cooperation in the areas of contract manufacturing and providing pharmaceutical development services. «Valartin Pharma» is a guarantee of quality, reliability, and strategic resilience even when facing challenges.

CEO Andrii Razumnyi





Valartin pharma
Production facilities
VALARTIN PHARMA is a modern Ukrainian pharmaceutical company engaged in the development and production of medicines, APIs and dietary supplements.
The key focus of the work is quality and production:
• Production facilities and processes are fully compliant with international standards GMP (Good Manufacturing Practice) as well as GSP/GDP and ISO 14001 (environmental management).
• The company has its own production complex, modern quality control laboratories, a Pharmaceutical Development Center and pharmaceutical warehouses.
• Providing consumers with high-quality, safe and affordable medicines through the introduction of modern technologies.


Valartin pharma
Production facilities
VALARTIN PHARMA LLC is actively engaged in research and development of generic drugs, dietary supplements and APIs.


Valartin pharma
Product range
The marketing strategy of VALARTIN PHARMA is focused on product branding and the formation of a unique selling proposition, which is a source of added value for all consumers.
Гепадиф
SORBEX DUO
SORBEX
СОРБЕКС
Neocardil
SORBEX Ultra
ГЕПАВАЛ
Aflazin
НУКЛЕКС
TAMICTOП

Product range



DOSAGE FORM	ACTUAL PRODUCTION VOLUMES (UNITS PER YEAR)	DESIGN CAPACITY (UNITS PER YEAR)
Pills	15 000 000	80 000 000
Capsules	30 000 000	120 000 000

The main indicator of the scientific and production level of **VALARTIN PHARMA** is its own manufacturing of the active pharmaceutical ingredient (API).

The company produces **Benzyldimethyl[3-(myristoylamino)propyl]ammonium** chloride monohydrate. This competence complements the main specialization: the production of generic drugs and medicines, based on plant extracts.

Distribution



The main sales market of VALARTIN PHARMA LLC is Ukraine. The Company also exports some of its products to the **EU (to the Baltic States and Bulgaria).**

Quality Assurance

Quality for VALARTIN PHARMA is not just a policy, but the foundation of every business process. In particular, the commitment to the highest standards is confirmed by official documents:

- Good Manufacturing Practice (GMP): two valid GMP certificates (No. 074/2024/GMP and No. 077/2024/GMP) issued by the State Service of Ukraine on Medicines. This ensures that medicines are produced according to strict international regulations.
- The manufacturing of dietary supplements complies to HAACP requirements confirmed by the certificate of Latvian Certification Center No SO1-PR-321.03.021A
- Good Distribution Practice (GDP): GDP certificate (No. 03/2021/GDP) confirms that the storage and transportation conditions of products also comply with European regulations.

The basis of the quality system is its own Quality Management Department, which includes quality assurance, quality control and validation departments.



Quality Control

VALARTIN PHARMA has its own certified physical and chemical laboratory, whose activities are confirmed by the State Service of Ukraine on Medicines (Certificate No. 403 of 2019). The laboratory is equipped with modern equipment and provides a full cycle of control:

- Incoming control of raw materials, analysis of intermediate and finished products (medicines and additives).
- Continuous monitoring of equipment cleaning (residual substances), microbiological monitoring of production and water quality control.
- Study of product stability throughout the entire shelf life and analytical support for the validation of production processes.





Advantages of cooperation with Valartin Pharma

VALARTIN PHARMA aims to ensure the sustainable development of the enterprise, in accordance with the approved long-term business strategy, taking into account adaptation to the conditions of martial law and the related security, economic and humanitarian crises.



VALARTIN PHARMA is a flexible and ambitious partner, ready for joint projects in Europe!

VALARTIN PHARMA demonstrates a clear strategy of integration into the European market, offering partners significant advantages:

- Readiness for localization — in particular, to transfer the production of drugs that were previously manufactured in EU and Asia directly to Ukraine.
- Openness to cooperation with European partners in the format of contract manufacturing.
- Logistical advantage due to Ukraine's geographical proximity to the EU countries.


For the value of life!



INDAR

COMPANY OVERVIEW

PrJSC “INDAR” stands as Ukraine’s sole full-cycle manufacturer of genetically engineered insulin and ranks among a few companies globally to hold such a distinction. At its core, INDAR is driven by a profound mission: safeguarding human health — our most precious natural resource — by guaranteeing access to life-saving therapies for those battling socially significant illnesses such as diabetes. With over twenty years of unwavering devotion to research, development, and production, INDAR plays a key role in strengthening healthcare systems both in Ukraine and across the world. The quality and safety of INDAR’s products have earned the trust of patients and partners not only in Ukraine but also in Brazil, Mexico, and other international markets.

The company’s journey began on 4 November 1997, when INDAR was officially registered by the state. This event marked the birth of a strategically vital enterprise, equipped with a full technological cycle for insulin production. A landmark achievement was the development of INDAR’s proprietary recombinant human insulin technology, which paved the way for the launch of HUMODAR insulin products in October 2000. Since then, the company has expanded its portfolio to include essential anticoagulants like heparin, haemostatic agents such as protamine sulphate, and other important medicines that are essential for treating patients.

Quality assurance is the keystone of INDAR’s operations. The company adheres to the highest international manufacturing standards, holding GMP certification from the State Service of Ukraine on Medicines and Drugs Control — a member of the Pharmaceutical Inspection Cooperation Scheme (PIC/S) — as well as certification from the Brazilian Health Regulatory Agency (ANVISA) and other regulatory bodies. INDAR’s Quality Policy is centred on the ongoing enhancement of a rigorous quality management system, fully compliant with GMP, GxP practices, ICH Q10 guidelines, and ISO 9001 and ISO 13485 standards.

On the international stage, INDAR positions itself as a technologically advanced and reliable partner, offering unique advantages particularly suited to the European market. Its principal competitive edge lies in its full-cycle biotechnological production, based on its own knowledge and decades of practical experience. Beyond supplying finished insulin products, INDAR actively engages in technology transfer through contractual partnerships, enabling foreign partners to establish local production facilities based on INDAR’s experience. The company’s expanding presence in global markets demonstrates a strategy built on product portfolio that inspires high level of trust among partners and promotes long-term cooperation.

PrJSC “INDAR” continues to move forward with ambitious plans, driven by innovation, scientific excellence, and the mission to provide millions of patients worldwide with safe, effective, and essential biological medicines.


PRIVATE JOINT STOCK COMPANY "ON THE PRODUCTION OF INSULIN "INDAR" (PrJSC “INDAR”)
indar
For the value of life!


PrJSC “INDAR” activity is focused on achieving goal: preserving of human’s health – the most valuable gift of nature. We are working to ensure long life of proper quality for millions of people worldwide with socially significant diseases such as Diabetes, HIV/AIDS and Tuberculosis.
Liubov Vyshnevska
Chairman of the Board PrJSC “INDAR”


Production Facilities
Kyiv, Ukraine
indar
For the value of life!



On the 4th of November 1997, PrJSC "INDAR« received the Certificate of State Registration. From that moment commenced the official history of creation and development of the one-of-a-kind strategically essential plant in Ukraine with the full technological cycle of insulin manufacturing. Employees of INDAR determined and settled a range of complex legal, property, personnel and financial tasks for putting the company into operation. After that, at the enterprise started the first research-and-development projects for highly-purified substances and new pharmaceutical products.

On the 21st of June 1999, PrJSC "INDAR« plant was put into operation. Every consecutive year the enterprisein-creased the manufacturing capacities. The key milestone of company development was its own manufacturing technology of recombinant human insulin elaboration.

Since October 2000, the plant has been started manufacturing of products under trademarks: HUMODAR (recombinant human insulin), MONODAR (mono-component porcine insulin) as well as products of other groups– anticoagulants (heparin) and hemostatic products (protamine) and other medicines.

And that is not the end of the history of PrJSC "INDAR", but rather the beginning, with new pace of development and incredibly ambitious plans.



PrJSC "INDAR" TODAY

The enterprise with the full technological cycle of genetically engineered insulin – from active pharmaceuticals ingredients (API) to finished dosage forms (FDF).

20 years of R&D and experience inmedication manufacturing.
The full range of recombinant human insulin products, anticoagulants and hemostatic medicines manufacturing based on proprietary technology.
The quality of products is trusted by patients and partners from **Ukraine, Brazil, Mexico** and other countries.

The near-term development strategy envisages product portfolio enhancement with immunoprophylaxis products (vaccines) as well as innovative medicines and medical devices that mee tall needs of people living with **Diabetes, HIV/AIDS and Tuberculosis.**

Product Range

PrJSC "INDAR" is the only one in Ukraine and one of the few companies in the world with the ful ltechnological cycle of production of genetically engineered insulin (r-DNA) – from substance to finished dosage forms. The company produces insulin in vials and cartridges under its trademark HUMODAR.

The insulin product range: short-actin ginsulin – regular insulin; intermediate-acting insulin – isophane insulin and pre-mixed insulin – biphasic isophane insulin.






Product Range



The portfolio of PrJSC "INDAR" products includes also medicines that influence blood system and hematopoiesis: solution for injection – HEPARIN-INDAR and its antidote – PROTAMINE SULPHATE; Thioctic acid, sold under the trademark THIOCTODAR.

Distribution

PrJSC "INDAR« is apharmaceutical company with strong export capabilities.
The company's products are successfully supplied to four continents: **from Brazil, Mexico and Paraguay, Bosnia and Herzegovina to India, Sri Lanka, Angola, Kenya, Tanzania and other countries of Africa.**



Quality Control

PrJSC "INDAR" is a guarantor of product quality.
The production of medicines of PrJSC "INDAR" is certified according to GMP requirements by the: State Service of Ukraine on Medicines and Drugs Control that is a member of PIC/S (Pharmaceutical Inspection Cooperation Scheme) and Brazilian Health Regulatory Agency (ANVISA) of the Federative Republic of Brazil and other counties.
The Quality Policy of PrJSC "INDAR" is aimed at provision and constant maintenance of a hig hquality of products and processes, ensured by the:
creation and constant improvement of the quality management system according to regulatory requirements, (GMP) regulations and other good practices (GxP), requirements to pharmaceutical quality systems **CH Q10, ISO 9001 and ISO 13485** international standards;
Quality improvement of products life cycle process organization;
Constant improvement of the technical level of production, implementation of the modern high-quality technologies;
Promotion of personnel responsibility and understanding of the fact that quality is created at each stage of the product life cycle, including pharmaceutical development, technology transfer and manufacturing.



PJSC "INDAR« positions itself in the international arena as a technologically independent partner with powerful advantages for cooperation, especially in the European market.

The main advantage is full – cycle biotechnological production. The company has not only the knowledge, but also the capacity to create vital biological products that may be of particula rinterest to the European market.

It is noteworthy that with in the frame work of the contracts, PrJSC "INDAR« not only supplies ready – made insulins, but also transfers its own technology for their production. And the active increase in its presence in foreign markets confirms that "PrJSC" INDAR« builds its success on the creation of an exclusive portfolio of products that ensures the success and loyalty of partners around the world".





Національно-виробниче видання
Stronger Together:
Ukraine's Pharmaceutical Sector and EU Partnerships
(Англійською мовою)

Автори:
М.К. Слободніченко, Л.С. Питель, О.В. Ісаєва,
Є.В. Лук'янчук, М. Пількевич, І.О. Грабова

Ця книга є глибоким аналітичним та навчально-освітнім оглядом, присвяченим формуванню, потужності та перспективам української фармацевтичної промисловості в контексті сучасних економічних і соціальних викликів. Видання фокусується на Україні як фармацевтичній державі, яка, попри випробування війни, демонструє надзвичайну життєздатність, професіоналізм та прагнення до інновацій. У публікації представлено, як галузь, спираючись на наукову школу, освітній потенціал та виробничі традиції, перетворюється на один із драйверів економічної стійкості та міжнародної репутації країни.

Автори розглядають макроекономічні умови, в яких розвивається фармацевтичний сектор, його внесок у національний валовий внутрішній продукт, динаміку виробництва, експорту та структурні зміни, що відбуваються під впливом реформ та європейської інтеграції. Особливу увагу приділено внутрішнім ресурсам галузі — від кваліфікованого персоналу та освітніх можливостей до сучасних технологій і потужностей українських підприємств, здатних конкурувати на світовому ринку.

Це не просто економічне дослідження — це філософія відродження фармацевтики як стратегічної галузі, що поєднує науку, інновації, соціальну відповідальність та державотворення. Книга утверджує віру в українського виробника, потенціал вітчизняної фармацевтичної освіти, силу партнерства між державою, бізнесом та наукою.

Видання адресоване міжнародним інституціям, інвесторам, науковій та фаховій спільноті, а також усім, хто вірить, що українська фармацевтика — це не лише галузь, а й символ стійкості, розвитку та інтелектуального майбутнього країни.

Коректори *Т.О. Ткачук, А.В. Петруняк*
Комп'ютерна верстка *О.В. Сікало*
Дизайн *О.І. Цоколенко*

Підписано до друку 19.11.2025.
Друк офсетний. Папір крейдований.
Формат 60x90⅛. Ум. друк. арк. 26.
Зам. № 140. Наклад 100 прим.

Видавець ТОВ «МОРІОН»
Свідоцтво суб'єкта видавничої справи
ДЛ № 540 від 24.01.2017 р.
02140, м. Київ, просп. Бажана, 10А
Тел./факс: (044) 585-97-10 (багатоканальний)
E-mail: public@morion.ua
www.morion.net

Виготовлювач: ТОВ «ПАБЛІШ ПРО»
Свідоцтво суб'єкта видавничої справи
ДК № 5400 від 26.07.2017 р.
02121, м. Київ, вул. Колекторна, 38/40
Тел.: (044) 501-36-70
www.publishpro.com.ua

Printed by Publish Pro:
publishpro.com.ua


MINISTRY
OF HEALTH
OF UKRAINE


MINISTRY OF ECONOMY,
ENVIRONMENT AND AGRICULTURE
OF UKRAINE

KYIV 2025